1 00:00:05,400 --> 00:00:08,360 >>WELCOME TO THE OPEN SESSION 2 00:00:08,360 --> 00:00:12,640 OF THE DIVISION OF MICROBIOLOGY 3 00:00:12,640 --> 00:00:13,200 AND INFECTIOUS DISEASE 4 00:00:13,200 --> 00:00:14,720 SUBCOMMITTEE OF COUNCIL. 5 00:00:14,720 --> 00:00:17,000 I'M JUST GOING TO START OFF WITH 6 00:00:17,000 --> 00:00:21,400 A FEW OF MY--A FEW REMARKS AND 7 00:00:21,400 --> 00:00:23,640 LET'S SEE, SO, OKAY, HERE WE GO, 8 00:00:23,640 --> 00:00:24,520 SO SOMEBODY'S RUNNING THE SLIDES 9 00:00:24,520 --> 00:00:26,760 FOR ME, IT LOOKS LIKE, GOOD. 10 00:00:26,760 --> 00:00:27,960 SO HERE'S THE AGENDA FOR TODAY, 11 00:00:27,960 --> 00:00:29,360 STARTING WITH THE DIRECTOR'S 12 00:00:29,360 --> 00:00:34,240 REPORT, I WILL GIVE YOU SOME 13 00:00:34,240 --> 00:00:35,000 PERSONNEL UPDATES, I WILL 14 00:00:35,000 --> 00:00:37,000 HIGHLIGHT A FEW BITS OF RESEARCH 15 00:00:37,000 --> 00:00:38,080 NEWS. 16 00:00:38,080 --> 00:00:41,280 I AM GOING TO THEN PRESENT YOU 17 00:00:41,280 --> 00:00:44,200 WITH AN FY23 CONCEPT. 18 00:00:44,200 --> 00:00:45,600 AND I'M GOING TO ASK FOR YOUR 19 00:00:45,600 --> 00:00:48,480 APPROVAL OF THAT AND ALSO THE 20 00:00:48,480 --> 00:00:50,920 FISCAL YEAR 23 SBIR CONTRACT 21 00:00:50,920 --> 00:00:53,080 TOPICS FROM BOTH THE DIVISION OF 22 00:00:53,080 --> 00:00:54,080 MICROBIOLOGY AND INFECTIOUS 23 00:00:54,080 --> 00:00:56,080 DISEASE ANDS FROM 1 OF OUR 24 00:00:56,080 --> 00:00:59,680 COLLEAGUES AT THE OFFICE OF DATA 25 00:00:59,680 --> 00:01:00,280 SCIENCE AND EMERGING 26 00:01:00,280 --> 00:01:01,400 TECHNOLOGIES AND THEN WE WILL GO 27 00:01:01,400 --> 00:01:03,200 INTO OUR CONSEPTD PRESENTATION 28 00:01:03,200 --> 00:01:05,640 BY MEMBERS OF DMIDS PROGRAM 29 00:01:05,640 --> 00:01:06,120 STAFF. 30 00:01:06,120 --> 00:01:07,960 NEXT SLIDE, PLEASE. 31 00:01:07,960 --> 00:01:09,800 SO FIRST OF ALL, NEW STAFF, I 32 00:01:09,800 --> 00:01:11,680 JUST WANT TO INTRODUCE YOU 33 00:01:11,680 --> 00:01:12,840 VIRTUALLY TO SOME PEOPLE WHO 34 00:01:12,840 --> 00:01:14,120 HAVE BEEN BROUGHT ON BOARD SINCE 35 00:01:14,120 --> 00:01:19,480 THE LAST TIME THAT WE MET. 36 00:01:19,480 --> 00:01:22,680 CATHERIN BIGGER IS IN THE OBRRTR 37 00:01:22,680 --> 00:01:27,560 SECTION, SHE IS A VIROLOGIST AND 38 00:01:27,560 --> 00:01:30,000 THE JOINT PROGRAM EXECUTIVE 39 00:01:30,000 --> 00:01:32,240 OFFICE FOR CBRN DEFENSE WHERE 40 00:01:32,240 --> 00:01:35,120 SHE WAS SERVING IN AN ADVISORY 41 00:01:35,120 --> 00:01:38,080 ROLE FOR MEDICAL MEASURE COUNTER 42 00:01:38,080 --> 00:01:39,200 DEVELOPMENT FOR BIOWARFARE 43 00:01:39,200 --> 00:01:41,880 AGENTS. 44 00:01:41,880 --> 00:01:48,520 AND THEN OLIVIA SPARER JOINED A 45 00:01:48,520 --> 00:01:49,720 COUPLE MONTHS AGO, SO SHE TOOK 46 00:01:49,720 --> 00:01:51,360 ON A NEW ROLE AND SHE'S 47 00:01:51,360 --> 00:01:52,360 EXPANDING OUR ROLE WITH THE 48 00:01:52,360 --> 00:01:55,200 OFFICE OF CLINICAL RESEARCH 49 00:01:55,200 --> 00:01:57,640 RESOURCES AND THE INFECTIOUS 50 00:01:57,640 --> 00:01:58,280 DISEASE CLINICAL RESEARCH 51 00:01:58,280 --> 00:01:59,280 DISEASE WORK AS A PROGRAM 52 00:01:59,280 --> 00:02:01,480 OFFICER AND AS A MANAGEMENT 53 00:02:01,480 --> 00:02:03,600 ANALYST. 54 00:02:03,600 --> 00:02:04,880 NEXT SLIDE, PLEASE. 55 00:02:04,880 --> 00:02:06,640 BRENDA LARKIN IS A PROGRAM 56 00:02:06,640 --> 00:02:08,120 OFFICER ALSO IN THE OFFICE OF 57 00:02:08,120 --> 00:02:09,560 CLINICAL RESEARCH RESOURCES AND 58 00:02:09,560 --> 00:02:13,440 SHE WILL WORK WITH IDCRC AND THE 59 00:02:13,440 --> 00:02:15,400 VTEUs BEFORE COMING TO DMID, 60 00:02:15,400 --> 00:02:17,880 SHE SPENT SEVERAL YEARS AT 61 00:02:17,880 --> 00:02:20,000 NIAID'S VACCINE RESEARCH CENTER 62 00:02:20,000 --> 00:02:22,520 WORKING ON VACCINE TESTING FOR 63 00:02:22,520 --> 00:02:25,480 HIV AND OTHER BIODEFENSE 64 00:02:25,480 --> 00:02:28,000 PATHOGENS AND THEN KRISTA, CATO, 65 00:02:28,000 --> 00:02:32,000 WHO IS A NURSE CONSULTANT WHO IS 66 00:02:32,000 --> 00:02:33,960 JOINING THE ENTERIC AND STI 67 00:02:33,960 --> 00:02:37,080 BRANCH WHERE SHE WILL SERVE AS A 68 00:02:37,080 --> 00:02:38,840 PROJECTED MANAGER, PRIOR TO 69 00:02:38,840 --> 00:02:42,240 JOINING OUR TEAM SHE OVERSAW 70 00:02:42,240 --> 00:02:44,120 IMPLEMENTATION AND PROTOCOL FOR 71 00:02:44,120 --> 00:02:51,840 THE NURSING PEDIATRIC OF CARE 72 00:02:51,840 --> 00:02:52,600 AT----BRENDA AND KRISTA, AND 73 00:02:52,600 --> 00:02:54,000 NEXT SLIDE, PLEASE AND THEN 74 00:02:54,000 --> 00:02:57,880 WE'VE HAD 1 SIGNIFICANT 75 00:02:57,880 --> 00:03:05,200 DEPARTURE, ALAN WAS THE CHIEF OF 76 00:03:05,200 --> 00:03:06,800 THE RESPIRATORY BRANCH UNTIL 77 00:03:06,800 --> 00:03:09,800 JUST THIS PAST MONTH HE HAD BEEN 78 00:03:09,800 --> 00:03:11,600 INFORMALLY DETAILED TO 79 00:03:11,600 --> 00:03:12,800 DR. FAUCI'S OFFICE WHERE HE 80 00:03:12,800 --> 00:03:16,160 SERVED AS A SENIOR ADVISOR FOR 81 00:03:16,160 --> 00:03:18,000 PANDEMIC PREPAREDNESS AND HE 82 00:03:18,000 --> 00:03:19,200 RECENTLY LEFT NIAID TO TAKE A 83 00:03:19,200 --> 00:03:21,040 POSITION IN THE PRIVATE SECTOR 84 00:03:21,040 --> 00:03:22,000 AND SEPARATE FROM FEDERAL 85 00:03:22,000 --> 00:03:24,600 SERVICE THAT WE HOPE HE WILL 86 00:03:24,600 --> 00:03:27,720 COME BACK SOMEDAY. 87 00:03:27,720 --> 00:03:28,800 NOW, TERESA HAUGEL IS NOT 88 00:03:28,800 --> 00:03:32,880 LEAVING, SHE IS ACTING CHIEF OF 89 00:03:32,880 --> 00:03:34,280 THE RESPIRATORY BRANCH AND I AM 90 00:03:34,280 --> 00:03:36,400 GLAD SHE WAS ABLE TO TAKE ON 91 00:03:36,400 --> 00:03:37,480 THESE ADDITIONAL DUTIES IN,A 92 00:03:37,480 --> 00:03:39,320 DITION TO EVERYTHING ELSE THAT 93 00:03:39,320 --> 00:03:41,400 SHE'S RESPONSIBLE FOR SO NOW I 94 00:03:41,400 --> 00:03:43,360 WILL HIGHLIGHT RESEARCH NEWS, 95 00:03:43,360 --> 00:03:44,560 CONDUCTED BY OUR EXTRAMURAL 96 00:03:44,560 --> 00:03:48,680 INVESTIGATORS AND SUPPORTED BY 97 00:03:48,680 --> 00:03:50,400 OUR DMIDRESOURCES. 98 00:03:50,400 --> 00:03:52,560 ONE OF OUR MOST INTENSE EFFORTS 99 00:03:52,560 --> 00:03:55,760 IN THE PAST YEAR FOR THE 100 00:03:55,760 --> 00:03:58,200 PANDEMIC RESPONSE HAS BEEN THE 101 00:03:58,200 --> 00:03:59,280 DMID MIX AND MATCH CLINICAL 102 00:03:59,280 --> 00:04:03,520 TRIAL WHICH WAS DESIGNED TO TEST 103 00:04:03,520 --> 00:04:05,920 THE SAFETY AND IMMUNE O 104 00:04:05,920 --> 00:04:07,520 GENESISISSITY OF ALL POSSIBLE 105 00:04:07,520 --> 00:04:10,760 COMBINATIONS OF LICENSED AND 106 00:04:10,760 --> 00:04:11,400 AUTHORIZED SARS-COV-2 VACCINES 107 00:04:11,400 --> 00:04:14,760 WHEN THEY WERE USED AS A PRIME 108 00:04:14,760 --> 00:04:18,000 OR A BOOST IN COMBINATION OF 109 00:04:18,000 --> 00:04:20,480 WITH OTHER VACCINES. 110 00:04:20,480 --> 00:04:22,680 SO A PRELIMINARY REPORT OF 111 00:04:22,680 --> 00:04:24,520 RESULTS WAS PUBLISHED IN THE NEW 112 00:04:24,520 --> 00:04:25,920 ENGLAND JOURNAL IN OCTOBER AND 113 00:04:25,920 --> 00:04:28,480 THEN THESE DATA,OT PRIMING AND 114 00:04:28,480 --> 00:04:30,240 BOOSTING COMBINATIONS WAS ALSO 115 00:04:30,240 --> 00:04:34,480 PRESENTED TO THE FDA VP A C, AND 116 00:04:34,480 --> 00:04:36,640 TO THE ACIP AND THESE PROVIDED A 117 00:04:36,640 --> 00:04:40,240 BASIS FOR THE RECOMMENDATION OF 118 00:04:40,240 --> 00:04:41,280 THE ACIP ULTIMATELY, WHAT 119 00:04:41,280 --> 00:04:44,280 ULTIMATELY CAME OUT OF THE ACIP, 120 00:04:44,280 --> 00:04:46,720 AND BUT DIFFERENT MRNA VACCINES 121 00:04:46,720 --> 00:04:48,800 COULD BE COMBINED SAFELY IN 122 00:04:48,800 --> 00:04:50,080 PRIME BOOST COMBINATIONS AND THE 123 00:04:50,080 --> 00:04:54,480 STUDY ALSO PROVIDED A VIEWS FOR 124 00:04:54,480 --> 00:04:57,240 MRNA VACCINES FOLLOWING THE J& 125 00:04:57,240 --> 00:04:57,720 JR VACCINE. 126 00:04:57,720 --> 00:04:59,640 SAMPLES FROM THIS STUDY PROVIDED 127 00:04:59,640 --> 00:05:03,320 DATA SHOWED THAT BOOSTING 128 00:05:03,320 --> 00:05:05,280 GENERATED NEUTRALIZING ANTIBODY 129 00:05:05,280 --> 00:05:07,480 RESPONSE THAT WOULD BE PARTIALLY 130 00:05:07,480 --> 00:05:10,320 EFFECTIVE AGAINST THE OMICRON 131 00:05:10,320 --> 00:05:13,080 VARIANT WHICH WAS VERY VARIANTS 132 00:05:13,080 --> 00:05:15,680 OF CONCERN. 133 00:05:15,680 --> 00:05:18,200 NEXT SLIDE, PLEASE. 134 00:05:18,200 --> 00:05:20,040 INVESTIGATORS AT THE UNIVERSITY 135 00:05:20,040 --> 00:05:21,200 OF PENNSYLVANIA SRMTED THROUGH 136 00:05:21,200 --> 00:05:23,680 OUR CENTERS OF EXCELLENCE AND 137 00:05:23,680 --> 00:05:25,280 INFLUENZA RESEARCH AND RESPONSE 138 00:05:25,280 --> 00:05:26,280 REPORTED IN DECEMBER, JUDGE UTV 139 00:05:26,280 --> 00:05:29,840 A FEW WEEKS AGO IN A PREPRINT 140 00:05:29,840 --> 00:05:32,320 THAT PREEXISTING IMMUNITY 141 00:05:32,320 --> 00:05:34,200 AGAINST CURRENTLY CIRCULATING H3 142 00:05:34,200 --> 00:05:36,640 N2 VIRUSES IS LOW. 143 00:05:36,640 --> 00:05:38,040 AND THAT CIRCULATING STRAINS MAY 144 00:05:38,040 --> 00:05:40,600 NOT BE WELL NEUTRALIZED BY 145 00:05:40,600 --> 00:05:44,000 ANTIBODIES THAT ARE GENERATED BY 146 00:05:44,000 --> 00:05:45,840 THE NORTHERN HEMISPHERE VACCINE. 147 00:05:45,840 --> 00:05:47,560 THIS IS BECAUSE THERE HAVE BEEN 148 00:05:47,560 --> 00:05:51,760 SEVERAL NEW SUBTUITIONS THAT 149 00:05:51,760 --> 00:05:54,480 HAVE EVOLVED RELATIVE TO THE 150 00:05:54,480 --> 00:05:57,320 2021-22 STRAIN SELECTION FOR 151 00:05:57,320 --> 00:05:57,680 THAT VACCINE. 152 00:05:57,680 --> 00:06:00,880 WE DID NOT HAVE A SIGNIFICANT 153 00:06:00,880 --> 00:06:02,640 FLU VACCINE IN 2020-21 BUT I'M 154 00:06:02,640 --> 00:06:03,800 CONCLUDE FREE RADICALS GENERATED 155 00:06:03,800 --> 00:06:06,080 THESE DATA THAT THESE 156 00:06:06,080 --> 00:06:06,760 NONPHARMACEUTICAL INTERVENTIONS 157 00:06:06,760 --> 00:06:09,600 THAT MIGHT HAVE MINIMIZED 158 00:06:09,600 --> 00:06:10,400 INFLUENZA TRANSMISSION LAST YEAR 159 00:06:10,400 --> 00:06:13,800 SUCH AS MASKING AND SOCIAL 160 00:06:13,800 --> 00:06:14,880 DISTANCING ALSO MIGHT CONTINUE 161 00:06:14,880 --> 00:06:17,600 TO PROVIDE BENEFIT TO US DURING 162 00:06:17,600 --> 00:06:30,080 THIS RESPIRATORY VIRUS SEASON. 163 00:06:30,080 --> 00:06:30,640 NEXT SLIDE, PLEASE. 164 00:06:30,640 --> 00:06:32,920 STAFF MEMBERS IN OUR OFFICE OF 165 00:06:32,920 --> 00:06:33,880 BIODEFENSE AND TRANSLATIONAL 166 00:06:33,880 --> 00:06:37,480 RESEARCH RESOURCES WHAT WE CALL 167 00:06:37,480 --> 00:06:38,480 OBRRTR, IN DMIDGENERATED DATA 168 00:06:38,480 --> 00:06:40,840 FOR THE FDA THAT,A LOWED FOR 169 00:06:40,840 --> 00:06:41,880 ANIMAL MODEL QUALIFICATION 170 00:06:41,880 --> 00:06:44,520 THROUGH THE FDA DRUG DEVELOPMENT 171 00:06:44,520 --> 00:06:45,240 TOOL PROGRAM. 172 00:06:45,240 --> 00:06:47,760 IN IS THE FIRST TIME THAT 173 00:06:47,760 --> 00:06:49,120 AN ANIMAL MODEL HAS BEEN 174 00:06:49,120 --> 00:06:49,760 QUALIFIED IN THAT PROGRAM. 175 00:06:49,760 --> 00:06:51,280 THIS IS THE RESULT OF OVER 10 176 00:06:51,280 --> 00:06:53,360 YEARS OF WORK ON THE PART OF 177 00:06:53,360 --> 00:06:55,080 DMIDAND FDA STAFF AND THIS 178 00:06:55,080 --> 00:07:00,800 ANIMAL MODEL IS QUALIFIED FOR 179 00:07:00,800 --> 00:07:01,640 TESTING THERAPEUTICS AGAINST 180 00:07:01,640 --> 00:07:03,920 [INDISCERNIBLE], AND THIS WILL 181 00:07:03,920 --> 00:07:05,160 ALLOW FOR NIAID AND INDUSTRY 182 00:07:05,160 --> 00:07:09,080 PARTNERS TO APPROVE DRUGS OF 183 00:07:09,080 --> 00:07:09,720 THERAPEUTIC TREATMENTS FOR 184 00:07:09,720 --> 00:07:11,280 [INDISCERNIBLE] USING THE ANIMAL 185 00:07:11,280 --> 00:07:14,080 PATHWAY. 186 00:07:14,080 --> 00:07:15,200 NEXT SLIDE, PLEASE. 187 00:07:15,200 --> 00:07:17,680 A NUMBER OF DMID STAFF MEMBERS 188 00:07:17,680 --> 00:07:18,800 HAVE RECEIVED AWARDS SINCE LAST 189 00:07:18,800 --> 00:07:20,880 TIME WE MET AND I WOULD LIKE TO 190 00:07:20,880 --> 00:07:21,360 RECOGNIZE THEM. 191 00:07:21,360 --> 00:07:23,560 OF THOSE THAT ARE IN OUR 192 00:07:23,560 --> 00:07:26,000 COMMISSIONED CORPS, THE PUBLIC 193 00:07:26,000 --> 00:07:32,320 HEALTH SERVICE AWARDS 194 00:07:32,320 --> 00:07:32,960 DR. CHRISTINA CARDEMIL RECEIVED 195 00:07:32,960 --> 00:07:34,880 OUTSTANDING SERVICE MEDAL FOR 196 00:07:34,880 --> 00:07:35,440 CONTINUING OUTSTANDING 197 00:07:35,440 --> 00:07:37,160 LEADERSHIP IN GLOBAL AND 198 00:07:37,160 --> 00:07:40,800 DOMESTIC DISEASE PREVENTION AND 199 00:07:40,800 --> 00:07:42,000 CONTROL. 200 00:07:42,000 --> 00:07:42,880 DR. LORI NEWMAN RECEIVED 201 00:07:42,880 --> 00:07:43,880 ACCOMMODATION FOR TRAINING OF 202 00:07:43,880 --> 00:07:46,520 STAFF FROM NIH AND OTHER 203 00:07:46,520 --> 00:07:48,560 AGENCIES IN OPIOID OVERDOSE 204 00:07:48,560 --> 00:07:50,480 RESPONSE IN RESPONSE TO THE 205 00:07:50,480 --> 00:07:57,560 NATIONAL EPIDEMIC ON OPIOID 206 00:07:57,560 --> 00:07:58,640 OVERDOSE. 207 00:07:58,640 --> 00:08:00,280 AND JOHN PESCE, COMBINATION FOR 208 00:08:00,280 --> 00:08:03,200 2 PROJECTS IF PARTICIPATION IN 209 00:08:03,200 --> 00:08:06,480 THE FDA OPIOID OVERDOSE RESPONSE 210 00:08:06,480 --> 00:08:07,640 AND NALOXONE TRAINING TEAM AND 211 00:08:07,640 --> 00:08:09,280 ALSO FOR HIS CONTRIBUTIONS TO 212 00:08:09,280 --> 00:08:15,040 THE PACE OPIOID PLAN DEVELOPMENT 213 00:08:15,040 --> 00:08:16,720 TEAM. 214 00:08:16,720 --> 00:08:18,840 >> NEXT SLIDE, PLEASE. 215 00:08:18,840 --> 00:08:21,880 THE HARRIET P. DUSTIN AWARD IS 216 00:08:21,880 --> 00:08:24,040 BESTOWED FOR OUTSTANDING WORK IN 217 00:08:24,040 --> 00:08:25,440 SCIENCE AS IT RELATES TO 218 00:08:25,440 --> 00:08:28,480 MEDICINE AND SCIENTISTS IN ANY 219 00:08:28,480 --> 00:08:33,080 FIELD, ANY COUNTRY CLINICAL, 220 00:08:33,080 --> 00:08:34,040 NONCLINICAL, CHEMICAL, 221 00:08:34,040 --> 00:08:35,080 NONCHEMICAL, BIOPHYSICAL ARE ALL 222 00:08:35,080 --> 00:08:36,720 ELELIMINATEDDIBLE FOR THE AWARD, 223 00:08:36,720 --> 00:08:38,120 THE MAJOR CONTRIBUTION WOULD BE 224 00:08:38,120 --> 00:08:40,120 THAT THE AWARDEE MADE AN 225 00:08:40,120 --> 00:08:41,240 OUTSTANDING CONTRIBUTION THAT 226 00:08:41,240 --> 00:08:43,080 HAS BEEN NATIONALLY OR 227 00:08:43,080 --> 00:08:44,160 INTERNATIONALLY RECOGNIZED WE 228 00:08:44,160 --> 00:08:48,200 ARE PLEASED THAT DR. JOHN BIGEL, 229 00:08:48,200 --> 00:08:50,680 RECEIVED THIS AWARD FOR HIS 230 00:08:50,680 --> 00:08:52,160 LEADERSHIP IN LAUNCHING AND 231 00:08:52,160 --> 00:08:55,560 IMPLEMENTING THE ACT STUDIES 232 00:08:55,560 --> 00:08:57,680 DURING THE CURRENT PANDEMIC. 233 00:08:57,680 --> 00:08:59,200 NEXT SLIDE, PLEASE. 234 00:08:59,200 --> 00:09:01,720 SO DR. FAUCI, MENTIONED OUR 235 00:09:01,720 --> 00:09:04,120 WORKSHOP ON PANDEMIC 236 00:09:04,120 --> 00:09:06,240 PREPAREDNESS AND HOW WE DELVED 237 00:09:06,240 --> 00:09:08,680 INTO THE PROTOTYPE PATHOGEN 238 00:09:08,680 --> 00:09:10,240 APPROACH TO ACCELERATE THE 239 00:09:10,240 --> 00:09:10,920 DEVELOPMENT OF MEDICAL 240 00:09:10,920 --> 00:09:12,680 COUNTERMEASURES AT THAT 241 00:09:12,680 --> 00:09:13,280 WORKSHOP. 242 00:09:13,280 --> 00:09:15,720 THIS WORKSHOP WAS THE--THE HAGZ 243 00:09:15,720 --> 00:09:17,040 RATIONAL WAS TO FOCUS I 244 00:09:17,040 --> 00:09:18,840 HAVEROLOGYSTS AND OTHER THOUGHT 245 00:09:18,840 --> 00:09:21,400 LEADERS ON OUR PROTOTYPE 246 00:09:21,400 --> 00:09:23,120 PATHOGEN PLAN AND AS YOU MIGHT 247 00:09:23,120 --> 00:09:25,320 RECALL, THAT'S BASED UPON THE 248 00:09:25,320 --> 00:09:26,400 CONCEPT THAT THERE'S PROBABLY 249 00:09:26,400 --> 00:09:29,480 ONLY A LIMITED NUMBER OF--EVEN 250 00:09:29,480 --> 00:09:31,760 THOUGH IT SEEMS AN INFINITE 251 00:09:31,760 --> 00:09:33,640 NUMBER OF RNA VIRUSES OUT THERE, 252 00:09:33,640 --> 00:09:34,840 THERE'S A LIMITED NUMBER OF 253 00:09:34,840 --> 00:09:36,080 VIRAL FAMILIES THAT ARE LIKELY 254 00:09:36,080 --> 00:09:39,560 TO SPILL OVER FROM THEIR 255 00:09:39,560 --> 00:09:41,160 ZOONOTIC RESERVOIR AND CAUSE AN 256 00:09:41,160 --> 00:09:45,000 OUTBREAK OR AN EPIDEMIC OR A 257 00:09:45,000 --> 00:09:47,480 PANDEMIC THAT IMPACTS HUMANS. 258 00:09:47,480 --> 00:09:49,880 SO THIS--IF WE KNOW WHAT THOSE 259 00:09:49,880 --> 00:09:58,120 FAMILIES ARE, PERHAPS WE CAN 260 00:09:58,120 --> 00:09:59,280 DEVELOP PROTOTYPE VACCINES 261 00:09:59,280 --> 00:10:01,400 AGAINST PATHOGENS AND BE BETTER 262 00:10:01,400 --> 00:10:03,680 PREPARED SHOULD AN EPIDEMIC 263 00:10:03,680 --> 00:10:05,000 ARISE FROM A VIRUS WITHIN THAT 264 00:10:05,000 --> 00:10:05,240 FAMILY. 265 00:10:05,240 --> 00:10:09,000 SO AT THIS WORKSHOP WHICH WAS 266 00:10:09,000 --> 00:10:11,200 LED BY CHRISTINA [INDISCERNIBLE] 267 00:10:11,200 --> 00:10:16,440 OUR DEPUTY DIRECTOR VIROLOGYST, 268 00:10:16,440 --> 00:10:18,000 AND TO IDENTIFY GAPS AND 269 00:10:18,000 --> 00:10:19,440 KNOWLEDGES IN THESE PATHOGENS 270 00:10:19,440 --> 00:10:20,800 AND PROPOSE SPECIFIC VIRUSES 271 00:10:20,800 --> 00:10:22,400 WITHIN THAT FAMILY THAT WE 272 00:10:22,400 --> 00:10:24,200 SHOULD SUPPORT MORE INTENSIVE 273 00:10:24,200 --> 00:10:27,080 STUDY IN THAT MIGHT REPRESENT 274 00:10:27,080 --> 00:10:28,160 THE BEST PROTOTYPE THAT MIGHT 275 00:10:28,160 --> 00:10:30,000 LEAD TO RESEARCH THAT MIGHT LEAD 276 00:10:30,000 --> 00:10:31,080 TOWARD AN EFFICACIOUS VACCINE. 277 00:10:31,080 --> 00:10:33,160 SO NEXT SLIDE, SO THE FAMILIES 278 00:10:33,160 --> 00:10:38,840 OF RNA VIRUSES MOST LIKELY TO 279 00:10:38,840 --> 00:10:41,080 CAUSE SIGNIFICANT EPIDEMICS OR 280 00:10:41,080 --> 00:10:41,840 PANDEMICS ARE DEPICTED ON THIS 281 00:10:41,840 --> 00:10:44,680 SLIDE AND IN THE PAST 2 YEARS 282 00:10:44,680 --> 00:10:50,640 WE'VE MADE SUBSTANTIAL 283 00:10:50,640 --> 00:10:53,040 INVESTMENTS IN VACCINES FOR 284 00:10:53,040 --> 00:10:58,120 CORONAVIRUSS AND ALSO FOR 285 00:10:58,120 --> 00:10:59,520 ORTHOMYXOVIRIDACE, THAT INCLUDES 286 00:10:59,520 --> 00:11:01,520 INFLUENZA A, MAYBE WITH THE 287 00:11:01,520 --> 00:11:03,480 EXCEPTION OF THE FILO I HAVE 288 00:11:03,480 --> 00:11:05,280 RIEROUSS, WE PROBABLY LACK THE 289 00:11:05,280 --> 00:11:06,560 FOUNDATION TO RESPOND QUICKLY 290 00:11:06,560 --> 00:11:13,040 SHOULD A SPILL OVER FROM A 291 00:11:13,040 --> 00:11:15,280 ZOONOTIC RESERVOIR LEAD TO AN 292 00:11:15,280 --> 00:11:17,360 EMDIPPIC, AND FOR THE HIGH 293 00:11:17,360 --> 00:11:20,880 CONSEQUENCE PATHOGENS THERE HAS 294 00:11:20,880 --> 00:11:23,440 BEEN SIGNIFICANT SUCCESS IN 295 00:11:23,440 --> 00:11:24,280 DEVELOPING SEVERAL VACCINES THAT 296 00:11:24,280 --> 00:11:27,640 ARE NOW AVAILABLE ON THE 297 00:11:27,640 --> 00:11:28,960 COMMERCIAL MARKET. 298 00:11:28,960 --> 00:11:31,000 SO WHILE THERE'S MORE WORK TO BE 299 00:11:31,000 --> 00:11:33,080 DONE FOR THE FILOs, THIS IS 300 00:11:33,080 --> 00:11:35,120 NOT AN AREA THAT HAS BEEN 301 00:11:35,120 --> 00:11:35,600 NEGLECTED. 302 00:11:35,600 --> 00:11:39,480 SO NEXT SLIDE, PLEASE. 303 00:11:39,480 --> 00:11:41,080 SO THIS LEADS ME TO ASK FOR 304 00:11:41,080 --> 00:11:43,800 APPROVAL FOR WHAT WE HOPE WILL 305 00:11:43,800 --> 00:11:48,880 BECOME AN FY23 CONCEPT AND I'LL 306 00:11:48,880 --> 00:11:50,160 PRESENT YOU THE RATIONAL NOW AND 307 00:11:50,160 --> 00:11:51,680 WHAT WE PROPOSE TO DO. 308 00:11:51,680 --> 00:11:54,400 I WILL JUST NOTE, WE DO NOT HAVE 309 00:11:54,400 --> 00:11:56,080 ACCESS TO FUNDS TO SUPPORT THIS 310 00:11:56,080 --> 00:11:56,320 RIGHT NOW. 311 00:11:56,320 --> 00:11:58,280 THERE IS TALK OF IMPROVING OUR 312 00:11:58,280 --> 00:12:01,280 ABILITY TO RESPOND TO A 313 00:12:01,280 --> 00:12:02,880 PANDEMIC, AND OTHER SOURCE OF 314 00:12:02,880 --> 00:12:05,040 PANDEMICS IN THE FUTURE, THERE'S 315 00:12:05,040 --> 00:12:06,360 INTEREST IN NIAID, AND THE REST 316 00:12:06,360 --> 00:12:07,680 OF THE NIH IN SUPPORTING 317 00:12:07,680 --> 00:12:10,400 RESEARCH IN THIS AREA, AND THERE 318 00:12:10,400 --> 00:12:12,400 MAY BE APPROPRIATIONS EITHER 319 00:12:12,400 --> 00:12:13,720 SPECIFICALLY TO NIAID FOR 320 00:12:13,720 --> 00:12:15,440 PANDEMIC PREPAREDNESS IN THE 321 00:12:15,440 --> 00:12:16,680 FUTURE OR SOMETHING THAT MIGHT 322 00:12:16,680 --> 00:12:18,160 COME TO THE DEPARTMENT OF HEALTH 323 00:12:18,160 --> 00:12:19,680 AND HUMAN SERVICES THAT WOULD BE 324 00:12:19,680 --> 00:12:22,680 TRANSFERRED TO US IN ORDER TO 325 00:12:22,680 --> 00:12:24,720 ADDRESS THIS. 326 00:12:24,720 --> 00:12:27,320 WE'RE NOT PROPOSING THAT 327 00:12:27,320 --> 00:12:29,360 ANYTHING, THAT ANY FUNDS THAT 328 00:12:29,360 --> 00:12:31,240 WOULD COME OUT OF THIS CONCEPT 329 00:12:31,240 --> 00:12:33,600 THAT WOULD SUPPORT PROJECTS IN 330 00:12:33,600 --> 00:12:34,560 THIS CONCEPT WOULD TAKE AWAY 331 00:12:34,560 --> 00:12:38,680 FROM THE PAY LINE OR ANOTHER 332 00:12:38,680 --> 00:12:39,640 INVESTIGATOR INITIATED STUDIES. 333 00:12:39,640 --> 00:12:42,480 SO THE TITLE OF THIS IS RESEARCH 334 00:12:42,480 --> 00:12:45,280 CENTERS TO DEVELOP VACCINES IN 335 00:12:45,280 --> 00:12:46,200 MONOCLONAL ANTIBODIES FOR 336 00:12:46,200 --> 00:12:47,240 PANDEMIC PREPAREDNESS, THE 337 00:12:47,240 --> 00:12:48,680 OBJECTIVES WOULD BE TO ADVANCE 338 00:12:48,680 --> 00:12:50,440 THE KNOWLEDGE NEEDED TO DEVELOP 339 00:12:50,440 --> 00:12:52,080 VACCINES AND MONOCLONE AT 340 00:12:52,080 --> 00:12:54,880 ANTIBODIES FOR PROTOTYPE VIRAL 341 00:12:54,880 --> 00:12:56,640 PATHOGENS AND THE VIRUS FAMILIES 342 00:12:56,640 --> 00:12:58,200 THAT HAVE PANDEMIC POTENTIAL FOR 343 00:12:58,200 --> 00:13:04,280 WHICH WE CURRENTLY DON'T HAVE 344 00:13:04,280 --> 00:13:04,480 IT. 345 00:13:04,480 --> 00:13:06,440 SO, THE KEY FEATURES, AND THE 346 00:13:06,440 --> 00:13:09,160 FOCUS OF THESE PROPOSED CENTERS 347 00:13:09,160 --> 00:13:13,080 ARE SUMMARIZED ON THIS SLIDE, 348 00:13:13,080 --> 00:13:14,480 AND THE 5 FAMILY VIRAL FAMILIES 349 00:13:14,480 --> 00:13:16,240 FOR WHICH WE DON'T HAVE ADEQUATE 350 00:13:16,240 --> 00:13:19,080 KNOWLEDGE TO EVEN THINK ABOUT 351 00:13:19,080 --> 00:13:20,120 APPROACHING A VACCINE FOR SOME 352 00:13:20,120 --> 00:13:22,040 OF THE MEMBERS OF THE VIRAL 353 00:13:22,040 --> 00:13:25,120 FAMILIES AT LEAST ARE DEPICTED 354 00:13:25,120 --> 00:13:26,280 ON THE RIGHT. 355 00:13:26,280 --> 00:13:27,920 THE CENTERS WOULD INCLUDE 356 00:13:27,920 --> 00:13:29,280 MULTIDISCIPLINARY TEAMS THAT 357 00:13:29,280 --> 00:13:32,680 WOULD BE FOCUSED ON BASIC I 358 00:13:32,680 --> 00:13:33,480 HAVEROLOGY, STRUCTURAL BIOLOGY, 359 00:13:33,480 --> 00:13:35,840 ANTIGEN MAPPING AND INVITRO 360 00:13:35,840 --> 00:13:36,480 TESTING AND/OR MODEL DEVELOPMENT 361 00:13:36,480 --> 00:13:41,680 AS WELL AS VAC SEEB AND 362 00:13:41,680 --> 00:13:43,320 MONOCLONAL ANTIBODY TESTING AND 363 00:13:43,320 --> 00:13:44,600 I& D ENABLING RESEARCH THAT 364 00:13:44,600 --> 00:13:47,800 COULD LEAD TO HUMAN TRIALS IN 365 00:13:47,800 --> 00:13:48,480 HUMANS PHASE 1 CLINICAL TRIALS 366 00:13:48,480 --> 00:13:52,120 SO THE FOCUS WOULD BE ON 367 00:13:52,120 --> 00:13:53,680 PROTOTYPE PATHOGENS THAT ARE 368 00:13:53,680 --> 00:14:12,080 IDENTIFIED IN THE WORKSHOP--OR 369 00:14:12,080 --> 00:14:14,000 PERHAPS MORE THE STAGE OF 370 00:14:14,000 --> 00:14:15,040 DEVELOPMENT THAT COULD BE 371 00:14:15,040 --> 00:14:16,480 SUPPORTED BY THESE CENTERS, FOR 372 00:14:16,480 --> 00:14:18,240 THOSE VIRUSES THAT WE HAVE VERY 373 00:14:18,240 --> 00:14:19,400 LITTLE UNDERSTANDING OF THE 374 00:14:19,400 --> 00:14:20,800 VIRUS LIFE CYCLE FOR EXAMPLE, 375 00:14:20,800 --> 00:14:23,800 THE CENTERS MIGHT SUPPORT BASIC 376 00:14:23,800 --> 00:14:26,040 RESEARCH, STRUCTURAL BIOLOGY, 377 00:14:26,040 --> 00:14:28,280 AND/OR MODEL DEVELOPMENT MOVING 378 00:14:28,280 --> 00:14:30,600 ALONG TO ANTIGEN DESIGN, ASSAY 379 00:14:30,600 --> 00:14:31,720 DEVELOPMENT AND KREENING FOR 380 00:14:31,720 --> 00:14:34,880 ACTIVITY OF THAT PROPOSED 381 00:14:34,880 --> 00:14:37,360 COUNTER MEASURE, MOVING ON TO 382 00:14:37,360 --> 00:14:39,080 ADJUVANT PAIRING AND TESTING AND 383 00:14:39,080 --> 00:14:40,400 I& D ENABLING STUDYINGS WHICH 384 00:14:40,400 --> 00:14:41,760 IT MIGHT ULTIMATELY LEAD TO A 385 00:14:41,760 --> 00:14:43,600 PHASE 1 CLINICAL TRIAL. 386 00:14:43,600 --> 00:14:45,680 AND THEN A TRANSITION TO 387 00:14:45,680 --> 00:14:51,920 PARTNERS THAT MIGHT TAKE IT FOR 388 00:14:51,920 --> 00:14:52,480 FURTHER PERHAPS 389 00:14:52,480 --> 00:14:54,040 COMMERCIALIZATION. 390 00:14:54,040 --> 00:14:54,960 NEXT SLIDE, PLEASE. 391 00:14:54,960 --> 00:14:57,640 AND THEN SUMMARIZED ON THIS 392 00:14:57,640 --> 00:14:58,920 SLIDE, WE DEPICT HOW WE WOULD 393 00:14:58,920 --> 00:15:00,560 PROPOSE THAT THIS PROGRAM COULD 394 00:15:00,560 --> 00:15:03,240 INTERACT WITH OTHER RESEARCH 395 00:15:03,240 --> 00:15:05,920 PROGRAMS WITH PROGRAMS SUPPORTED 396 00:15:05,920 --> 00:15:06,400 BY OUR DIVISION. 397 00:15:06,400 --> 00:15:07,480 MANY OF YOU MIGHT BE FAMILIAR 398 00:15:07,480 --> 00:15:09,280 WITH THE CENTERS FOR RESEARCH 399 00:15:09,280 --> 00:15:11,440 AND EMERGING INFECTIOUS DISEASES 400 00:15:11,440 --> 00:15:12,640 OR THE CREEDS. 401 00:15:12,640 --> 00:15:16,040 WE ENVISION THESE ARE 402 00:15:16,040 --> 00:15:18,320 LONGITUDINAL STUDIES AND WHERE 403 00:15:18,320 --> 00:15:21,280 SAMPLES ARE COLLECTED THAT MIGHT 404 00:15:21,280 --> 00:15:24,400 BE APPROXIMATE TO WHERE SPILL 405 00:15:24,400 --> 00:15:27,600 OVER EVENTS FROM ZOONOTIC 406 00:15:27,600 --> 00:15:28,480 RESERVOIRS MIGHT BE, THIS 407 00:15:28,480 --> 00:15:30,880 PROGRAM COULD SUPPORT THE 408 00:15:30,880 --> 00:15:32,760 REAGENTS AND PERHAPS CLINICAL 409 00:15:32,760 --> 00:15:35,680 SALES FOR THESE PROPOSED 410 00:15:35,680 --> 00:15:37,880 RESEARCH CENTERS TO USE. 411 00:15:37,880 --> 00:15:39,440 WE HAVE STRUCTURAL GENOMIC 412 00:15:39,440 --> 00:15:40,800 CENTERS WHICH ARE WITH 413 00:15:40,800 --> 00:15:42,200 STRUCTURAL BIOLOGY AND HELP 414 00:15:42,200 --> 00:15:43,400 SOLVE ANTIGEN STRUCTURE IF THAT 415 00:15:43,400 --> 00:15:46,080 HAPPENED TO BE IN NEED, THERE'S 416 00:15:46,080 --> 00:15:47,280 GENERALLY THIS IS SIMILAR TO THE 417 00:15:47,280 --> 00:15:50,080 PROGRAM THAT WE PROPOSED, 418 00:15:50,080 --> 00:15:51,040 ANTIVIRAL DRUG DISCOVERY, THE 419 00:15:51,040 --> 00:15:53,080 AVID CENTERS WHICH WILL BE 420 00:15:53,080 --> 00:15:55,200 AWARDED SOMETIME THIS YEAR, WE 421 00:15:55,200 --> 00:16:07,840 ENVISION THAT THERE MIGHT BE 422 00:16:07,840 --> 00:16:11,600 SHARE AND SHUTTERS, AND IND 423 00:16:11,600 --> 00:16:12,640 ENABLING AND RESEARCH CENTERS 424 00:16:12,640 --> 00:16:15,520 AND THEIR RESEARCH PROJECT. 425 00:16:15,520 --> 00:16:20,080 AND WE ENVISION THAT ANY 426 00:16:20,080 --> 00:16:22,520 CANDIDATE, AND LOOKED LIKE A 427 00:16:22,520 --> 00:16:25,480 SUCCESSFUL CANDIDATE GOING 428 00:16:25,480 --> 00:16:28,160 FORWARD INTO PHASE 1 THROUGH OUR 429 00:16:28,160 --> 00:16:30,280 INFECT YOWZ DISEASE RESEARCH 430 00:16:30,280 --> 00:16:34,400 CONSORTIUM WHICH IS ALREADY 431 00:16:34,400 --> 00:16:34,640 FUNDED. 432 00:16:34,640 --> 00:16:41,640 SO THAT WAS QUITE A BIT, MAYBE I 433 00:16:41,640 --> 00:16:42,960 SHOULD SEE IF ANYBODY HAS ANY 434 00:16:42,960 --> 00:16:45,600 QUESTIONS THAT THEY WOULD LIKE 435 00:16:45,600 --> 00:16:49,680 TO PROPOSE OR ASK QUESTIONS OR 436 00:16:49,680 --> 00:16:50,080 GIVE FEEDBACK. 437 00:16:50,080 --> 00:16:51,840 IT SOUNDS LIKE WE DON'T NEED A 438 00:16:51,840 --> 00:16:53,040 FORMAL VOTE ON THIS BUT WE'RE 439 00:16:53,040 --> 00:16:55,800 HAPPY TO GET FEEDBACK ON THIS 440 00:16:55,800 --> 00:16:56,240 PROPOSED INITIATIVE. 441 00:16:56,240 --> 00:16:57,160 ANYTHING FROM THE AUDIENCE, 442 00:16:57,160 --> 00:17:00,120 OTHERWISE I WILL CONTINUE TO 443 00:17:00,120 --> 00:17:01,600 MOVE FORWARD-- 444 00:17:01,600 --> 00:17:01,880 >> EMILY? 445 00:17:01,880 --> 00:17:02,280 >> YES? 446 00:17:02,280 --> 00:17:05,680 >> I HAVE MAYBE 1 OR 2 447 00:17:05,680 --> 00:17:06,120 QUESTIONS. 448 00:17:06,120 --> 00:17:08,680 ONE, IT'S OBVIOUSLY VERY 449 00:17:08,680 --> 00:17:08,920 EXCITING. 450 00:17:08,920 --> 00:17:11,800 I WONDER WHETHER YOU HAVE GIVEN 451 00:17:11,800 --> 00:17:15,120 ANY THOUGHT TO HOW 1 COULD 452 00:17:15,120 --> 00:17:18,920 INVOLVE THIRD WORLD COUNTRIES OR 453 00:17:18,920 --> 00:17:21,480 THE SOUTH IN THIS EFFORT FOR A 454 00:17:21,480 --> 00:17:22,640 NEW PANDEMIC. 455 00:17:22,640 --> 00:17:24,960 IF THERE'S A LESSON FROM COVID 456 00:17:24,960 --> 00:17:29,880 HAS BEEN 1 LESSON IS, BOY WE'VE 457 00:17:29,880 --> 00:17:30,960 REALLY EXCITEDDED--SUCCEEDED IN 458 00:17:30,960 --> 00:17:32,480 VACCINE DEVELOPMENT VERY RAPIDLY 459 00:17:32,480 --> 00:17:34,360 FROM THE PRIVATE SECTOR AND 460 00:17:34,360 --> 00:17:35,560 PUBLIC SECTOR HERE IN THE U.S., 461 00:17:35,560 --> 00:17:40,080 BUT MUCH OF THE WORLD HAS GOTTEN 462 00:17:40,080 --> 00:17:40,600 LEFT OUT. 463 00:17:40,600 --> 00:17:42,440 IS THERE ANY THOUGHT TO A 464 00:17:42,440 --> 00:17:46,640 MECHANISM TO, IN THIS NEW EFFORT 465 00:17:46,640 --> 00:17:50,080 TO TRY TO PROSPECTIVELY INVOLVE 466 00:17:50,080 --> 00:17:51,480 LESS DEVELOPED COUNTRIES IN SOME 467 00:17:51,480 --> 00:17:51,680 WAY. 468 00:17:51,680 --> 00:17:54,040 I'M NOT SURE I KNOW HOW TO DO 469 00:17:54,040 --> 00:17:55,320 THAT, ANDLET SECOND THING IS, 470 00:17:55,320 --> 00:17:58,560 ALSO THE PRIVATE SECTOR PLAYED A 471 00:17:58,560 --> 00:18:03,080 BIG ROLE IN COVID. 472 00:18:03,080 --> 00:18:10,480 AND THIS, LOOKS--IS THERE 473 00:18:10,480 --> 00:18:11,000 ANY--IN THE INITIATIVE. 474 00:18:11,000 --> 00:18:14,040 >> SO I THINK I WILL RESPOND TO 475 00:18:14,040 --> 00:18:16,400 THE FIRST INVOLVING LOW AND 476 00:18:16,400 --> 00:18:17,480 MIDDLE INCOME COUNTRIES 477 00:18:17,480 --> 00:18:18,520 INVESTIGATORS IN THIS 478 00:18:18,520 --> 00:18:18,840 INITIATIVE. 479 00:18:18,840 --> 00:18:20,680 I THINK THERE CERTAINLY COULD BE 480 00:18:20,680 --> 00:18:22,440 ROOM FOR THAT, I THINK WE'RE 481 00:18:22,440 --> 00:18:26,200 TALKING ABOUT VIRUSES THAT MIGHT 482 00:18:26,200 --> 00:18:27,520 FIRST ARISE FROM ZOONOTIC 483 00:18:27,520 --> 00:18:30,600 RESERVOIRS THAT ARE OUTSIDE OF 484 00:18:30,600 --> 00:18:34,280 OUR BORDERS THAT ARE EX-U.S. AND 485 00:18:34,280 --> 00:18:35,680 CERTAINLY INVOLVING 486 00:18:35,680 --> 00:18:39,320 INVESTIGATORS OUTSIDE OF THE 487 00:18:39,320 --> 00:18:41,480 U.S. TO SHARE THEIR--WHAT 488 00:18:41,480 --> 00:18:42,880 THEY'VE LEARNED, WHAT THEIR LABS 489 00:18:42,880 --> 00:18:46,920 ARE DOING AND REAGENTS AND 490 00:18:46,920 --> 00:18:48,280 SEQUENCES MIGHT LEAD TO 491 00:18:48,280 --> 00:18:49,520 PRODUCTIVE COLLABORATIONS SO I 492 00:18:49,520 --> 00:18:50,480 THINK THAT'S AN IMPORTANT 493 00:18:50,480 --> 00:18:50,680 COMMENT. 494 00:18:50,680 --> 00:18:51,440 THANK YOU FOR THAT. 495 00:18:51,440 --> 00:18:55,080 YES, AND I THINK THAT ON SECOND 496 00:18:55,080 --> 00:18:57,080 QUESTION WITH REGARD TO THE 497 00:18:57,080 --> 00:18:57,880 INVOLVEMENT OF INDUSTRY, YOU 498 00:18:57,880 --> 00:19:00,320 HAVE FOUND IT VERY USEFUL IN THE 499 00:19:00,320 --> 00:19:03,080 PAST TO INCLUDE AND SOMETIMES IN 500 00:19:03,080 --> 00:19:05,120 WRITING A FUNDING OPPORTUNITY 501 00:19:05,120 --> 00:19:08,320 ANNOUNCEMENT TO MAKE INDUSTRY 502 00:19:08,320 --> 00:19:10,040 COLLABORATION MANDATORY BUT THAT 503 00:19:10,040 --> 00:19:11,760 ISN'T JUST BIG PHARMA. 504 00:19:11,760 --> 00:19:12,920 THAT'S OFTEN SMALL BIOTECH OR 505 00:19:12,920 --> 00:19:14,880 SOME OF THE NONPROFITS THAT HAVE 506 00:19:14,880 --> 00:19:16,200 BEEN SPECIFICALLY FORMED TO, YOU 507 00:19:16,200 --> 00:19:18,480 KNOW TO MOVE PRODUCTS FORWARD. 508 00:19:18,480 --> 00:19:22,880 THAT MIGHT NOT HAVE HAD A STRONG 509 00:19:22,880 --> 00:19:24,040 COMPELLING COMMERCIAL MARKET. 510 00:19:24,040 --> 00:19:26,560 SO, YES, I TAKE YOUR POINT AT 511 00:19:26,560 --> 00:19:29,120 BOTH OF THOSE AND BOTH OF THOSE 512 00:19:29,120 --> 00:19:30,880 COULD BE GETTING INCORPORATED 513 00:19:30,880 --> 00:19:33,040 SOMEHOW SHOULD THIS INITIATIVE 514 00:19:33,040 --> 00:19:35,000 BE SUPPORTED, SHOULD WE EVER GET 515 00:19:35,000 --> 00:19:36,680 AN ALLOCATION OF FUNDS TO 516 00:19:36,680 --> 00:19:37,360 SUPPORT THIS INITIATIVE. 517 00:19:37,360 --> 00:19:43,560 ARE THERE MORE COMMENTS FROM-- 518 00:19:43,560 --> 00:19:44,640 >> YEAH, EMIMPEDIMENTSY, I JUST 519 00:19:44,640 --> 00:19:45,800 HAD A CLARIFICATION, THE FOCUS 520 00:19:45,800 --> 00:19:48,120 OF THAT IS PREPAREDNESS, RIGHT 521 00:19:48,120 --> 00:19:48,640 DISM. 522 00:19:48,640 --> 00:19:48,960 >> CORRECT. 523 00:19:48,960 --> 00:19:52,680 >> AND SO AS YOGI, BEARRA WOULD 524 00:19:52,680 --> 00:19:55,400 SAY IT'S DIFFICULT TO MAKE 525 00:19:55,400 --> 00:19:56,000 PREDICTIONS, ESPECIALLY ABOUT 526 00:19:56,000 --> 00:19:58,480 THE FUTURE AND SO THE 527 00:19:58,480 --> 00:19:59,560 BIODIVERSITY THAT'S OUT THERE 528 00:19:59,560 --> 00:20:02,640 AND THE VARIANT STUFF WILL 529 00:20:02,640 --> 00:20:04,960 INEVITABLY GOING TO HAPPEN AND 530 00:20:04,960 --> 00:20:06,360 THIS MAY RELATE TO HARRY'S 531 00:20:06,360 --> 00:20:07,680 QUESTION, IS THERE A THOUGHT TO 532 00:20:07,680 --> 00:20:10,480 TRY TO LINK THIS TO MAYBE SOME 533 00:20:10,480 --> 00:20:11,720 OF THE EPIDEMIOLOGICAL 534 00:20:11,720 --> 00:20:17,600 CHARACTERIZATIONS THAT MIGHT BE 535 00:20:17,600 --> 00:20:19,840 ONGOING IN OTHER WORDS, GET A 536 00:20:19,840 --> 00:20:23,960 LEG UP ON--I RATHER THAN HAVING 537 00:20:23,960 --> 00:20:24,640 INFRASTRUCTURE AND CAPABILITY 538 00:20:24,640 --> 00:20:25,720 AVAILABLE TO HAVE AS EARLY AS 539 00:20:25,720 --> 00:20:26,560 POSSIBLE KNOWLEDGE ABOUT WHAT 540 00:20:26,560 --> 00:20:30,280 YOU WILL BE DIRECTING YOUR 541 00:20:30,280 --> 00:20:31,040 EFFORTS AGAINST. 542 00:20:31,040 --> 00:20:33,000 I DON'T KNOW IF THAT'S A PART 543 00:20:33,000 --> 00:20:33,960 YOU'RE THINKING ABOUT OR JUST 544 00:20:33,960 --> 00:20:37,880 NOT MAKING THAT PART OF THIS 545 00:20:37,880 --> 00:20:38,200 CONCEPT. 546 00:20:38,200 --> 00:20:40,880 >> YEAH, SO, YOU WOULD THINK 547 00:20:40,880 --> 00:20:44,000 LIKE FORECASTING IS WHAT YOU'RE 548 00:20:44,000 --> 00:20:45,200 SUGGESTING, I THINK? 549 00:20:45,200 --> 00:20:46,600 >> WELL, THAT'S PRETTY DIFFICULT 550 00:20:46,600 --> 00:20:48,120 BUT YOU KNOW YOUR COMMENT ABOUT 551 00:20:48,120 --> 00:20:52,680 FLU FOR EXAMPLE AND YOU KNOW A 552 00:20:52,680 --> 00:20:54,680 LOT OF INFECTIOUS DISEASES WHEN 553 00:20:54,680 --> 00:20:55,880 THERE'S NO CONTROL MEASURES IN 554 00:20:55,880 --> 00:20:57,880 PLACE AND THEN YOU GET THE 555 00:20:57,880 --> 00:20:59,480 REBOUNDS AND SO SOME OF THE 556 00:20:59,480 --> 00:21:03,240 REBOUNDS WE MIGHT BE ABLE TO GET 557 00:21:03,240 --> 00:21:04,640 A LITTLE ADVANCED WARNING IF 558 00:21:04,640 --> 00:21:05,960 YOU'RE PARTNERING PERHAPS WITH 559 00:21:05,960 --> 00:21:06,560 THE EPIDEMIOLOGIST, I THINK 560 00:21:06,560 --> 00:21:10,160 THAT'S WHAT I WANTED TO SAY. 561 00:21:10,160 --> 00:21:12,800 >> YEAH, I THINK--I MEAN WE DO 562 00:21:12,800 --> 00:21:13,480 ENVISION PRIMARILY LABORATORY 563 00:21:13,480 --> 00:21:17,600 BASED RESEARCH ON VIRUSES AND 564 00:21:17,600 --> 00:21:18,880 PRODUCT DEVELOPMENT AS BEING THE 565 00:21:18,880 --> 00:21:23,680 MAIN THRUST OF THESE CENTERS BUT 566 00:21:23,680 --> 00:21:25,400 CERTAINLY, YOU KNOW THE 567 00:21:25,400 --> 00:21:26,480 EPIDEMIOLOGY THIS THESE DAYS AND 568 00:21:26,480 --> 00:21:30,160 HOW VIRUSES ARE EVOLVING ENDS UP 569 00:21:30,160 --> 00:21:31,320 BEING VERY IMPORTANT AND PERHAPS 570 00:21:31,320 --> 00:21:33,240 IN KNOWING WHAT TO TEST NEXT IN 571 00:21:33,240 --> 00:21:34,480 YOUR ANIMAL MODEL FOR EXAMPLE, I 572 00:21:34,480 --> 00:21:36,600 MEAN WE'RE DOING THAT NOW WITH 573 00:21:36,600 --> 00:21:37,960 CORONAVIRUS VALID AND RELIABLE 574 00:21:37,960 --> 00:21:38,160 YABTS. 575 00:21:38,160 --> 00:21:39,960 SO YEAH, THERE MIGHT BE 576 00:21:39,960 --> 00:21:42,920 OPPORTUNITY TO INCORPORATE THAT 577 00:21:42,920 --> 00:21:45,480 INTO THIS INITIATIVE AS WELL. 578 00:21:45,480 --> 00:21:47,720 >> EMILY MAY I MAKE A QUICK 579 00:21:47,720 --> 00:21:47,960 COMMENT? 580 00:21:47,960 --> 00:21:48,840 NYES. 581 00:21:48,840 --> 00:21:52,880 >> SO PART OF THIS 582 00:21:52,880 --> 00:21:55,920 EPIDEMIOLOGICAL WORK IS GOING TO 583 00:21:55,920 --> 00:21:58,280 BE DONE BY THE CREEDS THAT EMILY 584 00:21:58,280 --> 00:21:59,240 SUGGESTED AND WE'RE PLANNING TO 585 00:21:59,240 --> 00:22:01,920 MAKE SURE THAT THE CREEDS ARE IN 586 00:22:01,920 --> 00:22:03,440 VERY CLOSE COLLABORATION AND 587 00:22:03,440 --> 00:22:04,360 INCORPORATION WITH THESE NEW 588 00:22:04,360 --> 00:22:06,160 CENTERS BECAUSE OF COURSE YOU 589 00:22:06,160 --> 00:22:08,520 NEED BOTH ASPECTS, YOU NEED THE 590 00:22:08,520 --> 00:22:09,920 BASIC BIOLOGY AND PROPER 591 00:22:09,920 --> 00:22:11,480 DEVELOPMENT BUT YOU ALSO NEED TO 592 00:22:11,480 --> 00:22:12,960 FIGURE OUT WAYS EMERGING AT THE 593 00:22:12,960 --> 00:22:13,280 SAME TIME. 594 00:22:13,280 --> 00:22:16,800 BUT WE HAVE A--YEAH, SO DECREASE 595 00:22:16,800 --> 00:22:18,280 THE SPECIALIZED IN DOING EXACTLY 596 00:22:18,280 --> 00:22:19,760 THAT. 597 00:22:19,760 --> 00:22:21,440 SO WE HOPE TO PUT THESE GROUPS 598 00:22:21,440 --> 00:22:24,680 TOGETHER, AGAIN IF WE ARE ABLE 599 00:22:24,680 --> 00:22:36,560 TO AWARD THESE CENTERS. 600 00:22:36,560 --> 00:22:38,640 >> OKAY, SO NOW WE DO HAVE 601 00:22:38,640 --> 00:22:40,480 CONTRACTS THAT REALLY DO REQUIRE 602 00:22:40,480 --> 00:22:41,040 VOTING IS,A PROVE WILLA. 603 00:22:41,040 --> 00:22:42,680 CAN YOU MOVE ME TO THE 604 00:22:42,680 --> 00:22:43,440 NEXT--YES. 605 00:22:43,440 --> 00:22:45,920 SO I WILL PRESENT TO YOU 3 606 00:22:45,920 --> 00:22:47,280 PROPOSED TOPICS THAT THE 607 00:22:47,280 --> 00:22:50,680 DIVISION OF MICROBIOLOGY AND 608 00:22:50,680 --> 00:22:57,560 INFECTIOUS DISEASES PUT FORWARD 609 00:22:57,560 --> 00:23:03,040 AND THEN MY COLLEAGUE WILL DRIEB 610 00:23:03,040 --> 00:23:04,320 2 THAT HIS OFFICE PUTTING 611 00:23:04,320 --> 00:23:04,800 FORWARD. 612 00:23:04,800 --> 00:23:13,920 THE FIRST IS ENTITLED ADAPTATION 613 00:23:13,920 --> 00:23:14,720 ADAPTATION 614 00:23:14,720 --> 00:23:16,360 OF CRISPR-BASED INVITRO 615 00:23:16,360 --> 00:23:20,080 DIAGNOSTICS FOR RAPID DETECTION 616 00:23:20,080 --> 00:23:27,560 OF SELECTED UCARIOTIC PATHOGENS. 617 00:23:27,560 --> 00:23:35,800 THIS WOULD BE OVER OTHER 618 00:23:35,800 --> 00:23:38,200 TROPICAL DISEASES, PATHOGENS 619 00:23:38,200 --> 00:23:38,760 THAT THERE'S CURRENTLY 620 00:23:38,760 --> 00:23:41,120 DIFFICULTY OR LACK OF GOOD FIELD 621 00:23:41,120 --> 00:23:42,280 DEPLOYABLE ASSAYS THAT ARE 622 00:23:42,280 --> 00:23:43,680 SENSITIVE AND SPECIFIC. 623 00:23:43,680 --> 00:23:46,840 SO THIS WOULD APPLY TO 624 00:23:46,840 --> 00:23:48,800 CRISPR-CAS TO DEVELOP NEW 625 00:23:48,800 --> 00:23:51,800 ASSAYS. 626 00:23:51,800 --> 00:23:53,680 NEXT SLIDE, PLEASE. 627 00:23:53,680 --> 00:23:56,240 THE SECOND TOPIC IS MODULAR 628 00:23:56,240 --> 00:23:58,080 SAMPLE FOR I INFIELD VIRAL 629 00:23:58,080 --> 00:23:59,640 DISCOVERY, AND THE FOCUS HERE IS 630 00:23:59,640 --> 00:24:00,480 TO IMPROVE SAMPLE PROCESSING IN 631 00:24:00,480 --> 00:24:04,640 THE FIELD FOR SOME OF THESE HIGH 632 00:24:04,640 --> 00:24:06,680 CONSEQUENCE PATHOGENS SUCH AS 633 00:24:06,680 --> 00:24:11,320 FILO, P A RI, AND FLAVI-VIRUSES, 634 00:24:11,320 --> 00:24:13,080 THESE INFIELD SAMPLING PROCESSES 635 00:24:13,080 --> 00:24:17,280 WOULD STABILIZE THE EXTRACTED 636 00:24:17,280 --> 00:24:18,480 SAMPLES FROM ANY--HOPEFULLY ANY 637 00:24:18,480 --> 00:24:19,840 TYPE OF CLINICAL SAMPLE FOR 638 00:24:19,840 --> 00:24:21,080 ALLOW FOR STORAGE AND FIELD 639 00:24:21,080 --> 00:24:22,480 ENVIRONMENTS WHERE THERE MIGHT 640 00:24:22,480 --> 00:24:23,400 NOT BE REFRIGERATION AND THERE 641 00:24:23,400 --> 00:24:26,960 MIGHT NEED TO BE TRANSPORT PRIOR 642 00:24:26,960 --> 00:24:29,720 TO THE DIAGNOSTIC ANALYSIS, 643 00:24:29,720 --> 00:24:31,120 ACTUALLY BEING DONE. 644 00:24:31,120 --> 00:24:32,960 IDEALLY THESE WOULD BE MODULAR 645 00:24:32,960 --> 00:24:39,240 SYSTEMS AND ALLOW FOR HIGH 646 00:24:39,240 --> 00:24:40,280 THROUGH PUT PROCESSING AND AND 647 00:24:40,280 --> 00:24:44,080 WOULD BE ABLE TO IMPLEMENT 648 00:24:44,080 --> 00:24:45,480 PROCESSING FOR THINGS 649 00:24:45,480 --> 00:24:47,440 LABORATORIES WITH LARGE 650 00:24:47,440 --> 00:24:48,480 PROCESSING OR CENTRIFUGES. 651 00:24:48,480 --> 00:24:50,480 SO THAT'S NUMBER 2, AND OUR 652 00:24:50,480 --> 00:24:53,280 THIRD TOPIC IS ENTITLED 653 00:24:53,280 --> 00:24:55,040 ARTIFICIAL INTELLIGENCE TO 654 00:24:55,040 --> 00:24:56,080 IMPROVE CLINICAL MICROSCOPY FOR 655 00:24:56,080 --> 00:24:57,280 THE DIAGNOSIS OF INFECTIOUS 656 00:24:57,280 --> 00:25:01,840 DISEASES AND THIS WOULD CALL FOR 657 00:25:01,840 --> 00:25:05,280 PROPOSALS TO-DISMF AND A LOT OF 658 00:25:05,280 --> 00:25:09,480 THINGS, AFB SMEARS ARE DONE BY 659 00:25:09,480 --> 00:25:11,640 TECHNICIANS SO TRAINING AND 660 00:25:11,640 --> 00:25:13,760 HUMAN FATIGUE, LIMITS SOMETIMES 661 00:25:13,760 --> 00:25:16,480 THE ABILITY TO PERFORM THESE 662 00:25:16,480 --> 00:25:18,200 STUDIES WELL. 663 00:25:18,200 --> 00:25:20,960 BUT WE PROPOSE THAT SCANNING AN 664 00:25:20,960 --> 00:25:24,080 ARTIFICIAL INTELLIGENT SYSTEMS 665 00:25:24,080 --> 00:25:28,000 COULD IMPROVE BOTH SENSITIVITY 666 00:25:28,000 --> 00:25:31,080 AND MAYBE THE SPECIFICITY OF 667 00:25:31,080 --> 00:25:33,520 IDENTIFYING TB AND SPUTUM FOR 668 00:25:33,520 --> 00:25:35,080 EXAMPLE OR MALARIA ON A BLOOD 669 00:25:35,080 --> 00:25:40,080 SMEAR OR SOME SORTS OF OPEN 670 00:25:40,080 --> 00:25:41,040 PARASITES ON STOOL SMEARS. 671 00:25:41,040 --> 00:25:43,120 SO THE PURPOSE OF THIS WOULD BE 672 00:25:43,120 --> 00:25:46,480 TO DEVELOP AI APPLICATIONS TO 673 00:25:46,480 --> 00:25:50,200 IMPROVE CLINICAL MICROSCOPY. 674 00:25:50,200 --> 00:25:50,720 NEXT SLIDE, PLEASE. 675 00:25:50,720 --> 00:25:55,800 SO NOW I'M GOING TO INTRODUCE MY 676 00:25:55,800 --> 00:25:57,480 COLLEAGUE DR. WILBERT VAN P A 677 00:25:57,480 --> 00:26:02,640 NHOUSE, WHO JOINED US AS THIS 678 00:26:02,640 --> 00:26:04,640 LAST YEAR AND HE WILL PRESENT 679 00:26:04,640 --> 00:26:07,960 THE NEXT 2 SBIR CONTRACT TOPICS. 680 00:26:07,960 --> 00:26:11,880 WILBER, ARE YOU HERE? 681 00:26:11,880 --> 00:26:12,480 >> THANKS, EMILY. 682 00:26:12,480 --> 00:26:12,640 YES. 683 00:26:12,640 --> 00:26:16,120 GO TO THE NEXT SLIDE, PLEASE. 684 00:26:16,120 --> 00:26:16,360 YEAH. 685 00:26:16,360 --> 00:26:18,280 SO OUR OFFICE WAS LOOKING AT 686 00:26:18,280 --> 00:26:22,000 TOPICS THAT SPAN THE ENTIRE 687 00:26:22,000 --> 00:26:23,720 NIAID INTEREST AREA AROUND DATA 688 00:26:23,720 --> 00:26:26,320 SCIENCE, SO THESE ARE NOT 689 00:26:26,320 --> 00:26:27,480 DIVISION SPECIFIC BUT WE'RE 690 00:26:27,480 --> 00:26:28,640 GRATEFUL TO EMILY AND FOR THE 691 00:26:28,640 --> 00:26:31,680 COUNCIL HERE TO LOOK AT THEM. 692 00:26:31,680 --> 00:26:33,880 THESE BOTH ARE ABOUT 693 00:26:33,880 --> 00:26:35,760 TECHNOLOGIES AND SOFTWARE FOR 694 00:26:35,760 --> 00:26:36,080 DATA SCIENCE. 695 00:26:36,080 --> 00:26:40,240 THE FIRST 1 IS ABOUT ADVANCE AND 696 00:26:40,240 --> 00:26:41,240 IMMERSIVE VISUALIZATION TOOLS 697 00:26:41,240 --> 00:26:43,680 FOR DISEASE RESEARCH. 698 00:26:43,680 --> 00:26:45,880 THIS ADDRESSES THE AMOUNT AND 699 00:26:45,880 --> 00:26:47,160 COMPLEXITY OF BIOMEDICAL DATA 700 00:26:47,160 --> 00:26:48,040 THAT IS GROWING. 701 00:26:48,040 --> 00:26:50,120 THE INCREASING NEED FOR NEW DATA 702 00:26:50,120 --> 00:26:51,480 VISUALIZATION TOOLS THAT WILL 703 00:26:51,480 --> 00:26:53,280 ENABLE RESEARCHERS TO EXPLORE, 704 00:26:53,280 --> 00:26:55,280 UNDERSTAND AND COMMUNICATION 705 00:26:55,280 --> 00:26:56,440 COMPLEX DATA, ESPECIALLY ACROSS 706 00:26:56,440 --> 00:26:57,720 MULTIPLE SOURCES AND PLATFORMS 707 00:26:57,720 --> 00:27:00,400 AND THE PURPOSE IS TO SUPPORT 708 00:27:00,400 --> 00:27:02,600 DEVELOPMENT, ENHANCEMENT OR 709 00:27:02,600 --> 00:27:05,160 ADAPTATION, OFF VISUALIZATION 710 00:27:05,160 --> 00:27:07,480 TOOLS, SPECIALLY IMMERSIVE 3D 711 00:27:07,480 --> 00:27:09,080 VISUALIZATION TOOLS, COMBINED 712 00:27:09,080 --> 00:27:11,320 WITH MACHINE LEARNING ALGORITHMS 713 00:27:11,320 --> 00:27:13,280 TO ACCELERATE RESEARCH DATA 714 00:27:13,280 --> 00:27:15,560 ANALYSIS ACROSS INFECTIOUS AND 715 00:27:15,560 --> 00:27:17,360 IMMUNE-MEDIATED DISEASES. 716 00:27:17,360 --> 00:27:18,680 THE NEXT SLIDE, PLEASE. 717 00:27:18,680 --> 00:27:21,400 THE SECOND TOPIC IS A BROAD 718 00:27:21,400 --> 00:27:23,080 TOPIC THAT'S A CONTINUATION OF 719 00:27:23,080 --> 00:27:26,640 LAST YEAR AS WELL, THAT INCLUDES 720 00:27:26,640 --> 00:27:29,440 DATA SCIENCE TOOLS FOR INFECT, 721 00:27:29,440 --> 00:27:30,160 MEDIATED DISEASE RESEARCH, 722 00:27:30,160 --> 00:27:33,000 SIGNIFICANCE IS THAT REALLY TO 723 00:27:33,000 --> 00:27:34,160 OPTIMALLY LEVERAGE POTENTIAL 724 00:27:34,160 --> 00:27:35,920 AVAILABLE DATA FOR BIOMEDICAL 725 00:27:35,920 --> 00:27:37,280 RESEARCH AND DISCOVERY, NEW 726 00:27:37,280 --> 00:27:39,560 COMPUTATIONAL TOOLS ARE NEEDED 727 00:27:39,560 --> 00:27:42,520 FOR FINDING DATA, CURATING DATA, 728 00:27:42,520 --> 00:27:43,920 INTEGRATING DATA,ANALIZING 729 00:27:43,920 --> 00:27:46,560 SHARINGING THAT DATA AND THE 730 00:27:46,560 --> 00:27:47,960 PURPOSES IS REALLY ACROSS THE 731 00:27:47,960 --> 00:27:51,000 BOARD TO SUPPORT DEVELOPMENT AND 732 00:27:51,000 --> 00:27:52,440 ENHANCEMENT OF TOOLS, SOFTWARE 733 00:27:52,440 --> 00:27:54,280 WORK FLOWS, DATA MODELS, 734 00:27:54,280 --> 00:27:55,320 DATABASE MODELS, ET CETERA THAT 735 00:27:55,320 --> 00:27:56,880 CAN BE READILY USED BY 736 00:27:56,880 --> 00:27:58,520 RESEARCHERS TO FIND AND USE DATA 737 00:27:58,520 --> 00:27:59,920 MORE EFFECTIVELY FOR THEIR 738 00:27:59,920 --> 00:28:02,120 RESEARCH ON INFECT RELATED 739 00:28:02,120 --> 00:28:02,480 DISEASES. 740 00:28:02,480 --> 00:28:03,760 AND THERE ARE A VARIETY OF 741 00:28:03,760 --> 00:28:06,920 INTEREST AREAS THAT ARE 742 00:28:06,920 --> 00:28:08,560 SPECIFIED IN TOPIC DESCRIPTION 743 00:28:08,560 --> 00:28:09,440 BUT THEY REALLY GO ACROSS ALL 744 00:28:09,440 --> 00:28:11,560 THE WAY TO FINDING AND 745 00:28:11,560 --> 00:28:26,320 DISCOVERING AND USING TO SHARING 746 00:28:26,320 --> 00:28:26,520 DATA. 747 00:28:26,520 --> 00:28:27,760 >> THANK YOU RNLINGS ANY 748 00:28:27,760 --> 00:28:30,960 QUESTIONS FOR THE SWIL 749 00:28:30,960 --> 00:28:31,240 CONTRACTS. 750 00:28:31,240 --> 00:28:34,040 HARRY DO YOU HAVE YOUR HAND 751 00:28:34,040 --> 00:28:34,280 RAISED? 752 00:28:34,280 --> 00:28:36,960 >> YEAH, I KNOW I'M HERE HERE AT 753 00:28:36,960 --> 00:28:40,080 STANFORD AND OTHER INSTITUTIONS, 754 00:28:40,080 --> 00:28:41,520 ESPECIALLY WITH MACHINE 755 00:28:41,520 --> 00:28:44,480 LEARNING, ENHANCED ABILITY TO 756 00:28:44,480 --> 00:28:46,600 MAKE DIAGNOSIS FROM VISUAL DATA 757 00:28:46,600 --> 00:28:49,760 SUCH AS X-RAYS OR SLIDES, THAT 758 00:28:49,760 --> 00:28:54,680 TYPE OF THING, THE KEY TO THOSE 759 00:28:54,680 --> 00:28:55,680 ARE LARGE QUANTITIES OF PAST 760 00:28:55,680 --> 00:28:58,640 MATERIAL THAT HAS BEEN LOOKED AT 761 00:28:58,640 --> 00:28:59,720 BY SO CALLED KNOWLEDGEABLE 762 00:28:59,720 --> 00:29:02,640 PEOPLE THAT YOU CAN USE TO TEACH 763 00:29:02,640 --> 00:29:03,280 THE MACHINE LEARNING. 764 00:29:03,280 --> 00:29:06,560 AND I'M JUST THINK BEING IT FOR 765 00:29:06,560 --> 00:29:08,880 ALL YOUR MICROBIAL DIAGNOSIS, I 766 00:29:08,880 --> 00:29:10,760 DON'T KNOW WHERE THOSE EXIST. 767 00:29:10,760 --> 00:29:12,080 I KNOW MUCH LESS ABOUT THAT BUT 768 00:29:12,080 --> 00:29:13,040 IT WOULD BEIGATE IF YOU WERE 769 00:29:13,040 --> 00:29:14,920 GOING TO DO THESE THINGS TO 770 00:29:14,920 --> 00:29:16,400 BEGIN TO FIND VALIDATED LEARNING 771 00:29:16,400 --> 00:29:19,480 SETS THAT YOU CAN USE FOR REALLY 772 00:29:19,480 --> 00:29:25,360 SMART PEOPLE WHO MAKE THESE 773 00:29:25,360 --> 00:29:26,600 THINGS. 774 00:29:26,600 --> 00:29:29,360 >> YEAH, I AGREE, CAN TAKE--I 775 00:29:29,360 --> 00:29:30,320 HAVE PERSPECTIVE TO IT BUT 776 00:29:30,320 --> 00:29:32,080 THERE'S A LOT OF WORK IN 777 00:29:32,080 --> 00:29:33,160 THINKING ABOUT KNOWLEDGE AND 778 00:29:33,160 --> 00:29:36,080 DATABASES FOR THESE TYPES OF 779 00:29:36,080 --> 00:29:37,080 DATA AND IT'S WELL UNDERSTOOD 780 00:29:37,080 --> 00:29:39,360 THE NEED FOR CASTING AND THE 781 00:29:39,360 --> 00:29:41,680 LACK OF THEM NOW AND HOW TO 782 00:29:41,680 --> 00:29:43,080 SUPPORT THAT IS A BIG QUESTION 783 00:29:43,080 --> 00:29:44,840 BUT THERE ARE DEFINITELY VARIOUS 784 00:29:44,840 --> 00:29:46,600 EFFORTS ONGOING AND WE HAVE SOME 785 00:29:46,600 --> 00:29:48,600 FOLLOW US OUT ON KNOWLEDGE BASED 786 00:29:48,600 --> 00:29:50,680 DATABASE GENERATION AS WELL. 787 00:29:50,680 --> 00:29:52,920 BUT THESE SBIR TOPICS THAT I WAS 788 00:29:52,920 --> 00:29:54,560 TALKING ABOUT ARE MOSTLY 789 00:29:54,560 --> 00:29:55,680 OBVIOUSLY TO BUILD THE TOOLS ON 790 00:29:55,680 --> 00:29:59,280 TOP OF THESE THINGS, BUT 791 00:29:59,280 --> 00:29:59,840 DEFINITELY WORTH--DEFINITELY 792 00:29:59,840 --> 00:30:01,240 RECOGNIZE THE POINT YOU ARE 793 00:30:01,240 --> 00:30:02,400 MAKING. 794 00:30:02,400 --> 00:30:04,280 >> YEAH, I THINK THAT WE'LL SEE 795 00:30:04,280 --> 00:30:06,040 WHAT COMES IN AND WE WILL SEE 796 00:30:06,040 --> 00:30:07,560 WHAT HURDLES THEY FACE IN PEER 797 00:30:07,560 --> 00:30:09,760 REVIEW AND IF WE NEED TO, YOU 798 00:30:09,760 --> 00:30:11,680 KNOW GO BACK BECAUSE 799 00:30:11,680 --> 00:30:13,080 THE--BECAUSE THE DATA FEED IS 800 00:30:13,080 --> 00:30:13,400 INSUFFICIENT. 801 00:30:13,400 --> 00:30:14,480 WE WILL HAVE TO THINK ABOUT HOW 802 00:30:14,480 --> 00:30:19,680 TO ADDRESS THAT PROBLEM. 803 00:30:19,680 --> 00:30:22,680 OKAY, SO I THINK THAT CONCLUDES 804 00:30:22,680 --> 00:30:23,440 THE DIRECTOR'S REMARKS. 805 00:30:23,440 --> 00:30:24,760 REMEMBER THAT WE DO NEED VOTES 806 00:30:24,760 --> 00:30:29,280 AND I THINK THERE'S ALSO A TEXT 807 00:30:29,280 --> 00:30:30,080 FIELD FOR COMMENTS. 808 00:30:30,080 --> 00:30:32,280 WE WILL NEED VOTES ON EACH OF 809 00:30:32,280 --> 00:30:36,000 THESE PROPOSED TOPICS FROM THE 810 00:30:36,000 --> 00:30:38,160 SUBCOUNCIL MEMBERS. 811 00:30:38,160 --> 00:30:42,600 AND OUR NEXT SPEAKER IS DR. LEAH 812 00:30:42,600 --> 00:30:44,480 VINCENT WHO'S PROGRAM STAFF AND 813 00:30:44,480 --> 00:30:46,600 ESTID AND SHE WILL PRESENT TO 814 00:30:46,600 --> 00:30:51,080 YOU A CONCEPT FOR CLEARANCE. 815 00:30:51,080 --> 00:30:51,280 LEAH? 816 00:30:51,280 --> 00:30:52,040 >> THANK YOU. 817 00:30:52,040 --> 00:30:53,080 GOOD AFTERNOON. 818 00:30:53,080 --> 00:30:55,320 I'M DR. LEAH VINCENT, PROGRAM 819 00:30:55,320 --> 00:30:57,080 OFFICER WITHIN THE DIVISION OF 820 00:30:57,080 --> 00:30:58,800 MICROBIOLOGY AND INFECTIOUS 821 00:30:58,800 --> 00:30:59,080 DISEASES. 822 00:30:59,080 --> 00:31:00,400 THANK YOU FOR HAVING ME TODAY TO 823 00:31:00,400 --> 00:31:02,560 SPEAK WITH YOU ABOUT OUR 824 00:31:02,560 --> 00:31:03,400 PROPOSED INITIATIVE, 825 00:31:03,400 --> 00:31:05,240 UNDERSTANDING THE CLINICAL 826 00:31:05,240 --> 00:31:11,040 HISTORY OF BACTERIAL STI TO 827 00:31:11,040 --> 00:31:30,120 ACCELERATE DIAGNOSTIC AND 828 00:31:30,120 --> 00:31:34,120 VACCINE DEVELOPMENT. 829 00:31:34,120 --> 00:31:35,440 THE OBJECTIVE IS TO SUPPORT 830 00:31:35,440 --> 00:31:40,280 STUDIES ON THE CLINICAL STORY OF 831 00:31:40,280 --> 00:31:41,160 SYPHILIS, GONORRHEA, CHLAMYDIA 832 00:31:41,160 --> 00:31:43,200 WITH THE GOAL OF ACCELLING 833 00:31:43,200 --> 00:31:44,600 DIAGNOSTIC AND VACCINE 834 00:31:44,600 --> 00:31:44,880 DEVELOPMENT. 835 00:31:44,880 --> 00:31:48,640 THIS IS A NEW INIAATIVE WITH AN 836 00:31:48,640 --> 00:31:49,960 RO1 MECHANISM, WE ANTICIPATE 3-6 837 00:31:49,960 --> 00:31:52,600 AWARDS AND THE FIRST YEAR TOTAL 838 00:31:52,600 --> 00:32:05,000 COST FOR THE INITIATIVE IS 839 00:32:05,000 --> 00:32:06,120 $3.6 MILLION. 840 00:32:06,120 --> 00:32:09,360 CUC ESTIMATES HAVE SHOWN THAT 841 00:32:09,360 --> 00:32:10,880 STIs ARE SURGED FOR THE FIFTH 842 00:32:10,880 --> 00:32:13,080 STRAIGHT YEAR, NOT ONLY FOR 843 00:32:13,080 --> 00:32:15,480 SYPHILIS BUT ALSO GONORRHEA AND 844 00:32:15,480 --> 00:32:15,760 CHLAMYDIA. 845 00:32:15,760 --> 00:32:19,280 THE W. H. O. STI VACCINE WROTE 846 00:32:19,280 --> 00:32:21,800 THAT PUBLISHED JOINTLY WITH 847 00:32:21,800 --> 00:32:24,360 NIAID IN 2013 ADENTIFIED 848 00:32:24,360 --> 00:32:26,440 VACCINES FOR GONORRHEA SYPHILIS 849 00:32:26,440 --> 00:32:28,080 AND CHLAMYDIA AS CRITICAL TOOLS 850 00:32:28,080 --> 00:32:30,880 FOR RESPONDING TO THE STI 851 00:32:30,880 --> 00:32:31,680 EPIDEMICS. 852 00:32:31,680 --> 00:32:35,680 SINCE 2013 WHEN THE STI ROADMAP 853 00:32:35,680 --> 00:32:36,920 WAS PUBLISHED, NIAID HAS 854 00:32:36,920 --> 00:32:40,080 SUPPORTED 3 WORKSHOPS FOR STI 855 00:32:40,080 --> 00:32:43,600 DEVELOPMENT, FOR GONORRHEA, 856 00:32:43,600 --> 00:32:45,080 CHLAMYDIA, SYPHILIS IN THE 857 00:32:45,080 --> 00:32:47,520 ROADMAP AS WELL AS ALL 4 858 00:32:47,520 --> 00:32:49,120 WORKSHOPS, LACK OF KNOWLEDGE OF 859 00:32:49,120 --> 00:32:51,040 CLINICAL HISTORY OF INFECTION 860 00:32:51,040 --> 00:32:53,080 WAS CITED AS VACCINE DEVELOPMENT 861 00:32:53,080 --> 00:32:54,240 AND BETTER DIAGNOSTICS FOR 862 00:32:54,240 --> 00:32:56,040 CONTROL IN PARTICULAR IN GENERAL 863 00:32:56,040 --> 00:32:57,680 FOR SYPHILIS. 864 00:32:57,680 --> 00:33:00,920 IN 2021, THE NIAID WORKED WITH 865 00:33:00,920 --> 00:33:02,480 OTHER FEDERAL AGENCIES TO 866 00:33:02,480 --> 00:33:03,760 DEVELOP, IS TI NATIONAL STRAY 867 00:33:03,760 --> 00:33:06,560 JECTORY STIGIC PLAN. 868 00:33:06,560 --> 00:33:08,240 THIS PROPOSED INITIATIVE 869 00:33:08,240 --> 00:33:09,840 ADDRESSES THE NATIONAL PLAN TO 870 00:33:09,840 --> 00:33:11,680 ACCELERATE PROGRESS IN STI 871 00:33:11,680 --> 00:33:12,840 RESEARCH AND TECHNOLOGY AND 872 00:33:12,840 --> 00:33:14,280 INFORMATION BY FILLING THE GAP 873 00:33:14,280 --> 00:33:15,000 THAT'S HINDERING VEHICLE SEEN 874 00:33:15,000 --> 00:33:19,840 AND I DID AG NOOF THETIC 875 00:33:19,840 --> 00:33:32,680 DEVELOPMENT. 876 00:33:32,680 --> 00:33:33,440 --DIAGNOSTIC DEVELOPMENT. 877 00:33:33,440 --> 00:33:34,440 THERE WE GO. 878 00:33:34,440 --> 00:33:36,480 IN 2019 WE RELEASED A PROGRAM 879 00:33:36,480 --> 00:33:38,360 ANNOUNCEMENT TO GAUGE INTEREST 880 00:33:38,360 --> 00:33:46,080 AND DETERMINE IF INVESTIGATORS 881 00:33:46,080 --> 00:33:47,480 COULD SUCCESSFULLY WORK. 882 00:33:47,480 --> 00:33:48,440 TWO APPLICATIONS WERE 883 00:33:48,440 --> 00:33:49,920 SUCCESSFULLY FUNDED WHICH IS A 884 00:33:49,920 --> 00:33:51,960 LOWER SUCCESS RATE THAN THE 885 00:33:51,960 --> 00:33:53,120 LOWER OVERALL NIH SUCCESS RATE, 886 00:33:53,120 --> 00:33:54,440 BOTH OF THESE STUDIES IN 887 00:33:54,440 --> 00:33:56,280 SLIGHTLY DIFFERENT WAYS ARE 888 00:33:56,280 --> 00:33:57,400 TAKING ADVANTAGE OF SMALL 889 00:33:57,400 --> 00:34:00,760 WINDOWS BEFORE TREATMENT TO 890 00:34:00,760 --> 00:34:02,880 STUDY SPONTANEOUS CLEARANCE AND 891 00:34:02,880 --> 00:34:04,120 OTHER ASPECTS OF CHLAMYDIA 892 00:34:04,120 --> 00:34:04,920 INFECTION, SO BASED ON THE 893 00:34:04,920 --> 00:34:06,120 INTEREST WE SAW IN THE SUCK SEZ 894 00:34:06,120 --> 00:34:08,040 OF THE PA, THIS INITIATIVE WOULD 895 00:34:08,040 --> 00:34:09,080 CONTINUE TO ADVANCE OUR 896 00:34:09,080 --> 00:34:11,160 KNOWLEDGE WITH THE HISTORY 897 00:34:11,160 --> 00:34:19,320 STUDIES FOR BACTERIAL STIs. 898 00:34:19,320 --> 00:34:20,640 THIS INITIATIVE COULD HELP 899 00:34:20,640 --> 00:34:22,640 BRIDGE THE GAP FOR STIs WHEN 900 00:34:22,640 --> 00:34:24,280 IT COMES TO UNDERSTANDING THE 901 00:34:24,280 --> 00:34:32,680 CLINICAL HISTORY OF DISEASE 902 00:34:32,680 --> 00:34:34,160 AND--CLINICAL STUDIES WERE WELL 903 00:34:34,160 --> 00:34:37,520 DOCUMMED IN THE EXISTING STI 904 00:34:37,520 --> 00:34:38,840 RESEARCH PORTFOLIO, STI RESEARCH 905 00:34:38,840 --> 00:34:40,680 CENTERS ARE FUNDED TO SUPPORT 906 00:34:40,680 --> 00:34:41,840 VACCINE DEVELOPMENT BUT IMPROVED 907 00:34:41,840 --> 00:34:43,320 UNDERSTANDING OF CLINICAL 908 00:34:43,320 --> 00:34:45,280 HISTORY OF BACTERIAL STIs THAT 909 00:34:45,280 --> 00:34:46,120 WILL ONLY COMPLEMENT THIS 910 00:34:46,120 --> 00:34:46,680 EFFORT. 911 00:34:46,680 --> 00:34:48,280 SO A DEDICATED STUDY SECTION 912 00:34:48,280 --> 00:34:50,040 WITH BASIC STI AND EPIDEM 913 00:34:50,040 --> 00:34:51,280 YOJICAL AND CLINICAL EXPERTISE 914 00:34:51,280 --> 00:34:53,640 AND SET ASIDE FUNDING WILL BE 915 00:34:53,640 --> 00:35:00,920 BENEFICIAL FOR THESE 916 00:35:00,920 --> 00:35:01,280 APPLICATIONS. 917 00:35:01,280 --> 00:35:02,560 THE SCOPE OF THE WORK OVERALL 918 00:35:02,560 --> 00:35:04,480 WOULD BE RESEARCH TO HELP 919 00:35:04,480 --> 00:35:06,800 ACCELERATE BETTER DIAGNOSTIC 920 00:35:06,800 --> 00:35:07,480 DEVELOPMENT, ACCELERATE VACCINE 921 00:35:07,480 --> 00:35:09,600 DEVELOPMENT AND RESEARCH TO 922 00:35:09,600 --> 00:35:11,480 UNDERSTAND HUMAN IMMUNE RESPONSE 923 00:35:11,480 --> 00:35:12,480 AFTER INFECTION THROUGH 924 00:35:12,480 --> 00:35:13,600 DIAGNOSIS AND TREATMENT. 925 00:35:13,600 --> 00:35:15,240 EFFORTS COULD INCLUDE THOSE 926 00:35:15,240 --> 00:35:17,720 CERTAINLY NOT LIMITED TO 927 00:35:17,720 --> 00:35:18,920 CLINICAL HISTORY OF GENITAL 928 00:35:18,920 --> 00:35:21,240 INFECTION TO UNDERSTAND THE 929 00:35:21,240 --> 00:35:31,960 BETTER COMPLEXITY OF MAT 930 00:35:31,960 --> 00:35:34,280 TERNAL-FETAL INFECTION, FOR 931 00:35:34,280 --> 00:35:35,680 CHLAMYDIA PERHAPS EXPLORING 932 00:35:35,680 --> 00:35:36,560 PATHOGENESIS AND BIOMARKERS THAT 933 00:35:36,560 --> 00:35:38,880 LED TO LONG-TERM PUBLIC 934 00:35:38,880 --> 00:35:40,240 INFLAMMATORY DISEASE, THESE ARE 935 00:35:40,240 --> 00:35:48,160 NOT AN EXOFF THIVE LIST BUT 936 00:35:48,160 --> 00:35:49,760 RATHER--NOT AN EXHAUSTIVE LIST 937 00:35:49,760 --> 00:35:50,200 BUT RATHER EXAMPLES. 938 00:35:50,200 --> 00:35:51,760 I WOULD LIKE TO THANK THE 2 939 00:35:51,760 --> 00:35:53,440 DOCTORS WHO REVIEWED THIS 940 00:35:53,440 --> 00:35:53,960 CONCEPT WITH ME. 941 00:35:53,960 --> 00:35:56,080 WE TALKED ABOUT A LOT OF THINGS 942 00:35:56,080 --> 00:35:58,360 DURING OUR DISCUSSION BUT THESE 943 00:35:58,360 --> 00:36:00,480 2 PIECES OF FEEDBACK HERE WERE 944 00:36:00,480 --> 00:36:03,680 CRITICAL TO THE APPROVAL OF THE 945 00:36:03,680 --> 00:36:03,920 CONCEPT. 946 00:36:03,920 --> 00:36:06,680 THE DOCTORS WERE PARTICULARLY 947 00:36:06,680 --> 00:36:07,840 HELPFUL FOR PUTTING THIS INTO 948 00:36:07,840 --> 00:36:10,600 THE CONCEPT OF IMMEDIATEERN 949 00:36:10,600 --> 00:36:11,240 TIMES. 950 00:36:11,240 --> 00:36:14,640 WITH WE SPOKE, THE DOCTOR SAID 951 00:36:14,640 --> 00:36:15,800 USING NATURAL HISTORY PUT HER 952 00:36:15,800 --> 00:36:17,480 OFF, WE NEED TO FIGURE OUT 953 00:36:17,480 --> 00:36:18,440 BETTER LANGUAGE. 954 00:36:18,440 --> 00:36:19,880 BOTH SUGGESTED A CHANGE OF TITLE 955 00:36:19,880 --> 00:36:21,680 TO REFLECT THIS WHICH WE CHANGED 956 00:36:21,680 --> 00:36:23,520 FROM NATURAL HISTORY TO CLINICAL 957 00:36:23,520 --> 00:36:23,760 HISTORY. 958 00:36:23,760 --> 00:36:25,680 IT'S ALREADY A CHALLENGE IN 959 00:36:25,680 --> 00:36:27,400 THESE STUDIES FOR BACTERIAL 960 00:36:27,400 --> 00:36:29,360 STIs, WE'VE SEEN MORE NATURAL 961 00:36:29,360 --> 00:36:31,080 HISTORY STUDIES OF SOME VIRAL 962 00:36:31,080 --> 00:36:31,920 INFECTIONS, PARTICULARLY THOSE 963 00:36:31,920 --> 00:36:33,520 FOR WHICH THERE'S NO AVAILABLE 964 00:36:33,520 --> 00:36:34,360 TREATMENT AND THEREFORE PEOPLE 965 00:36:34,360 --> 00:36:35,680 ARE OBSERVED AND FOLLOWED AFTER 966 00:36:35,680 --> 00:36:36,640 INFECTION, HOWEVER IN THE 967 00:36:36,640 --> 00:36:40,000 CONTEXT OF A CURABLE BACTERIAL 968 00:36:40,000 --> 00:36:41,040 INFECTION, NATURAL HISTORY 969 00:36:41,040 --> 00:36:42,280 STUDIES BECOME MUCH MORE 970 00:36:42,280 --> 00:36:43,600 CHALLENGING BECAUSE YOU CAN'T 971 00:36:43,600 --> 00:36:47,120 LEAVE THOSE INFECTIONS 972 00:36:47,120 --> 00:36:47,400 UNTREATED. 973 00:36:47,400 --> 00:36:48,880 FURTHER WHAT MAY COME TO MIND 974 00:36:48,880 --> 00:36:51,360 WHEN PEOPLE THINK OF NATURAL 975 00:36:51,360 --> 00:36:52,480 HISTORY STUDIES OR STIs ARE 976 00:36:52,480 --> 00:36:53,880 STUDIES DONE IN THE PAST THAT 977 00:36:53,880 --> 00:36:54,880 WERE CONTINUED BEYOND THE POINT 978 00:36:54,880 --> 00:36:55,760 WHERE TREATMENT WAS AVAILABLE. 979 00:36:55,760 --> 00:36:57,760 HOWEVER THERE IS A FRAMEWORK 980 00:36:57,760 --> 00:36:59,560 TODAY TO PROPOSE STUDIES THAT 981 00:36:59,560 --> 00:37:00,720 ETHICALLY ADDRESS THESE CRITICAL 982 00:37:00,720 --> 00:37:03,880 RESEARCH QUESTIONS AND GAPS 983 00:37:03,880 --> 00:37:05,080 WHILE PROTECTING FULL 984 00:37:05,080 --> 00:37:06,320 PARTICIPANTS. 985 00:37:06,320 --> 00:37:07,280 SO AFTER LENGTHY DISCUSSION WE 986 00:37:07,280 --> 00:37:11,280 CAME UP WITH THE TERM CLINICAL 987 00:37:11,280 --> 00:37:12,880 VERSUS HISTORICAL HISTORY, 988 00:37:12,880 --> 00:37:13,880 NATURAL HISTORY COVERS 989 00:37:13,880 --> 00:37:16,760 SCREENING, BUT ALSO SCREENING 990 00:37:16,760 --> 00:37:17,360 AND DIAGNOSTIC--DIAGNOSIS 991 00:37:17,360 --> 00:37:18,880 THROUGH TREATMENT AND FOLLOW UP. 992 00:37:18,880 --> 00:37:20,880 THE OBJECTIVE WAS PRESENT A FULL 993 00:37:20,880 --> 00:37:22,080 CLINICAL PICTURE OF WHAT HAPPENS 994 00:37:22,080 --> 00:37:23,160 FOR THESE INFECTIONS IN THE 995 00:37:23,160 --> 00:37:26,080 CONTEXT OF A CURABLE DISEASE 996 00:37:26,080 --> 00:37:27,520 EMPLOY GIVEN THESE CONTEMPORARY 997 00:37:27,520 --> 00:37:29,240 STANDARDS FOR THIS STUDY, THIS 998 00:37:29,240 --> 00:37:30,000 REQUIRES INNOVATIVE APPROACHES 999 00:37:30,000 --> 00:37:31,680 FOR STUDY DESIGN WHICH WE LOOK 1000 00:37:31,680 --> 00:37:33,200 FORWARD TO SEEING IN 1001 00:37:33,200 --> 00:37:33,880 APPLICATIONS ADDRESSING THIS 1002 00:37:33,880 --> 00:37:34,680 SCIENTIFIC GAP. 1003 00:37:34,680 --> 00:37:37,160 ADDITIONALLY IT WAS NOTED THAT A 1004 00:37:37,160 --> 00:37:38,200 DEDICATED CONCEPT WITH A 1005 00:37:38,200 --> 00:37:42,520 SPECIFIC POOL OF VIEWERS, STI 1006 00:37:42,520 --> 00:37:45,880 EXPERTS, EPIDEMIOLOGICAL EXPERTS 1007 00:37:45,880 --> 00:37:46,680 AND PEOPLEATOLOGICAL EXPERTS, 1008 00:37:46,680 --> 00:37:47,920 THE FEEDBACK WAS VERY THOUGHTFUL 1009 00:37:47,920 --> 00:37:48,960 AND HELPFUL IN ADDRESSING THE 1010 00:37:48,960 --> 00:37:51,080 LANGUAGE AND COB SEPTORSS AROUND 1011 00:37:51,080 --> 00:37:52,520 THESE CITIES AND I DO APPRECIATE 1012 00:37:52,520 --> 00:37:53,680 THE INDEPTH CONVERSATIONS I WAS 1013 00:37:53,680 --> 00:38:15,920 ABLE TO HAVE WITH BOTH. 1014 00:38:15,920 --> 00:38:17,480 AND THAT TAKES ME BACK TO THE 1015 00:38:17,480 --> 00:38:18,440 OVERALL OBJECTIVE AND I AM HAPPY 1016 00:38:18,440 --> 00:38:27,480 TO TAKE ANYY REQUESTS AT THIS 1017 00:38:27,480 --> 00:38:27,760 TIME. 1018 00:38:27,760 --> 00:38:34,160 >> DR. TAYLOR, I SEE YOU ON 1019 00:38:34,160 --> 00:38:34,400 MUTE. 1020 00:38:34,400 --> 00:38:36,160 >> WORKING WITH THE LANGUAGE WE 1021 00:38:36,160 --> 00:38:38,400 DID TALK QUITE EXTENSIVELY ABOUT 1022 00:38:38,400 --> 00:38:40,120 THAT BECAUSE PEOPLE WILL SEE 1023 00:38:40,120 --> 00:38:43,480 NATURAL HISTORY AND JUST STOP 1024 00:38:43,480 --> 00:38:43,800 RIGHT THERE. 1025 00:38:43,800 --> 00:38:45,800 AND SO THE EXAMPLES OF PLACES 1026 00:38:45,800 --> 00:38:48,640 THAT HAD NATURAL HISTORY WERE 1027 00:38:48,640 --> 00:38:50,360 NATURAL HISTORY OF CONGENITAL 1028 00:38:50,360 --> 00:38:52,440 SYPHILIS, NATURAL HISTORY OF 1029 00:38:52,440 --> 00:38:56,120 PATHOGENESIS, AND ITEMS THAT 1030 00:38:56,120 --> 00:38:57,960 LEAD TO COMPLICATION SAYS AND 1031 00:38:57,960 --> 00:38:59,680 CELL QUELLA LIKE CHLAMYDIA AND 1032 00:38:59,680 --> 00:39:00,880 GONORRHEA SO IT WAS REALLY GREAT 1033 00:39:00,880 --> 00:39:02,480 TO WORK THROUGH THAT BECAUSE THE 1034 00:39:02,480 --> 00:39:05,000 CONTEXT IN WHICH NATURAL HISTORY 1035 00:39:05,000 --> 00:39:08,040 WAS BEING USED WAS ACTUALLY 1036 00:39:08,040 --> 00:39:09,640 GOOD, OR FINE BUT YOU HAD TO 1037 00:39:09,640 --> 00:39:11,160 REALLY DIG DEEP INTO THE 1038 00:39:11,160 --> 00:39:14,760 EXPLANATION TO FIND OUT WHAT WAS 1039 00:39:14,760 --> 00:39:16,840 MEANT IN THE CONTEMPORARY 1040 00:39:16,840 --> 00:39:18,080 CONTEXT ABOUT NATURAL HISTORY. 1041 00:39:18,080 --> 00:39:20,840 SO I JUST REALLY WANT TO THANK 1042 00:39:20,840 --> 00:39:22,680 LEAH FOR WORKING THAT OUT AND 1043 00:39:22,680 --> 00:39:23,840 FOR BEING FLEXIBLE ENOUGH TO 1044 00:39:23,840 --> 00:39:26,240 CHANGE SOME OF THESE THINGS THAT 1045 00:39:26,240 --> 00:39:27,680 REALLY COULD BE MISCONSTRUED. 1046 00:39:27,680 --> 00:39:30,360 SO THANKS A LOT LEAH. 1047 00:39:30,360 --> 00:39:30,840 >> YEAH. 1048 00:39:30,840 --> 00:39:33,360 >> I ALSO WANT TO THANK LEAH AND 1049 00:39:33,360 --> 00:39:37,280 ALSO STEPHANIE FOR GIVING THAT 1050 00:39:37,280 --> 00:39:39,320 INSIGHTFUL FEEDBACK BUT ALSO I 1051 00:39:39,320 --> 00:39:41,120 WANT TO EMPHASIZE AGAIN THAT 1 1052 00:39:41,120 --> 00:39:42,440 OF THE SUBJECTS OF OUR 1053 00:39:42,440 --> 00:39:44,480 DISCUSSION WAS LIKE, DO WE NEED 1054 00:39:44,480 --> 00:39:46,880 TO MAKE SURE THAT THE STUDY 1055 00:39:46,880 --> 00:39:48,120 SECTIONS COMBINE FOR DIFFERENT 1056 00:39:48,120 --> 00:39:49,720 EXPERTISE NEEDED FOR THIS, I 1057 00:39:49,720 --> 00:39:51,320 THINK THAT MIGHT BE MISS NOTHING 1058 00:39:51,320 --> 00:39:54,800 SOME OF THESE MAYBE, THAT'S WHY 1059 00:39:54,800 --> 00:39:56,240 THERE WERE ONLY 2 PREVIOUSLY 1060 00:39:56,240 --> 00:39:57,200 FUNDED APPLICATIONS JUST TO MAKE 1061 00:39:57,200 --> 00:40:00,280 SURE THAT THERE IS A STRONG 1062 00:40:00,280 --> 00:40:02,240 EPIDEMIOLOGY, CLINICAL AS WELL 1063 00:40:02,240 --> 00:40:04,800 AS THE--YOU KNOW THE BASIC 1064 00:40:04,800 --> 00:40:06,920 SCIENCE, THE VIEWERS BECAUSE I 1065 00:40:06,920 --> 00:40:08,600 THINK THAT COULD HAVE ACTUALLY 1066 00:40:08,600 --> 00:40:16,280 IMPROVED THE SUCCESS OF THESE 1067 00:40:16,280 --> 00:40:18,320 APPLICATIONS. 1068 00:40:18,320 --> 00:40:19,920 YEAH. 1069 00:40:19,920 --> 00:40:20,720 >> THANK YOU. 1070 00:40:20,720 --> 00:40:22,440 >> OKAY, THANKS TO ALL. 1071 00:40:22,440 --> 00:40:25,400 THANK YOU LEAH, AND I THINK WE 1072 00:40:25,400 --> 00:40:28,280 CAN GO ON, IF THERE AREN'T ANY 1073 00:40:28,280 --> 00:40:29,240 FURTHER QUESTIONS OR DISCUSSION 1074 00:40:29,240 --> 00:40:37,080 POINTS WE CAN GO ON TO THE NEXT 1075 00:40:37,080 --> 00:40:40,080 CONCEPT FOR PRESENTATION. 1076 00:40:40,080 --> 00:40:40,680 DR. SAM PERDUE, BACTERIAL 1077 00:40:40,680 --> 00:40:44,680 ONCOLOGY BRANCH WILL TALK ABOUT 1078 00:40:44,680 --> 00:40:47,680 UNDERSTANDING LONG-TERM SEQUEL A 1079 00:40:47,680 --> 00:40:49,040 IN LYME DISEASE. 1080 00:40:49,040 --> 00:40:49,440 >> THANK YOU. 1081 00:40:49,440 --> 00:40:53,480 I WILL CHECK TO SEE IF I HAVE 1082 00:40:53,480 --> 00:40:54,400 CONTROL. 1083 00:40:54,400 --> 00:40:55,120 START MY VIDEO. 1084 00:40:55,120 --> 00:40:59,760 HOST HAS ASKED. 1085 00:40:59,760 --> 00:41:01,680 WELL, I'M HITTING MY ARROW AND-- 1086 00:41:01,680 --> 00:41:03,360 >> PUT IT ON PRESENTATION AGAIN. 1087 00:41:03,360 --> 00:41:04,920 >> CLICK ON THE PRESENTATION 1088 00:41:04,920 --> 00:41:05,120 AGAIN. 1089 00:41:05,120 --> 00:41:07,160 >> THERE WE GO AND I CAN GO BACK 1090 00:41:07,160 --> 00:41:07,480 AND FORWARD. 1091 00:41:07,480 --> 00:41:09,400 THANK YOU VERY MUCH. 1092 00:41:09,400 --> 00:41:10,680 SO GOOD AFTERNOON, EVERYBODY, 1093 00:41:10,680 --> 00:41:13,240 I'M THE PERSON LISTED HERE, I'M 1094 00:41:13,240 --> 00:41:16,640 SAM PERDUE, SECTION CHIEF FOR 1095 00:41:16,640 --> 00:41:18,480 BASIC SCIENCES AND 1096 00:41:18,480 --> 00:41:19,240 BACTERIAEROLOGY IN MY ONCOLOGY 1097 00:41:19,240 --> 00:41:20,680 BRANCH AND THIS AFTERNOON I WILL 1098 00:41:20,680 --> 00:41:24,440 TALK A BIT ABOUT AN ISSUE THAT 1099 00:41:24,440 --> 00:41:26,640 WAS CONTROVERSIAL AND OFTEN 1100 00:41:26,640 --> 00:41:27,160 DOMINATED LYME DISEASE 1101 00:41:27,160 --> 00:41:30,000 DISCUSSION WHEN IS I JOINED 1102 00:41:30,000 --> 00:41:32,080 NIAID MORE THAN 20 YEARS AGO AND 1103 00:41:32,080 --> 00:41:34,280 IT REALLY HASN'T CHANGED MUCH 1104 00:41:34,280 --> 00:41:35,760 HERE IN 2022 AND THAT IS THE 1105 00:41:35,760 --> 00:41:36,880 ISSUE OF PERSISTENT SYMPTOMS 1106 00:41:36,880 --> 00:41:39,200 THAT HAVE BEEN ATTRIBUTED TO 1107 00:41:39,200 --> 00:41:40,480 LYME DISEASE, SOMETIMES WITHIN 1108 00:41:40,480 --> 00:41:43,440 THE MOTIER SPECIFIC PROPOSED 1109 00:41:43,440 --> 00:41:45,320 ETIOLOGIC FRAMEWORK OF CHRONIC 1110 00:41:45,320 --> 00:41:45,680 LIVE DISEASE. 1111 00:41:45,680 --> 00:41:51,880 WHICH PRESUMES THERE IS A 1112 00:41:51,880 --> 00:41:52,840 PERSISTENT POST ANTIBIOTIC 1113 00:41:52,840 --> 00:41:53,400 INFECTION. 1114 00:41:53,400 --> 00:41:55,440 SO THIS IS AN ISSUE WE THOUGHT 1115 00:41:55,440 --> 00:41:57,600 ABOUT A LOT. 1116 00:41:57,600 --> 00:41:58,440 WE'VE CONSIDERED INITIATIVES ON 1117 00:41:58,440 --> 00:42:00,480 THIS MANY TIMES OVER THE YEARS 1118 00:42:00,480 --> 00:42:02,040 AND WE FINALLY DECIDED THAT THIS 1119 00:42:02,040 --> 00:42:03,200 IS SOMETHING THAT'S PROBABLY 1120 00:42:03,200 --> 00:42:05,560 GOING TO REQUIRE A MULTIPRONGED 1121 00:42:05,560 --> 00:42:06,840 APPROACH BUT 1 OF THOSE PRONGS 1122 00:42:06,840 --> 00:42:16,040 WOULD BE A TARGETED RESEARCH. 1123 00:42:16,040 --> 00:42:19,040 THIS WOULD BE UNDERSTANDING THE 1124 00:42:19,040 --> 00:42:20,880 LONG-TERM LINGERING AND SYMPTOMS 1125 00:42:20,880 --> 00:42:23,560 OF WITH ACUTE LYME DISEASE 1126 00:42:23,560 --> 00:42:24,440 DISTION DIAGNOSIS. 1127 00:42:24,440 --> 00:42:26,400 THESE HAVE OFTEN BEEN 1128 00:42:26,400 --> 00:42:29,600 SPECIFICALLY MORE LABELED AS STL 1129 00:42:29,600 --> 00:42:31,240 OR POST TREATMENT LYME DISEASE, 1130 00:42:31,240 --> 00:42:32,280 BUT REGARD WILL OF WHAT YOU CALL 1131 00:42:32,280 --> 00:42:34,640 IT, THAT WILL BE THE NATURE OF 1132 00:42:34,640 --> 00:42:35,680 WHAT I DESCRIBE HERE. 1133 00:42:35,680 --> 00:42:37,720 NOW AS YOU MAY BE AWARE, THERE 1134 00:42:37,720 --> 00:42:40,760 HAVE BEEN ELEVATED 1135 00:42:40,760 --> 00:42:42,280 CONGRESSIONAL, THERE'S BEEN 1136 00:42:42,280 --> 00:42:43,440 ELEVATED CONGRESSIONAL INTEREST 1137 00:42:43,440 --> 00:42:45,480 TO A COMPANY OF A VERY CONSIST 1138 00:42:45,480 --> 00:42:48,120 AND THEN THE PERSISTENT ADVOCACY 1139 00:42:48,120 --> 00:42:50,160 INTEREST IN LYME DISEASE 1140 00:42:50,160 --> 00:42:53,120 SPECIFICALLY AND IN OTHER 1141 00:42:53,120 --> 00:42:53,880 TICK-BORNE DISEASES, AND FOR THE 1142 00:42:53,880 --> 00:42:55,840 SAKE OF TIME I WILL NOT GO 1143 00:42:55,840 --> 00:42:57,400 THROUGH EVERYTHING WE'VE DONE 1144 00:42:57,400 --> 00:42:58,480 BUT SUFFICE IT TO SAY WE 1145 00:42:58,480 --> 00:43:00,880 CONTINUE TO BE AND ARE ACTIVELY 1146 00:43:00,880 --> 00:43:02,440 ENGAGED IN MULTIPLE ACTIVITIES 1147 00:43:02,440 --> 00:43:04,600 ESPECIALLY OVER THE PAST 5 YEARS 1148 00:43:04,600 --> 00:43:05,960 WHETHER THEY BE ADVISORY 1149 00:43:05,960 --> 00:43:06,800 COMMITTEES OR STRATEGIC 1150 00:43:06,800 --> 00:43:08,200 PLANNINGS OR D.O.D. 1151 00:43:08,200 --> 00:43:11,560 COLLABORATIONS OR WORKING GROUPS 1152 00:43:11,560 --> 00:43:13,520 AND MANY OF THOSE IF NOT MOST OF 1153 00:43:13,520 --> 00:43:14,880 THEM HAVE STEMMED FROM THE 2 1154 00:43:14,880 --> 00:43:16,080 PIECES OF LEGISLATION THAT ARE 1155 00:43:16,080 --> 00:43:18,480 LISTED AT THE TOP AND THE BOTTOM 1156 00:43:18,480 --> 00:43:18,840 OF THE SLIDE. 1157 00:43:18,840 --> 00:43:23,480 AND IN EACH OF THOSE THE ISSUE 1158 00:43:23,480 --> 00:43:24,800 WAS ATTRIBUTED TO LYME DISEASE 1159 00:43:24,800 --> 00:43:26,880 AND THEIR TREATMENT HAS 1160 00:43:26,880 --> 00:43:30,600 GENERATED A CONSIDERABLE AMOUNT 1161 00:43:30,600 --> 00:43:31,400 OF ATTENTION. 1162 00:43:31,400 --> 00:43:32,880 SO JUST AS BACKGROUND, I THINK 1163 00:43:32,880 --> 00:43:36,000 MOST OF YOU ARE PROBABLY AWARE 1164 00:43:36,000 --> 00:44:02,240 OF THIS, BUT LYME--IT'S CAUSED 1165 00:44:02,240 --> 00:44:04,000 BY THE BLACK LEGGED TICK SHOWN 1166 00:44:04,000 --> 00:44:05,520 IN THE SLIDES TO THE RIGHT OR 1167 00:44:05,520 --> 00:44:06,720 LEFT WHICH SHOWS WE WERE 1168 00:44:06,720 --> 00:44:07,880 TRANSMITTED BY THE TICK RATHER 1169 00:44:07,880 --> 00:44:09,560 SHOWN ON THE RIGHT OR THE LEFT 1170 00:44:09,560 --> 00:44:14,600 AND CAUSED BY THE BACTERIA 1171 00:44:14,600 --> 00:44:18,280 [INDISCERNIBLE] SO WHEN YOU LOOK 1172 00:44:18,280 --> 00:44:21,440 AT LYME DISEASE THERE ARE SOME 1173 00:44:21,440 --> 00:44:22,760 CLASSIC SYMPTOMS, HEADACHE, 1174 00:44:22,760 --> 00:44:26,240 FATIGUE, FEVER, THE CLASSIC 1175 00:44:26,240 --> 00:44:28,280 RASH, AND THIS DOES NOT ALWAYS 1176 00:44:28,280 --> 00:44:31,360 LOOK LIKE A BULLS EYE, THERE ARE 1177 00:44:31,360 --> 00:44:33,560 KNOWN EXTRA CUTANEOUS EXTRA 1178 00:44:33,560 --> 00:44:37,280 SYMPTOMS THAT ARE--SUCH AS 1179 00:44:37,280 --> 00:44:38,480 CARDITEIS, MENINGITIS, 1180 00:44:38,480 --> 00:44:39,520 NEUROLOGICAL COMPLICATIONS AND 1181 00:44:39,520 --> 00:44:41,120 ARTHRITIS AND ABOUT 10% OF 1182 00:44:41,120 --> 00:44:45,480 PATIENTS WITH LYME ARTHRITIS MAY 1183 00:44:45,480 --> 00:44:47,400 HAVE A PERSISTENT ARTHRITIS 1184 00:44:47,400 --> 00:44:48,920 AFTER TREATMENT THAT IS 1185 00:44:48,920 --> 00:44:50,880 RESPONSIVE TO SOME OF THE 1186 00:44:50,880 --> 00:44:54,240 MEDICATIONS USED FOR AUTOIMMUNE 1187 00:44:54,240 --> 00:44:54,480 ARTHRITIS. 1188 00:44:54,480 --> 00:44:56,000 NOW DEPENDING ON WHEN YOU LOOK 1189 00:44:56,000 --> 00:44:57,080 AT THE LITERATURE, YOU WILL SEE 1190 00:44:57,080 --> 00:44:59,120 THAT APPROXIMATELY, OR IT'S BEEN 1191 00:44:59,120 --> 00:45:00,560 REPORTED THAT APPROXIMATELY 1192 00:45:00,560 --> 00:45:03,760 10-20% OF PEOPLE WITH ACUTE LYME 1193 00:45:03,760 --> 00:45:05,160 DISEASE CONTINUE TO HAVE 1194 00:45:05,160 --> 00:45:07,920 SYMPTOMS AFTER THE STANDARD 1195 00:45:07,920 --> 00:45:09,120 TREATMENT OF DOXYCYCLINE AND 1196 00:45:09,120 --> 00:45:11,360 THAT'S BEEN DETERMINED AS I 1197 00:45:11,360 --> 00:45:15,560 MENTIONED POST TREATMENT LYME 1198 00:45:15,560 --> 00:45:16,280 DISEASE. 1199 00:45:16,280 --> 00:45:18,760 ALSO HAVE WITH COMPLIAICATES 1200 00:45:18,760 --> 00:45:20,280 THINGS A BIT MANY SIGNS AND 1201 00:45:20,280 --> 00:45:22,080 SYMPTOMS THAT AFFECT MULTIPLE 1202 00:45:22,080 --> 00:45:25,400 ORGANS AND SYSTEMS THAT ARE 1203 00:45:25,400 --> 00:45:26,360 POPULARLY ATTRIBUTED TO CHRONIC 1204 00:45:26,360 --> 00:45:28,840 LYME DISEASE, SO THE PURPOSE OF 1205 00:45:28,840 --> 00:45:29,760 THIS INITIATIVE IS TO GET AT 1206 00:45:29,760 --> 00:45:32,480 SOME OF WHAT IS GOING ON HERE. 1207 00:45:32,480 --> 00:45:34,200 SO FOR TREATMENT, YOU HAVE GOT 1208 00:45:34,200 --> 00:45:37,840 MOST CASES RESOLVED WITH ORAL 1209 00:45:37,840 --> 00:45:41,240 DOXYCYCLINE OR WITH IV 1210 00:45:41,240 --> 00:45:42,360 SETRIPSYCHE LYNN WHEN IT IS 1211 00:45:42,360 --> 00:45:43,760 INDICATED AND 1 THING THAT HAS 1212 00:45:43,760 --> 00:45:45,120 BEEN CENTRAL TO ALL OF THIS 1213 00:45:45,120 --> 00:45:47,880 BECAUSE WITH WITHIN THE CHRONIC 1214 00:45:47,880 --> 00:45:49,400 LYME DISEASE ARGUMENT I'VE 1215 00:45:49,400 --> 00:45:50,120 MENTIONED, THERE'S BEEN 1216 00:45:50,120 --> 00:45:53,440 DISCUSSION THAT PATIENTS PEDE 1217 00:45:53,440 --> 00:45:55,000 EXTENDED LONG-TERM INTRAVENOUS 1218 00:45:55,000 --> 00:45:56,880 ANTIBI POTTICS, THERE ARE 5 1219 00:45:56,880 --> 00:45:58,400 CLINICAL TRIALS, SOME BY NIH, 1220 00:45:58,400 --> 00:46:01,000 SOME IN EUROPE THAT HAVE 1221 00:46:01,000 --> 00:46:02,640 DEMONSTRATED THAT LONG-TERM 1222 00:46:02,640 --> 00:46:03,800 INTRAVENOUS ANTIBIOTICS DO NOT 1223 00:46:03,800 --> 00:46:05,480 IMPROVE OUTCOMES AND IF THERE'S 1224 00:46:05,480 --> 00:46:07,880 BEEN A TRANSIENT IMPROVEMENT, IT 1225 00:46:07,880 --> 00:46:10,080 IS OUTWEIGHED BY THE LEVEL OF 1226 00:46:10,080 --> 00:46:10,280 RISK. 1227 00:46:10,280 --> 00:46:11,160 I SHOULD ALSO POINT OUT THAT 1228 00:46:11,160 --> 00:46:15,120 HOWEVER, WHEN YOU LOOK AT 1229 00:46:15,120 --> 00:46:16,440 PARTICULARLY THE [INDISCERNIBLE] 1230 00:46:16,440 --> 00:46:18,480 PAPER, THE FIRST STUDY THAT WAS 1231 00:46:18,480 --> 00:46:20,080 DONE, AND THEY RECRUITED 1232 00:46:20,080 --> 00:46:21,200 PATIENTS WHO HAD DISABILITY 1233 00:46:21,200 --> 00:46:23,880 AFTER A CLEAR UNEQUIVOCAL LYME 1234 00:46:23,880 --> 00:46:26,360 DISEASE DIAGNOSIS, THEY HAD 1235 00:46:26,360 --> 00:46:27,320 SUBSTANTIAL LEVELS OF 1236 00:46:27,320 --> 00:46:27,640 DISABILITY. 1237 00:46:27,640 --> 00:46:30,680 SO THIS IS NOT AN IMAGINARY 1238 00:46:30,680 --> 00:46:33,080 THING, PEOPLE ARE TRULY SICK AND 1239 00:46:33,080 --> 00:46:34,600 TRULY, TRULY ILIN SOME CASES 1240 00:46:34,600 --> 00:46:38,800 AFTER HAVING AN INITIAL DOSE OF 1241 00:46:38,800 --> 00:46:39,680 LYME DISEASE FOR PRIMARY 1242 00:46:39,680 --> 00:46:39,960 TREATMENT. 1243 00:46:39,960 --> 00:46:41,880 SO WHAT WE HAVE IS THIS KIND 1244 00:46:41,880 --> 00:46:43,080 OF--THIS IS THE SITUATION WHERE 1245 00:46:43,080 --> 00:46:43,760 WE ARE TODAY. 1246 00:46:43,760 --> 00:46:47,520 WE HAVE PEOPLE WITH KNOWN 1247 00:46:47,520 --> 00:46:48,400 UNEQUIVOCAL LYME DISEASE. 1248 00:46:48,400 --> 00:46:50,240 THEY'RE TREATED, MOST DO OKAY, 1249 00:46:50,240 --> 00:46:52,000 BUT SOME HAVE PERSISTENT 1250 00:46:52,000 --> 00:46:52,280 SYMPTOMS. 1251 00:46:52,280 --> 00:46:54,960 YOU ALSO HAVE ANOTHER GROUP THAT 1252 00:46:54,960 --> 00:46:57,080 HAS UNKNOWN SYMPTOMS, THEY MAY 1253 00:46:57,080 --> 00:47:01,600 NOT MEET THE KIND OF STANDARD 3 1254 00:47:01,600 --> 00:47:03,440 TEAR CRITERIA FOR LYME DISEASE 1255 00:47:03,440 --> 00:47:06,280 OR THE EM RASH BUT NEVERTHELESS 1256 00:47:06,280 --> 00:47:09,080 VISIT BEEN DIAGNOSED AS LYME 1257 00:47:09,080 --> 00:47:10,120 DISEASE JUST THROUGH PHYSICIAN 1258 00:47:10,120 --> 00:47:12,440 ASSESSMENT OR WHO HAVE 1259 00:47:12,440 --> 00:47:15,480 SELF-DIAGNOSED IN LYME DISEASE 1260 00:47:15,480 --> 00:47:20,920 IN SOME CASES AND THEY HAD THIS 1261 00:47:20,920 --> 00:47:22,360 COLLECTION OF PERSISTENT 1262 00:47:22,360 --> 00:47:24,480 SYMPTOMS WHICH IS CALLED 1263 00:47:24,480 --> 00:47:26,920 LONG-TERM LYME DISEASE WHICH 1264 00:47:26,920 --> 00:47:28,840 NEEDS EABT BIOTICSS, AND IF YOU 1265 00:47:28,840 --> 00:47:30,120 DON'T SUPPORT LONG-TERM 1266 00:47:30,120 --> 00:47:30,800 ANTIBIOTICS THEN THEREFORE THAT 1267 00:47:30,800 --> 00:47:37,480 YOU ARE NOT SUPPORTIVE OF 1268 00:47:37,480 --> 00:47:38,680 PERSISTENT SYMPTOMS OF LYME 1269 00:47:38,680 --> 00:47:38,920 DISEASE. 1270 00:47:38,920 --> 00:47:40,560 AND SO WE WERE GOING TO TACKLE 1271 00:47:40,560 --> 00:47:42,280 THIS AND 1 WAY IS THROUGH THIS 1272 00:47:42,280 --> 00:47:44,360 INITIATIVE AND LOOK AT PEOPLE 1273 00:47:44,360 --> 00:47:45,160 WITH PERSISTENT SYMPTOMS THAT 1274 00:47:45,160 --> 00:47:47,480 ARE KNOWN TO BE TEMPORARILY 1275 00:47:47,480 --> 00:47:49,480 ASSOCIATE WIDE AN KRARKS CUTE 1276 00:47:49,480 --> 00:47:51,280 LYME DISEASE DIAGNOSIS AND POST 1277 00:47:51,280 --> 00:47:52,960 TREATMENT LYME DISEASE SYNDROME. 1278 00:47:52,960 --> 00:47:55,880 AND THEN DETERMINE WHAT IS 1279 00:47:55,880 --> 00:47:56,880 CAUSING THAT AND FROM THAT 1280 00:47:56,880 --> 00:47:58,240 DETERMINE WHAT THE MOST 1281 00:47:58,240 --> 00:47:59,400 EFFECTIVE APPROACH TO DIAGNOSIS 1282 00:47:59,400 --> 00:47:59,920 AND TREATMENT ARE. 1283 00:47:59,920 --> 00:48:03,640 WE ARE NOT IN ANY WAY DISMISSING 1284 00:48:03,640 --> 00:48:05,160 LONG-TERM ANTIBIOTICS IN SOME 1285 00:48:05,160 --> 00:48:06,840 CASES THAT IS THE MOST EFFECTIVE 1286 00:48:06,840 --> 00:48:07,680 DIAGNOSIS AND TREATMENT BUT WE 1287 00:48:07,680 --> 00:48:10,160 WANT TO SEE WHAT IS GOING ON. 1288 00:48:10,160 --> 00:48:14,720 IS IT 1 THING, MULTIPLE THINGS, 1289 00:48:14,720 --> 00:48:15,000 SO FORTH. 1290 00:48:15,000 --> 00:48:17,880 SO IF YOU LOOK AT OUR CURRENT 1291 00:48:17,880 --> 00:48:18,960 PORTFOLIO, WE DO NOT HAVE A LOT 1292 00:48:18,960 --> 00:48:22,080 IN THE ISSUE OF PERSISTENCE OR 1293 00:48:22,080 --> 00:48:22,520 PERSISTENT SYMPTOMS. 1294 00:48:22,520 --> 00:48:25,360 WE HAVE A FAIR AMOUNT IN LYME 1295 00:48:25,360 --> 00:48:25,640 ARTHRITIS. 1296 00:48:25,640 --> 00:48:28,520 IF YOU LOOK AT THE LYME 1297 00:48:28,520 --> 00:48:29,640 COMMUNITY, THEY SEE LYME 1298 00:48:29,640 --> 00:48:30,840 ARTHRITIS AS A SEPARATE THING, 1299 00:48:30,840 --> 00:48:33,240 MOST OF THEM ARE SUFFERING FROM, 1300 00:48:33,240 --> 00:48:34,880 AND THEY'RE REALLY INTERESTED, 1301 00:48:34,880 --> 00:48:36,760 AND THIS GOES TO CONGRESS AS 1302 00:48:36,760 --> 00:48:41,800 WELL, REALLY INTERESTED MORE IN 1303 00:48:41,800 --> 00:48:49,080 THE GENERAL CAUSES OF-- SYMPTOMS 1304 00:48:49,080 --> 00:48:49,480 FOR LYME DISEASE. 1305 00:48:49,480 --> 00:48:52,400 WE DIDN'T WANT TO DISMISS LYME 1306 00:48:52,400 --> 00:48:53,760 ARTHRITIS AND I PERSONALLY 1307 00:48:53,760 --> 00:48:55,320 BELIEVE THERE MAY BE THINGS WE 1308 00:48:55,320 --> 00:48:57,480 CAN LEARN WITH LYME ARTHRITIS TO 1309 00:48:57,480 --> 00:48:58,960 OTHER CONDITIONS, OTHER SIGNS 1310 00:48:58,960 --> 00:49:00,480 AND SYMPTOMS BUT WITHIN THE 1311 00:49:00,480 --> 00:49:01,840 FRAMEWORK OF WHY WE CAN'T 1312 00:49:01,840 --> 00:49:03,920 ADDRESS IT WITHIN OUR CURRENT 1313 00:49:03,920 --> 00:49:05,320 INIAATIVES OR CURRENT 1314 00:49:05,320 --> 00:49:08,000 ACTIVITIES, WE DON'T GET A 1315 00:49:08,000 --> 00:49:09,040 TREMENDOUS AMOUNT ON THIS AND 1316 00:49:09,040 --> 00:49:11,480 WHEN IT DOES GET TO PEER REVIEW, 1317 00:49:11,480 --> 00:49:12,320 IT DOES NOT DO PARTICULARLY 1318 00:49:12,320 --> 00:49:14,720 WELL, SO WE HAVE A RELATIVELY 1319 00:49:14,720 --> 00:49:15,120 SMALL PORTFOLIO. 1320 00:49:15,120 --> 00:49:20,000 SO WHEN YOU LOOK AT THESE 1321 00:49:20,000 --> 00:49:20,680 PERSISTENT SYMPTOMS ATTRIBUTED 1322 00:49:20,680 --> 00:49:21,840 TO LYME DISEASE AND I'LL TAKE A 1323 00:49:21,840 --> 00:49:23,560 STEP BACK AND LOOK AT THIS 1324 00:49:23,560 --> 00:49:23,800 TITLE. 1325 00:49:23,800 --> 00:49:25,000 WE'VE GONE BACK AND FORTH WITH 1326 00:49:25,000 --> 00:49:26,640 THE TITLE A BIT AND THIS IS SORT 1327 00:49:26,640 --> 00:49:28,040 OF THE TITLE WE'RE SIT NOTHING 1328 00:49:28,040 --> 00:49:29,560 RIGHT NOW AND LINDA MIGHT 1329 00:49:29,560 --> 00:49:30,760 ADDRESS THIS TOO, BUT LINDA AND 1330 00:49:30,760 --> 00:49:32,920 I TALKED ABOUT THIS AS WELL, YOU 1331 00:49:32,920 --> 00:49:34,680 COULD HAVE A PERSISTENT OR 1332 00:49:34,680 --> 00:49:35,880 CHRONIC INFECTION, PEAR HAPPENS 1333 00:49:35,880 --> 00:49:38,880 IN SOME CASES IT'S NOT A CLEAR, 1334 00:49:38,880 --> 00:49:41,280 NOT PERHAPS IT'S A CO-INFECTION 1335 00:49:41,280 --> 00:49:43,840 ISSUE, WHICH IS A POPULAR 1336 00:49:43,840 --> 00:49:46,000 PROPOSAL FOR WHAT IS CAUSING 1337 00:49:46,000 --> 00:49:46,840 CHRONIC ILLNESS, THERE ARE 1338 00:49:46,840 --> 00:49:48,600 PEOPLE THAT LOOKEDDA THE 1339 00:49:48,600 --> 00:49:49,680 AUTOIMMUNE RESPONSE, WE ARE 1340 00:49:49,680 --> 00:49:51,480 PEOPLE LOOKING AT INFLAMMATORY 1341 00:49:51,480 --> 00:49:54,280 RESPONSES, IT IS PROPOSED, IT IS 1342 00:49:54,280 --> 00:49:57,360 MORE OF A GENERAL POST INFECTION 1343 00:49:57,360 --> 00:49:59,080 SYNDROME, PERHAPS WE CAN LEARN 1344 00:49:59,080 --> 00:50:00,280 SOMETHING FROM COVID LONG 1345 00:50:00,280 --> 00:50:01,600 HAULERS IN THIS CASE, THAT IS 1346 00:50:01,600 --> 00:50:03,680 NOT SPECIFIC TO LYME BUT IT IS 1347 00:50:03,680 --> 00:50:06,160 VERY REAL IN TERMS OF RECOVERING 1348 00:50:06,160 --> 00:50:07,240 IN CERTAIN INFECTIONS TCAN BE 1349 00:50:07,240 --> 00:50:08,200 OTHER DISEASES AND THEN THE 1350 00:50:08,200 --> 00:50:09,600 FRAME, WITHIN ALL OF THESE 1351 00:50:09,600 --> 00:50:11,160 FRAMEWORKS THERE COULD BE 1352 00:50:11,160 --> 00:50:12,480 GENETIC DETERMINANTS TO THESE, 1353 00:50:12,480 --> 00:50:13,480 THERE COULD BE MICROBIOME 1354 00:50:13,480 --> 00:50:14,360 EFFECTS AND SO FORTH. 1355 00:50:14,360 --> 00:50:21,840 THAT WE WOULD NEED TO LOOK AT. 1356 00:50:21,840 --> 00:50:24,280 AND SO IN 2021 WE HAD A 1357 00:50:24,280 --> 00:50:28,920 WORKSHOP, AN INTERNAL WORKSHOP 1358 00:50:28,920 --> 00:50:29,880 WITH OUTSIDE INVESTIGATORS AND 1359 00:50:29,880 --> 00:50:31,760 INSIDE FOLKS WHO HAD DIFFERENT 1360 00:50:31,760 --> 00:50:33,760 PERSPECTIVES ON WHAT IS CAUSING 1361 00:50:33,760 --> 00:50:34,880 THIS FROM--THERE WERE SOME WHO 1362 00:50:34,880 --> 00:50:37,280 BELIEVED VERY MUCH IN PERSISTENT 1363 00:50:37,280 --> 00:50:39,000 INFECTION, SOME WHO DID NOT 1364 00:50:39,000 --> 00:50:40,000 BELIEVE IN PERSISTENT INFECTION, 1365 00:50:40,000 --> 00:50:41,720 AND ALL THE BUTLES TO THE LEFT 1366 00:50:41,720 --> 00:50:43,680 TO GET A HANDLE ON WHAT WAS 1367 00:50:43,680 --> 00:50:45,760 GOING ON AND THEN WE DECIDED TO 1368 00:50:45,760 --> 00:50:52,280 FOLLOW THAT UP WITH AN ACTUAL 1369 00:50:52,280 --> 00:50:52,800 RESEARCH INITIATIVE. 1370 00:50:52,800 --> 00:50:54,120 SO THE SCOPE OF SUPPORT FOR THIS 1371 00:50:54,120 --> 00:50:56,120 WILL BE RESEARCH ON MECHANISMS 1372 00:50:56,120 --> 00:50:58,720 OF PERSISTENT SIGNS AND SYMPTOMS 1373 00:50:58,720 --> 00:51:05,560 FOLLOWED BY--OR FOLLOWING A 1374 00:51:05,560 --> 00:51:06,880 DEFINED B.BURGDORFERI INFECTION, 1375 00:51:06,880 --> 00:51:11,040 IT WILL ALSO INCLUDE IDENTIFYING 1376 00:51:11,040 --> 00:51:15,960 MARKERS PREDISPOSING INDIVIDUALS 1377 00:51:15,960 --> 00:51:19,120 TO PERSISTENT SYMPTOMS WILL 1378 00:51:19,120 --> 00:51:19,760 FOLLOWING TREATMENT, THAT DOES 1379 00:51:19,760 --> 00:51:21,000 NOT MEAN THAT PEOPLE HAD A 1380 00:51:21,000 --> 00:51:22,200 PARTICULAR MECHANISM AND THEY 1381 00:51:22,200 --> 00:51:24,240 HAD A DRUG OR SMALL MOLECULE 1382 00:51:24,240 --> 00:51:25,400 THAT BLOCKS THAT, THAT THEY 1383 00:51:25,400 --> 00:51:27,080 CAN'T USE THAT TO SUPPORT THEIR 1384 00:51:27,080 --> 00:51:28,280 HYPOTHESIS, BUT IT'S 1385 00:51:28,280 --> 00:51:29,280 NONAPOPTOTIC A PROPOSAL TO 1386 00:51:29,280 --> 00:51:30,680 DEVELOP NEW DRUGS FOR TREATING 1387 00:51:30,680 --> 00:51:34,080 LYME DISEASE AT THIS STAGE. 1388 00:51:34,080 --> 00:51:37,600 AND WILL NOT SRMT AT THIS STAGE 1389 00:51:37,600 --> 00:51:42,440 CLINICAL TRIALS. 1390 00:51:42,440 --> 00:51:44,920 SO DR. STEWARD AND 1391 00:51:44,920 --> 00:51:45,600 DR. [INDISCERNIBLE] WERE MEMBERS 1392 00:51:45,600 --> 00:51:47,040 AND IT WAS INTERESTING TO TALK 1393 00:51:47,040 --> 00:51:50,280 TO THEM BECAUSE THEY GOT AT IT 1394 00:51:50,280 --> 00:51:51,080 FROM DIFFERENT PERSPECTIVES. 1395 00:51:51,080 --> 00:51:53,720 DR. STEWART HAD THE GLOBAL 1396 00:51:53,720 --> 00:51:56,400 PERSPECTIVE AND DR. BACKSTED HAD 1397 00:51:56,400 --> 00:51:57,560 THE PERSPECTIVE OF WORKING IN 1398 00:51:57,560 --> 00:51:59,320 THE LYME DEC COMMUNITY SO IT WAS 1399 00:51:59,320 --> 00:52:01,160 INTERESTING AND VALUABLE TO GET 1400 00:52:01,160 --> 00:52:03,600 BOTH PERSPECTIVES ON THIS. 1401 00:52:03,600 --> 00:52:05,240 THERE WAS OVERALL SUPPORT OF THE 1402 00:52:05,240 --> 00:52:07,200 OVERALL ARCHING NEED AND GOAL. 1403 00:52:07,200 --> 00:52:09,640 THERE WAS A VIEW OF POTENTIAL 1404 00:52:09,640 --> 00:52:11,960 APPLICABILITY TO OTHER 1405 00:52:11,960 --> 00:52:12,680 INFECTIOUS DISEASES, CERTAINLY 1406 00:52:12,680 --> 00:52:14,200 BOTH OF THEM MENTIONED WHAT 1407 00:52:14,200 --> 00:52:15,920 WE'RE LEARNING FROM COVID LAWNG 1408 00:52:15,920 --> 00:52:18,800 HAULERS MAY COME INTO PLAY. 1409 00:52:18,800 --> 00:52:20,520 DID HAVE A DISCUSSION ABOUT I 1410 00:52:20,520 --> 00:52:23,560 THINK MOST PARTICULARLY WITH 1411 00:52:23,560 --> 00:52:25,080 LINDA ABOUT UTILIZING HUMAN 1412 00:52:25,080 --> 00:52:27,400 CLINICAL SAMPLES VERSUS ANIMAL 1413 00:52:27,400 --> 00:52:28,240 SAMPLES WHEN POSSIBLE. 1414 00:52:28,240 --> 00:52:30,120 AND TO EXPAND ON THAT, 1 OF MY 1415 00:52:30,120 --> 00:52:32,200 CONCERNS IS THAT RESEARCH 1416 00:52:32,200 --> 00:52:33,080 INVESTIGATORS ARE INCREDIBLY 1417 00:52:33,080 --> 00:52:34,520 GOOD AT STATING THEIR RESEARCH 1418 00:52:34,520 --> 00:52:36,240 IS RELEVANT TO A SPECIFIC RFA, 1419 00:52:36,240 --> 00:52:39,560 AND WHAT WE WANT TO MAKE SURE IS 1420 00:52:39,560 --> 00:52:40,400 THAT WE'RE GETTING PROPOSALS 1421 00:52:40,400 --> 00:52:42,840 WHERE PEOPLE ARE CLEARLY LOOKING 1422 00:52:42,840 --> 00:52:45,560 AT SOMETHING THAT IS A KNOWN 1423 00:52:45,560 --> 00:52:47,560 PERSISTENT SYMPTOM AND THEY WORK 1424 00:52:47,560 --> 00:52:49,400 BACKWARDS FROM THERE, RATHER 1425 00:52:49,400 --> 00:52:50,080 THAN STARTING WITH WHATEVER 1426 00:52:50,080 --> 00:52:51,320 THEY'RE WORKING FOR AND SAYING, 1427 00:52:51,320 --> 00:52:54,560 WELL, THIS MIGHT BE RELEVANT TO 1428 00:52:54,560 --> 00:52:56,320 PERSISTENT SYMPTOMS, SO WE WANT 1429 00:52:56,320 --> 00:52:57,400 TO USE HUMAN CLINICAL SAMPLE 1430 00:52:57,400 --> 00:52:59,840 WHEN IS WE CAN BUT THAT'S NOT 1431 00:52:59,840 --> 00:53:01,520 GOING TO OBVIOUSLY DISMISS 1432 00:53:01,520 --> 00:53:03,080 ANIMAL MODELS BUT WE WANT TO 1433 00:53:03,080 --> 00:53:04,720 MAKE SURE THESE PROPOSALS ARE 1434 00:53:04,720 --> 00:53:07,360 TIED VERY CLEARLY TO PERSISTENT 1435 00:53:07,360 --> 00:53:07,640 SYMPTOMS. 1436 00:53:07,640 --> 00:53:08,920 AND ALSO THERE WAS DISCUSSION OF 1437 00:53:08,920 --> 00:53:11,560 WHAT'S GOING ON WITH THE 1438 00:53:11,560 --> 00:53:12,200 MICROBIOME EFFECT WHETHER IT'S 1439 00:53:12,200 --> 00:53:13,880 GENERAL OR IN RESPONSE TO 1440 00:53:13,880 --> 00:53:14,600 ANTIBIOTIC THERAPY FOR EXAMPLE, 1441 00:53:14,600 --> 00:53:17,280 THAT COULD BE LEADING TO THESE 1442 00:53:17,280 --> 00:53:17,520 SYMPTOMS. 1443 00:53:17,520 --> 00:53:19,280 AND THERE WERE OTHER THINGS THAT 1444 00:53:19,280 --> 00:53:21,280 WE TALKED ABOUT, MANY OF THEM 1445 00:53:21,280 --> 00:53:21,880 HAVE BEEN INCORPORATED WITHIN 1446 00:53:21,880 --> 00:53:23,200 THE SLIDES THAT I SHOWED YOU. 1447 00:53:23,200 --> 00:53:26,040 SO AGAIN, HERE IS THE CONCEPT. 1448 00:53:26,040 --> 00:53:30,000 WE ARE GOING TO SUPPORT RESEARCH 1449 00:53:30,000 --> 00:53:32,240 AND PATHOGENESIS PERSISTENT 1450 00:53:32,240 --> 00:53:33,080 SYMPTOMS ATTRIBUTED TO LYME 1451 00:53:33,080 --> 00:53:34,160 DISEASE AND MARKERS PREDICTING 1452 00:53:34,160 --> 00:53:35,960 DEVELOPMENT AND IF YOU HAVE ANY 1453 00:53:35,960 --> 00:53:40,360 QUESTIONS I AM HAPPY TO ANSWER 1454 00:53:40,360 --> 00:53:40,680 IT. 1455 00:53:40,680 --> 00:53:45,080 >> I SEE HARRY HAS HIS HAND 1456 00:53:45,080 --> 00:53:45,640 RAISED. 1457 00:53:45,640 --> 00:53:59,640 >> JUST OUT OF CURIOSITY BEFORE. 1458 00:53:59,640 --> 00:54:01,400 >> WE WOULD PROBABLY FIND IT AS 1459 00:54:01,400 --> 00:54:02,800 DOCUMENTED SERIES POINTSOLOGY OR 1460 00:54:02,800 --> 00:54:03,880 EM RASH, BECAUSE WE WANT TO MAKE 1461 00:54:03,880 --> 00:54:06,960 SURE WE HAVE A CLEAR UNEQUIVOCAL 1462 00:54:06,960 --> 00:54:07,240 DIAGNOSIS. 1463 00:54:07,240 --> 00:54:10,200 >> AND JUST OUT OF CURIOSITY, 1464 00:54:10,200 --> 00:54:12,720 WITH THAT DEFINITION, WHAT 1465 00:54:12,720 --> 00:54:15,480 PROPORTION OF DOCUMENTED LYME 1466 00:54:15,480 --> 00:54:21,240 INFECTIONS DO YOU THINK HAVE 1467 00:54:21,240 --> 00:54:24,200 LONG-TERM SEQUELACE? 1468 00:54:24,200 --> 00:54:27,280 >> IT'S GENERALLY REPORTED AS 1469 00:54:27,280 --> 00:54:29,520 10-20%. 1470 00:54:29,520 --> 00:54:30,160 >> THAT'S TREATED 10-20%. 1471 00:54:30,160 --> 00:54:33,000 >> OBVIOUSLY IF YOU'RE NOT 1472 00:54:33,000 --> 00:54:34,280 TREATED, THERE ARE PROBLEMS BUT 1473 00:54:34,280 --> 00:54:35,280 THAT'S A DIFFERENT QUESTION 1474 00:54:35,280 --> 00:54:35,480 THERE. 1475 00:54:35,480 --> 00:54:40,480 >> DO WE HAVE ANY OTHER COMMENTS 1476 00:54:40,480 --> 00:54:42,960 OR QUESTIONS FROM SOME COUNCIL 1477 00:54:42,960 --> 00:54:43,200 MEMBERS? 1478 00:54:43,200 --> 00:54:46,600 >> I JUST WANT TO SAY IN SUPPORT 1479 00:54:46,600 --> 00:54:48,000 OF SAM HERE THAT YOU KNOW THIS 1480 00:54:48,000 --> 00:54:49,120 IS A REALLY DIFFICULT AREA AND 1481 00:54:49,120 --> 00:54:52,080 FROM THE BEGINNING IN THE 1990S 1482 00:54:52,080 --> 00:54:54,560 AND CONNECTICUT PEOPLE WERE 1483 00:54:54,560 --> 00:54:55,240 DEVELOPING PERSISTENT SYMPTOMS, 1484 00:54:55,240 --> 00:54:57,040 SO, YOU KNOW IN THOSE DAYS, 1485 00:54:57,040 --> 00:54:58,480 OFFENSE TIMES IT WAS A 1486 00:54:58,480 --> 00:54:59,400 CONSIDERABLE DELAY IN THE 1487 00:54:59,400 --> 00:55:00,920 DIAGNOSIS, SO SOME OF THE 1488 00:55:00,920 --> 00:55:03,000 PERRISTENT ISSUES THEY HAD WERE 1489 00:55:03,000 --> 00:55:04,280 ACTUALLY CHRONIC TISSUE DAMAGE 1490 00:55:04,280 --> 00:55:05,760 FROM AN UNTREATED INFECTION. 1491 00:55:05,760 --> 00:55:07,520 YOU KNOW WE'VE SEEN MORE IN THE 1492 00:55:07,520 --> 00:55:09,440 LAST, I THINK, YOU KNOW 5-10 1493 00:55:09,440 --> 00:55:13,560 YEARS OR PEOPLE WHO HAVE BEEN 1494 00:55:13,560 --> 00:55:14,480 PURPOSELY DIAGNOSED AND TREATED 1495 00:55:14,480 --> 00:55:15,920 EARLY ON BUT IT TAKES THEM A 1496 00:55:15,920 --> 00:55:18,560 LONG TIME TO GET BACK TO NORMAL 1497 00:55:18,560 --> 00:55:20,720 OR WE FOLLOW THEM OUT FOR A YEAR 1498 00:55:20,720 --> 00:55:21,760 AND THEY'RE STILL NOT WHERE THEY 1499 00:55:21,760 --> 00:55:24,080 SHOULD BE AND SOMETIMES THEY 1500 00:55:24,080 --> 00:55:25,680 HAVE THESE REALLY DISABLING 1501 00:55:25,680 --> 00:55:27,280 SYMPTOMS, SO I THINK THERE 1502 00:55:27,280 --> 00:55:29,800 IS--THERE IS A SIGNAL THERE 1503 00:55:29,800 --> 00:55:30,080 THAT'S REAL. 1504 00:55:30,080 --> 00:55:34,240 THE PROBLEM WITH TRYING TO STUDY 1505 00:55:34,240 --> 00:55:36,560 IN AN ANIMAL MODEL AT ALL IS 1506 00:55:36,560 --> 00:55:38,280 THAT THESE ARE SUGGESTIVE 1507 00:55:38,280 --> 00:55:40,480 DYSFUNCTIONS THAT ARE IN 1508 00:55:40,480 --> 00:55:41,560 MUSCULOSKELETAL AND PAIN AND 1509 00:55:41,560 --> 00:55:44,680 FATIGUE, YOU KNOW UNLIKE OTHER 1510 00:55:44,680 --> 00:55:45,960 INFECTIONS, LIME DISEASE, THESE 1511 00:55:45,960 --> 00:55:48,440 TYPES OF BACTERIAL INFECTIONS AS 1512 00:55:48,440 --> 00:55:49,720 AN EXTRA CELLULAR BACTERIUM, 1513 00:55:49,720 --> 00:55:51,720 THIS ORGANISM IS LISTED, IT'S A 1514 00:55:51,720 --> 00:55:53,320 STRONG TYPE 1 INTERFERON 1515 00:55:53,320 --> 00:55:54,120 RESPONSE. 1516 00:55:54,120 --> 00:55:55,800 AND YOU DON'T SEE PUSS IN THE 1517 00:55:55,800 --> 00:55:57,080 LESIONS OF AN EM LESION, IT'S 1518 00:55:57,080 --> 00:55:59,600 NOT THE SAME AND SO, I THINK WE 1519 00:55:59,600 --> 00:56:02,160 CAN LEARN SOMETHING FROM OTHER 1520 00:56:02,160 --> 00:56:04,120 TYPE DISEASES THAT ARE MORE TYPE 1521 00:56:04,120 --> 00:56:06,920 1 ASSOCIATED KLF-TWO IS WHY I 1522 00:56:06,920 --> 00:56:09,560 THINK AT THIS POINT IN TIME WITH 1523 00:56:09,560 --> 00:56:11,200 THE ONGOING EFFORT, WITH LONG 1524 00:56:11,200 --> 00:56:12,280 COVID, YOU MIGHT FIND PARALLELS 1525 00:56:12,280 --> 00:56:14,920 YOU COULD ARK PLIE TO A POST 1526 00:56:14,920 --> 00:56:21,480 COVID TREATMENT THAT, A POST 1527 00:56:21,480 --> 00:56:22,440 LYME DISEASE--POST TREATMENT 1528 00:56:22,440 --> 00:56:23,840 LYME DISEASE SYNDROME THAT MIGHT 1529 00:56:23,840 --> 00:56:27,840 HAVE ARISE IN SOME PEOPLE. 1530 00:56:27,840 --> 00:56:29,680 >> YEAH, SO I WOULD LIKE TO JUST 1531 00:56:29,680 --> 00:56:32,320 JOIN IN AND THANK SAM FOR A 1532 00:56:32,320 --> 00:56:33,640 TERRIFIC PRESENTATION AND 1533 00:56:33,640 --> 00:56:35,680 APPRECIATED THE COMMENTS AND I 1534 00:56:35,680 --> 00:56:37,480 THINK YOU KNOW MY VIEW IS 1535 00:56:37,480 --> 00:56:42,120 CHARACTERIZED AS GLOBAL, I THINK 1536 00:56:42,120 --> 00:56:44,440 IT'S--THE ISSUE HERE IS WE CAN 1537 00:56:44,440 --> 00:56:46,680 HEAR ECHOES OF MANY OTHER 1538 00:56:46,680 --> 00:56:47,920 DISEASES, ISSUES THAT ARE 1539 00:56:47,920 --> 00:56:50,200 PHASING MANY OTHER DISEASES, 1540 00:56:50,200 --> 00:56:53,480 INCLUDING THE DEFINITION OF WHAT 1541 00:56:53,480 --> 00:56:58,080 IS THE CONDITION SPECIFICALLY AS 1542 00:56:58,080 --> 00:56:59,240 BEING UNDER INVESTIGATION AND 1543 00:56:59,240 --> 00:57:01,560 THIS MAY LEAD TO SOME OF THAT 1544 00:57:01,560 --> 00:57:05,080 DEFINITION IS THEN THE FURTHER 1545 00:57:05,080 --> 00:57:06,320 UNDERSTANDING OF WHAT'S SPECIFIC 1546 00:57:06,320 --> 00:57:09,680 TO LYME DISEASE VERSUS OTHER 1547 00:57:09,680 --> 00:57:12,600 DISEASES AND WHAT'S IN COMMON. 1548 00:57:12,600 --> 00:57:16,440 SO, I THINK THIS IS A REALLY 1549 00:57:16,440 --> 00:57:18,680 GREAT ADDITION. 1550 00:57:18,680 --> 00:57:23,120 >> THANK YOU. 1551 00:57:23,120 --> 00:57:23,760 ANY OTHER COMMENTS? 1552 00:57:23,760 --> 00:57:24,680 OKAY, THANK YOU SAM. 1553 00:57:24,680 --> 00:57:27,400 WE HAVE MOVING ON TO OUR NEXT 1554 00:57:27,400 --> 00:57:28,440 INITIATIVE, THE TITLE IS 1555 00:57:28,440 --> 00:57:30,280 PARTNERSHIPS FOR THE DEVELOPMENT 1556 00:57:30,280 --> 00:57:33,120 OF VACCINES AGAINST SELECT 1557 00:57:33,120 --> 00:57:34,320 BACTERIAL ENTERIC PATHOGENS. 1558 00:57:34,320 --> 00:57:36,640 AND DR. MELODY MILLS WILL GIVE 1559 00:57:36,640 --> 00:57:37,920 THE PRESENTATION. 1560 00:57:37,920 --> 00:57:39,480 ARE YOU THERE MELODY? 1561 00:57:39,480 --> 00:57:40,720 >> YES, I AM. 1562 00:57:40,720 --> 00:57:41,080 HI, EVERYONE. 1563 00:57:41,080 --> 00:57:43,280 THANK YOU FOR THE OPPORTUNITY TO 1564 00:57:43,280 --> 00:57:44,840 PRESENT THIS PARTICULAR 1565 00:57:44,840 --> 00:57:46,400 PARTNERSHIP THAT FOCUSES ON THE 1566 00:57:46,400 --> 00:57:49,480 DEVELOPMENT OF VACCINES AGAINST 1567 00:57:49,480 --> 00:57:50,920 SELECT ANTIMICROBIAL RESISTENT 1568 00:57:50,920 --> 00:57:51,480 ENTERIC PATHOGENS. 1569 00:57:51,480 --> 00:57:53,200 I AM A PROGRAM OFFICER, I AM 1570 00:57:53,200 --> 00:57:55,560 ALSO THE SECTION CHIEF OF THE 1571 00:57:55,560 --> 00:57:58,240 ENTERIC INFECTION SECTION IN THE 1572 00:57:58,240 --> 00:58:06,520 ENTERIC AND SEXUALLY TRANSMITTED 1573 00:58:06,520 --> 00:58:07,320 INFECTIONS BRANCH. 1574 00:58:07,320 --> 00:58:08,680 >> SO THE SINGULAR FOCUS OF THIS 1575 00:58:08,680 --> 00:58:11,320 OBJECTIVE IS TO ADVANCE ENTERIC 1576 00:58:11,320 --> 00:58:14,280 VACCINE CANDIDATES FURTHER ALONG 1577 00:58:14,280 --> 00:58:16,120 THE PRODUCT DEVELOPMENT 1578 00:58:16,120 --> 00:58:17,360 PIPELINE. 1579 00:58:17,360 --> 00:58:19,240 IT FOCUSES ON 3 GENRE OF FOOD 1580 00:58:19,240 --> 00:58:22,920 AND WATER BORN BACTERIAL 1581 00:58:22,920 --> 00:58:24,720 PATHOGENS THAT ARE ETEC WHICH 1582 00:58:24,720 --> 00:58:28,160 LOW AND MIDDLE INCOME COUNTRIES 1583 00:58:28,160 --> 00:58:32,640 CAUSINGS AN ACUTE INFANT 1584 00:58:32,640 --> 00:58:34,480 DIARRHEA AND NATIONALLY IN HIGH 1585 00:58:34,480 --> 00:58:35,360 INCOME COUNTRIES, INTERNATIONAL 1586 00:58:35,360 --> 00:58:41,240 TRAVELS DIE EVERY YEAR, 1587 00:58:41,240 --> 00:58:44,360 SHIGGELLA, THAT ARE MOST 1588 00:58:44,360 --> 00:58:52,240 RESPONSIBLE FOR THE SHIGELLA AND 1589 00:58:52,240 --> 00:58:56,680 SARA TYPE PARATYPHY A CAUSES 1590 00:58:56,680 --> 00:58:58,760 TYPHOID FEVER. 1591 00:58:58,760 --> 00:58:59,400 THERE'S ANOTHER ENTERIC FEVER, 1592 00:58:59,400 --> 00:59:01,560 THIS IS A NEW CONCEPT. 1593 00:59:01,560 --> 00:59:04,560 THE MECHANISM IS A MILESTONE 1594 00:59:04,560 --> 00:59:07,880 DRIVEN RO1 AND WE ANTICIPATE 5-7 1595 00:59:07,880 --> 00:59:09,080 AWARDS AND THE FIRST YEAR TOTAL 1596 00:59:09,080 --> 00:59:14,560 COST IS SHOWN ON THE SLIDE. 1597 00:59:14,560 --> 00:59:16,680 5.2 MILLION. 1598 00:59:16,680 --> 00:59:18,680 SO IN TERMS OF THE SCOPE OF 1599 00:59:18,680 --> 00:59:19,920 SUPPORT, A CRITICAL REQUIREMENT 1600 00:59:19,920 --> 00:59:22,680 FOR THIS PARTNERSHIP CONCEPT IS 1601 00:59:22,680 --> 00:59:24,560 HAVING LEAD VACCINE CANDIDATES 1602 00:59:24,560 --> 00:59:25,080 AVAILABLE. 1603 00:59:25,080 --> 00:59:26,240 THEY'RE READY FOR FURTHER 1604 00:59:26,240 --> 00:59:27,760 DEVELOPMENT TOWARDS CLINICAL 1605 00:59:27,760 --> 00:59:28,720 STUDIES AND TRIALS. 1606 00:59:28,720 --> 00:59:32,480 AREAS OF INTEREST MAY INCLUDE 1607 00:59:32,480 --> 00:59:33,080 REDESIGNING THE CONSTRUCTS, 1608 00:59:33,080 --> 00:59:35,520 BROADENING THE CANDIDATES BY 1609 00:59:35,520 --> 00:59:36,440 INCORPORATING ADDITIONAL 1610 00:59:36,440 --> 00:59:40,000 COMPONENTS SUCH AS SPECIFIC 1611 00:59:40,000 --> 00:59:43,760 ANTIGENS OR SEROTYPE SPECIFIC 1612 00:59:43,760 --> 00:59:44,520 COMPONENTS. 1613 00:59:44,520 --> 00:59:46,600 OPTIMIZING CONSTRUCT AND 1614 00:59:46,600 --> 00:59:47,440 POTENTIALLY GENERATING 1615 00:59:47,440 --> 00:59:51,080 VACCINATION VACCINES, THE WORK 1616 00:59:51,080 --> 00:59:53,160 PROPOSED CAN SPAN THE RANGE OF 1617 00:59:53,160 --> 00:59:53,720 TRANSLATIONAL ACTIVITIES BUT 1618 00:59:53,720 --> 00:59:56,760 CLINICAL TRIALS WOULD NOTED BE 1619 00:59:56,760 --> 00:59:57,080 ALLOWED. 1620 00:59:57,080 --> 00:59:59,800 THIS PARTNERSHIP WOULD TARGET 1621 00:59:59,800 --> 01:00:01,120 VACCINES APPLICABLE TO BOTH 1622 01:00:01,120 --> 01:00:03,200 DOMESTIC AND INTERNATIONAL 1623 01:00:03,200 --> 01:00:03,800 POPULATIONS. 1624 01:00:03,800 --> 01:00:12,320 AND 2 OVERARCHING UNMET UNMET 1625 01:00:12,320 --> 01:00:16,200 PARTNERSHIPS, FIRST DISCIPLINARY 1626 01:00:16,200 --> 01:00:18,400 REALIA ON ALL AGES PARTICULARLY 1627 01:00:18,400 --> 01:00:19,680 CHILDREN AND SECOND THE 1628 01:00:19,680 --> 01:00:22,600 ANTIBIOTIC RESISTANCE IN THESE 1629 01:00:22,600 --> 01:00:26,080 PATHOGENS PARTICULARLY 1630 01:00:26,080 --> 01:00:26,880 SALMONELLA AND SHIGELLYME 1631 01:00:26,880 --> 01:00:29,000 ARTHRITISA, SO THERE ARE 1632 01:00:29,000 --> 01:00:29,480 LONG-TERM IMPACTS TO 1633 01:00:29,480 --> 01:00:31,200 DISCIPLINARY REAL AT DISEASES 1634 01:00:31,200 --> 01:00:32,960 THAT CAN BE SUBSTANTIAL, THE 1635 01:00:32,960 --> 01:00:34,720 EPIDEMIOLOGY CAN BE A MOVING 1636 01:00:34,720 --> 01:00:36,200 TARGET AND THE SPECIFIC 1637 01:00:36,200 --> 01:00:39,200 PATHOGENS DOES NOT NECESSARILY 1638 01:00:39,200 --> 01:00:39,720 OVERLAP GEOGRAPHICALLY, SO 1639 01:00:39,720 --> 01:00:41,360 DISCIPLINARY REAL DISEASES ARE 1640 01:00:41,360 --> 01:00:42,720 THE EIGHTH LEADING CAUSE OF 1641 01:00:42,720 --> 01:00:45,640 DEATH FOR ALL AGES GLOBALLY AND 1642 01:00:45,640 --> 01:00:47,280 IT'S ESPECIALLY PROBLEMATIC FOR 1643 01:00:47,280 --> 01:00:53,240 THOSE OVER 70 YEARS OF AGE A 1644 01:00:53,240 --> 01:00:58,000 GROUP THAT HAS DECREASED BY 1990 1645 01:00:58,000 --> 01:00:59,720 AND 2016 IT'S THE FIFTH LEADING 1646 01:00:59,720 --> 01:01:00,920 CAUSE OF DEATH FOR CHILDREN 1647 01:01:00,920 --> 01:01:06,480 UNDER 5 YEARS OF AGE AND THEIR 1648 01:01:06,480 --> 01:01:07,560 DIARRHEA'LL DISEASE OF CHILDREN 1649 01:01:07,560 --> 01:01:08,920 YOU SHOULD 5 AGE IS ASSOCIATE 1650 01:01:08,920 --> 01:01:11,600 WIDE AN INCREASED RISK OF 1651 01:01:11,600 --> 01:01:12,760 MORTALITY FROM SUBSEQUENT 1652 01:01:12,760 --> 01:01:13,960 INFECTIOUS DISEASE AND IT'S 1653 01:01:13,960 --> 01:01:16,920 IMPORTANT TO NOTE THAT THE 1654 01:01:16,920 --> 01:01:20,880 BURDEN OF DIAREAL DISEASES IS 1655 01:01:20,880 --> 01:01:22,480 UNDER REPORTED. 1656 01:01:22,480 --> 01:01:24,760 REPORTED BURDEN VARIES BY 1657 01:01:24,760 --> 01:01:26,280 REGIONAL DIFFERENCES BETWEEN AND 1658 01:01:26,280 --> 01:01:27,680 WITHIN COUNTRIES BETWEEN RURAL 1659 01:01:27,680 --> 01:01:29,680 AND URBAN AREAS IN THE COUNTRY 1660 01:01:29,680 --> 01:01:31,080 AND OFTEN THE DATA WE HAVE 1661 01:01:31,080 --> 01:01:34,200 AVAILABLE COMES ONLY FROM A 1662 01:01:34,200 --> 01:01:35,840 SPECIFIC AREA WITHIN A 1663 01:01:35,840 --> 01:01:40,080 COINCIDENTRY OR REGION OF THE 1664 01:01:40,080 --> 01:01:40,880 COUNTRY. 1665 01:01:40,880 --> 01:01:42,720 BUT SHIGELLA AND ETECH REPRESENT 1666 01:01:42,720 --> 01:01:44,840 THE SECOND LEADING CAUSE OF 1667 01:01:44,840 --> 01:01:46,720 DEATH DUE TO DIARRHEA IN 1668 01:01:46,720 --> 01:01:48,920 CHILDREN UNDER 5 YEARS AGE. 1669 01:01:48,920 --> 01:01:50,720 220 MILLION CASES ANNUALLY AND 1670 01:01:50,720 --> 01:01:53,320 MORE THAN 250,000 DEATHS 1671 01:01:53,320 --> 01:01:56,040 ANNUALLY THEY REPRESENT THE 1672 01:01:56,040 --> 01:02:00,680 CAUSES OF ABOUT 20% OF GLOBAL 1673 01:02:00,680 --> 01:02:01,440 PORTALLITY DUE TO DIAREAL 1674 01:02:01,440 --> 01:02:01,680 DISEASE. 1675 01:02:01,680 --> 01:02:07,120 AND THE AREA WITH THE GREATEST 1676 01:02:07,120 --> 01:02:08,080 DISEASE BURDEN TYPICALLY HAVE 1677 01:02:08,080 --> 01:02:09,480 RELATIVELY HEALTHCARE STRUCTURE, 1678 01:02:09,480 --> 01:02:13,320 POOR DISEASE SURVEILLANCE AND 1679 01:02:13,320 --> 01:02:14,080 INADEQUATE LABORATORY CAPACITY 1680 01:02:14,080 --> 01:02:23,320 TO DETECT THESE PATHOGENS. 1681 01:02:23,320 --> 01:02:24,480 SALMONELLA PARATYPHOID FEVER A 1682 01:02:24,480 --> 01:02:27,280 IS A MAJOR CAUSE OF DISABILITY 1683 01:02:27,280 --> 01:02:27,520 AND DEATH. 1684 01:02:27,520 --> 01:02:29,760 THE DISABILITY PEEKS IN THE 5-9 1685 01:02:29,760 --> 01:02:31,720 YEARS OF AGE RANGE. 1686 01:02:31,720 --> 01:02:36,200 AND WE KNOW THAT THERE ARE 1687 01:02:36,200 --> 01:02:37,480 ONGOING OUTBREAKS OF PARATYPHOID 1688 01:02:37,480 --> 01:02:41,800 FEVER AT THIS POINT IN TIME IN 1689 01:02:41,800 --> 01:02:43,080 ASIA AND AFRICA. 1690 01:02:43,080 --> 01:02:49,480 SO THE LONG-TERM HEALTH IMPACTS 1691 01:02:49,480 --> 01:02:51,080 CAN BE PARTICULARLY DRAMATIC 1692 01:02:51,080 --> 01:02:52,560 ESPECIALLY DURING CHILDHOOD OR 1693 01:02:52,560 --> 01:02:53,120 INFANCY. 1694 01:02:53,120 --> 01:02:57,840 SO THIS CAN HAPPEN, THESE LIFE 1695 01:02:57,840 --> 01:02:59,480 LONG REPERCUSSIONS CAN OCCUR 1696 01:02:59,480 --> 01:03:02,040 BOTH WITHIN SYMPTOMATIC BUT ALSO 1697 01:03:02,040 --> 01:03:06,200 ASYMPTOMATIC INFECTIONS AND WE 1698 01:03:06,200 --> 01:03:09,560 DO SEE CHILDHOOD DEVELOPMENT 1699 01:03:09,560 --> 01:03:12,360 OCCURS WITH THESE INFECTIONS, 1700 01:03:12,360 --> 01:03:13,280 THIS INVOLVES, STUNTING, 1701 01:03:13,280 --> 01:03:17,280 NUTRITION, THAT CAN LEAD TO 1702 01:03:17,280 --> 01:03:18,160 COGNITIVE IMPAIRMENT, COGNITIVE 1703 01:03:18,160 --> 01:03:19,400 IMPAIRMENT DEVELOPMENT AND THAT 1704 01:03:19,400 --> 01:03:21,960 CAN NEGATIVELY IMPACT THE 1705 01:03:21,960 --> 01:03:24,480 INDIVIDUALS EDUCATION AND THEIR 1706 01:03:24,480 --> 01:03:26,520 LIFE LONG ECONOMIC POTENTIAL. 1707 01:03:26,520 --> 01:03:30,480 THERE ARE ALSO HARMFUL SEQUELAI 1708 01:03:30,480 --> 01:03:32,760 THAT CAN AFFECT ALL AGES OF THE 1709 01:03:32,760 --> 01:03:35,280 POPULATION, FOR EXAMPLE, 1710 01:03:35,280 --> 01:03:36,000 ENVIRONMENTAL ENTERIC 1711 01:03:36,000 --> 01:03:40,040 DYSFUNCTION OR EED WHICH WAS 1712 01:03:40,040 --> 01:03:41,520 PREVIOUSLY HISTORICALLY KNOWN AS 1713 01:03:41,520 --> 01:03:44,840 STROPICAL SPRUE, THIS IS TOOKLY 1714 01:03:44,840 --> 01:03:46,840 PROBLEMATIC FOR CHILDREN AND 1715 01:03:46,840 --> 01:03:50,720 CAUSES GROWTH FAILURE, IT CAUSES 1716 01:03:50,720 --> 01:03:53,240 GUT ENTEROPEN MEETINGATHY THAT 1717 01:03:53,240 --> 01:03:54,560 INVOLVES STRUCTURAL AND CHANGES 1718 01:03:54,560 --> 01:03:57,480 IN THE SMALL INTESTINE AND YOU 1719 01:03:57,480 --> 01:04:01,080 SEE OTHER DELETERIOUS 1720 01:04:01,080 --> 01:04:06,240 MANIFESTATION SUCH AS GUT 1721 01:04:06,240 --> 01:04:07,640 INFLAMMATION, DYSENTERY, BOWEL 1722 01:04:07,640 --> 01:04:09,360 DISORDERS SUCH AS IRRITABLE 1723 01:04:09,360 --> 01:04:11,480 BOWEL DISORDER OR INFLAMMATORY 1724 01:04:11,480 --> 01:04:12,880 BOWEL DISEASE AND THESE 1725 01:04:12,880 --> 01:04:14,640 PATHOGENS PROMOTE THESE DISEASES 1726 01:04:14,640 --> 01:04:19,040 THROUGH PERMANENT CHANGES IN THE 1727 01:04:19,040 --> 01:04:22,800 MICROBIAL OR MICROBI OTA BEING 1728 01:04:22,800 --> 01:04:24,880 TESTED, DISRUPGDZ OF BARRIER AND 1729 01:04:24,880 --> 01:04:27,240 ALTERED IMMUNE RESPONSES 1730 01:04:27,240 --> 01:04:29,280 FOLLOWING THE INFECTION, 1731 01:04:29,280 --> 01:04:30,440 SHIGELLA AND SALMONELLA 1732 01:04:30,440 --> 01:04:34,240 INFECTIONS HAVE LONG BEEN LINKED 1733 01:04:34,240 --> 01:04:41,200 TO AN ARTHRITIS SEQUELACE AS 1734 01:04:41,200 --> 01:04:43,200 REFERRED TO ARB, SO ANOTHER 1735 01:04:43,200 --> 01:04:47,120 ISSUE FOR ENTERIC PATHOGENS, THE 1736 01:04:47,120 --> 01:04:51,360 CDC 2013 AND 2019 EABT BIOTICS 1737 01:04:51,360 --> 01:05:00,680 RESISTANCE THREATS FOR THE U.S., 1738 01:05:00,680 --> 01:05:02,200 CITED ESBL, AND SHIGELLA AS A 1739 01:05:02,200 --> 01:05:04,200 SERIOUS THREAT LEVEL, THE W. L. 1740 01:05:04,200 --> 01:05:05,480 O. PUBLISHED A PATHOGEN LIST FOR 1741 01:05:05,480 --> 01:05:09,200 RESEARCH AND DEVELOPMENT OF NEW 1742 01:05:09,200 --> 01:05:09,480 ANTIBIOTICS. 1743 01:05:09,480 --> 01:05:12,360 AND THEY IDENTIFIED THE MOST 1744 01:05:12,360 --> 01:05:14,480 IMPORTANT RESISTANT BACTERIA AT 1745 01:05:14,480 --> 01:05:15,640 A GLOBAL LEVEL. 1746 01:05:15,640 --> 01:05:18,640 SO SALMONELLA IS LISTED AS A 1747 01:05:18,640 --> 01:05:21,240 HIGH PRIORITY AND SHIGELLAWYERA 1748 01:05:21,240 --> 01:05:23,360 SPECIES ARE LISTED AS MEDIUM 1749 01:05:23,360 --> 01:05:23,640 PRIORITY. 1750 01:05:23,640 --> 01:05:27,560 BUT IN TOTAL THERE IS AN URGENT 1751 01:05:27,560 --> 01:05:29,240 NEED TO COMBAT MULTIRESISTANT 1752 01:05:29,240 --> 01:05:31,160 STRAINS OF THESE PATHOGENS AND 1753 01:05:31,160 --> 01:05:37,720 IN AS EARLY AS 2015 WE SAW 1754 01:05:37,720 --> 01:05:38,280 EXTREMELY DRUG-RESISTANT 1755 01:05:38,280 --> 01:05:39,480 SHIGELLOSIS IN THE U.S., SO 1756 01:05:39,480 --> 01:05:42,160 MULTIPLE MEETING IN THE LAST-10 1757 01:05:42,160 --> 01:05:44,520 YEARS WITH THE GLOBAL PARTNERS, 1758 01:05:44,520 --> 01:05:47,480 REPRESENTATIVES FROM OUR SISTER 1759 01:05:47,480 --> 01:05:50,680 AGENCIES AND LEADERS IN ACADEMIC 1760 01:05:50,680 --> 01:05:52,040 COMMUNITIES LED TO VIEW THAT 1761 01:05:52,040 --> 01:05:53,800 VACCINES ARE NEEDED FOR PRIMARY 1762 01:05:53,800 --> 01:05:56,240 PREVENTION OF DISEASE CAUSED BY 1763 01:05:56,240 --> 01:05:58,080 HIGH PRIMATES PORTY ENTERIC 1764 01:05:58,080 --> 01:05:59,280 BACTERIA AND ALTHOUGH THERE IS A 1765 01:05:59,280 --> 01:06:02,280 LONG HISTORY OF VACCINE RESEARCH 1766 01:06:02,280 --> 01:06:04,920 AND DEVELOPMENT FOR ENTERIC 1767 01:06:04,920 --> 01:06:06,440 PATHOGENS, NO LICENSE VACCINES 1768 01:06:06,440 --> 01:06:09,640 EXIST FOR THESE PARTICULAR BUGS. 1769 01:06:09,640 --> 01:06:11,080 AND INDEED, RECOGNITION OF THE 1770 01:06:11,080 --> 01:06:13,280 CRITICAL ROLE VACCINES WILL PLAY 1771 01:06:13,280 --> 01:06:14,280 IN PRIMARY DISEASE PREVENTION 1772 01:06:14,280 --> 01:06:15,880 ENERGIZE THE ACADEMIC AND 1773 01:06:15,880 --> 01:06:16,800 BUSINESS INTEREST, AND THE 1774 01:06:16,800 --> 01:06:19,320 TIMING OF THIS CONCEPT IS 1775 01:06:19,320 --> 01:06:22,240 PARTICULARLY HELPFUL BECAUSE IT 1776 01:06:22,240 --> 01:06:23,760 ALLOWS DEVELOPERS TO,A LIEN WITH 1777 01:06:23,760 --> 01:06:26,880 THE PUBLISHED W. H. O. PREFERRED 1778 01:06:26,880 --> 01:06:29,080 PRODUCT CHARACTERISTICS AND SO 1779 01:06:29,080 --> 01:06:31,800 THE ETEC PPC WAS PUBLISHED IN 1780 01:06:31,800 --> 01:06:34,640 AUGUST OF 2021, THE SHIGELLA, 1781 01:06:34,640 --> 01:06:37,560 PPC WAS PUBLISHED AT THE END OF 1782 01:06:37,560 --> 01:06:38,920 LAST NOVEMBER. 1783 01:06:38,920 --> 01:06:41,840 SO WE DO KNOW AS WELL THAT THERE 1784 01:06:41,840 --> 01:06:43,120 ARE MANY VACCINE CANDIDATES THAT 1785 01:06:43,120 --> 01:06:47,040 EXIST THAT CAN TAKE ADVANTAGE OF 1786 01:06:47,040 --> 01:06:48,960 THIS PARTNERSHIP. 1787 01:06:48,960 --> 01:06:50,480 SO DMID SUPPORTED RESEARCH AND 1788 01:06:50,480 --> 01:06:53,080 DEVELOPMENT FOR ALL 3 OF THESE 1789 01:06:53,080 --> 01:06:56,480 PATHOGENS, THROUGH VARIOUS 1790 01:06:56,480 --> 01:06:57,080 DIFFERENT MECHANISMS, VACCINE 1791 01:06:57,080 --> 01:06:58,800 CANDIDATES HAVE BEEN DEVELOPED 1792 01:06:58,800 --> 01:07:01,840 BY OTHER ACADEMIC INVESTIGATORS, 1793 01:07:01,840 --> 01:07:04,320 NONGOVERNMENTAL ORGANIZATIONS 1794 01:07:04,320 --> 01:07:05,280 AND THE PHARMACEUTICAL INDUSTRY 1795 01:07:05,280 --> 01:07:06,920 SO THE VARIETY OF CANDIDATES 1796 01:07:06,920 --> 01:07:08,760 HAVE BEEN GENERATED USING 1797 01:07:08,760 --> 01:07:10,440 DIFFERENT PLATFORMS AND 1798 01:07:10,440 --> 01:07:11,000 FORMULATIONS. 1799 01:07:11,000 --> 01:07:14,880 FOR INSTANCE WE HAVE BOTH LIVE 1800 01:07:14,880 --> 01:07:16,760 ORAL ATTENUATE VACCINES, 1801 01:07:16,760 --> 01:07:19,520 CONJUGATE CANDIDATES, JON JUGATE 1802 01:07:19,520 --> 01:07:22,440 VACCINE CANDIDATES WE SEE SINGLE 1803 01:07:22,440 --> 01:07:23,880 AND COMBINATION VACCINE 1804 01:07:23,880 --> 01:07:26,680 CONSTRUCTS AND 1 EXAMPLE OF A 1805 01:07:26,680 --> 01:07:29,760 NICE PLATFORM IS THE GENERALIZED 1806 01:07:29,760 --> 01:07:32,920 MODULES FOR MEMBRANE ANTIGENS 1807 01:07:32,920 --> 01:07:34,960 THAT USE OUTER MEMBRANE 1808 01:07:34,960 --> 01:07:38,280 VESICLINGS FROM ENGINEER GRAM 1809 01:07:38,280 --> 01:07:40,880 NEGATIVE BACTERIA AS CARRIERS 1810 01:07:40,880 --> 01:07:42,840 FOR RECOMBIN ANT PROTEINS AND 1811 01:07:42,840 --> 01:07:47,560 POLYSACCHARIDES SUCH AS THE 1812 01:07:47,560 --> 01:07:47,840 O-ANTIGEN. 1813 01:07:47,840 --> 01:07:50,760 SO I WANT TO THANK THE ADVISORY 1814 01:07:50,760 --> 01:07:52,200 COUNCIL MEMBERS, DOCTORS HARRY 1815 01:07:52,200 --> 01:07:54,240 GREEN BURG AND TIENER FOR THEIR 1816 01:07:54,240 --> 01:07:57,960 FEEDBACK, THEY WERE OVERALL 1817 01:07:57,960 --> 01:07:58,280 SUPPORTIVE. 1818 01:07:58,280 --> 01:08:00,360 DR. GREEN BERG WANTED TO KNOW IF 1819 01:08:00,360 --> 01:08:01,480 THERE WERE VACCINE CANDIDATES 1820 01:08:01,480 --> 01:08:04,400 AVAILABLE SO I ADDED MORE DETAIL 1821 01:08:04,400 --> 01:08:06,080 TO THE PRESENTATION ABOUT THAT, 1822 01:08:06,080 --> 01:08:09,800 HE DID COMMENT THAT THE POETIC 1823 01:08:09,800 --> 01:08:11,360 TEBTIAL MANUFACTURES MIGHT 1824 01:08:11,360 --> 01:08:31,680 BE--THEY MIGHT EXIST IN LOW AND 1825 01:08:31,680 --> 01:08:33,520 MIDDLE INCOME COUNTRIES. 1826 01:08:33,520 --> 01:08:35,200 C TYNER SAID THAT WAS HIS HOPES 1827 01:08:35,200 --> 01:08:37,560 AND THAT'S THE END OF MY 1828 01:08:37,560 --> 01:08:38,480 PRESENTATION AND I'M HAPPY TO 1829 01:08:38,480 --> 01:08:43,560 TAKE ANY QUESTIONS OR CONCERNS. 1830 01:08:43,560 --> 01:08:44,880 >> ANY ON COUNCIL HAVE A 1831 01:08:44,880 --> 01:08:54,840 QUESTION OR FEEDBACK FOR THIS 1832 01:08:54,840 --> 01:08:55,560 CONCEPT FOR MELODY? 1833 01:08:55,560 --> 01:08:57,280 GARY, I THINK YOU HAVE YOUR HAND 1834 01:08:57,280 --> 01:08:57,440 UP? 1835 01:08:57,440 --> 01:08:59,960 >> AS 1 OF THE REVIEWERS, PICKED 1836 01:08:59,960 --> 01:09:01,200 A LOT OF PATHOGENS THAT HAVE 1837 01:09:01,200 --> 01:09:07,600 BEEN AROUND FOR A LONG TIME AND 1838 01:09:07,600 --> 01:09:12,680 THEY HAVE ENDURED. 1839 01:09:12,680 --> 01:09:13,680 WE NEEDED A VACCINE 40 YEARS AGO 1840 01:09:13,680 --> 01:09:19,760 AND WE STILL NEED IT SO I 1841 01:09:19,760 --> 01:09:24,480 APPLAUD YOUR PERSISTENCE. 1842 01:09:24,480 --> 01:09:29,160 >> THANK YOU HARRY. 1843 01:09:29,160 --> 01:09:29,440 OTHERS? 1844 01:09:29,440 --> 01:09:29,640 OKAY. 1845 01:09:29,640 --> 01:09:32,840 >> I HAVE A QUESTION FOR MELODY 1846 01:09:32,840 --> 01:09:33,600 BECAUSE SHE MENTIONED YOU HAVE 1847 01:09:33,600 --> 01:09:36,680 TO HAVE A VAC SIGN PAT TONIGHT 1848 01:09:36,680 --> 01:09:40,880 IN ORDER TO APPLY THAT OR 1849 01:09:40,880 --> 01:09:42,040 SOMETHING LIKE THAT, OR ANYMORE 1850 01:09:42,040 --> 01:09:44,520 FOR LIKE NEW APPROACHES FOR 1851 01:09:44,520 --> 01:09:45,080 VACCINES, YOU KNOW? 1852 01:09:45,080 --> 01:09:48,280 IF THEY'RE NOT IN THE VACCINES 1853 01:09:48,280 --> 01:09:51,200 DEVELOPED LIKE MRNA OR LIKE 1854 01:09:51,200 --> 01:09:52,680 TRYING NEW APPROACHES TO IMPROVE 1855 01:09:52,680 --> 01:09:54,040 THE VACCINES IN THAT PART OF 1856 01:09:54,040 --> 01:09:56,600 THESE OR IT WILL NOT BE? 1857 01:09:56,600 --> 01:09:58,280 >> WELL, AS A PARTNERSHIP 1858 01:09:58,280 --> 01:10:00,360 CONCEPT OR A PARTNERSHIP 1859 01:10:00,360 --> 01:10:03,480 INITIATIVE, THEY ARE USUALLY 1860 01:10:03,480 --> 01:10:05,280 FOCUSED ON OF COURSE I FORGOT TO 1861 01:10:05,280 --> 01:10:07,480 SAY SOMETHING THAT WAS VERY 1862 01:10:07,480 --> 01:10:10,360 IMPORTANT, WHICH WAS THAT THIS 1863 01:10:10,360 --> 01:10:13,480 IS ACTUALLY INTENDED TO BRIDGE 1864 01:10:13,480 --> 01:10:15,080 THE GAP BETWEEN--IN THE AREA OF 1865 01:10:15,080 --> 01:10:16,400 TRANSLATIONAL RESEARCH TO GET 1866 01:10:16,400 --> 01:10:19,720 TOWARDS CLINICAL TRIALS AND 1867 01:10:19,720 --> 01:10:20,160 CLINICAL STUDIES. 1868 01:10:20,160 --> 01:10:22,320 SO THAT WAS REALLY THE FOCUS OF 1869 01:10:22,320 --> 01:10:27,760 THIS SO IN A LOT OF MEETINGS 1870 01:10:27,760 --> 01:10:30,040 WE'VE HAD, PART OF THE 1871 01:10:30,040 --> 01:10:31,800 DISCUSSION WAS THE NEED TO LOOK 1872 01:10:31,800 --> 01:10:34,000 AT NEXT GENERATION VACCINES AND 1873 01:10:34,000 --> 01:10:36,280 DIFFERENT KINDS OF INNOVATION AT 1874 01:10:36,280 --> 01:10:40,080 THE SAME TIME GIVEN THE CURRENT 1875 01:10:40,080 --> 01:10:41,080 ISSUES, WE DIDN'T REALLY WANT TO 1876 01:10:41,080 --> 01:10:43,920 GIVE UP ON THE CURRENT VACCINE 1877 01:10:43,920 --> 01:10:44,800 CANDIDATES THAT ARE OUT THERE 1878 01:10:44,800 --> 01:10:47,440 AND AGAIN PART OF THE 1879 01:10:47,440 --> 01:10:48,520 PARTNERSHIP IS ALWAYS LOOKING AT 1880 01:10:48,520 --> 01:10:55,720 THINGS THAT HAVE TO HAVE A LEAD 1881 01:10:55,720 --> 01:10:56,440 PRODUCT. 1882 01:10:56,440 --> 01:10:58,760 SO THERE WASN'T AN INTEREST IN 1883 01:10:58,760 --> 01:11:01,840 DENYING BASIC DISCOVERY BUT 1884 01:11:01,840 --> 01:11:03,280 HOPEFULLY WHOEVER COMES IN WILL 1885 01:11:03,280 --> 01:11:04,880 HAVE A VACCINE CANDIDATE OF ANY 1886 01:11:04,880 --> 01:11:07,000 TYPE AS LONG AS IT'S A WORTH 1887 01:11:07,000 --> 01:11:07,720 WHILE VACCINE CANDIDATE AND OF 1888 01:11:07,720 --> 01:11:09,680 COURSE THAT WILL BE DETERMINED 1889 01:11:09,680 --> 01:11:15,880 IN PEER REVIEW, WE ARE HAPPY TO 1890 01:11:15,880 --> 01:11:19,640 SEE IT. 1891 01:11:19,640 --> 01:11:21,120 >> OR AN INNOVATIVE PLATFORM 1892 01:11:21,120 --> 01:11:25,080 COULD MEET THE MILESTONES OF AN 1893 01:11:25,080 --> 01:11:25,800 RO1 DRIVEN PLATFORM-- 1894 01:11:25,800 --> 01:11:27,120 >> YEAH, I THINK THAT COULD BE 1895 01:11:27,120 --> 01:11:32,120 INCLUDED IN THE LANGUAGE, THAT 1896 01:11:32,120 --> 01:11:37,720 IS NOT EXCLUDING--TO NOTE THAT 1897 01:11:37,720 --> 01:11:40,120 THERE ARE ANY OTHERS THAT MIGHT 1898 01:11:40,120 --> 01:11:42,280 ALREADY HAVE THAT PLATFORM IN 1899 01:11:42,280 --> 01:11:43,280 PLACE. 1900 01:11:43,280 --> 01:11:43,800 >> OKAY, THAT'S GREAT. 1901 01:11:43,800 --> 01:11:44,640 THANK YOU FOR THAT INSIGHT. 1902 01:11:44,640 --> 01:11:48,520 THAT IS VERY HELPFUL. 1903 01:11:48,520 --> 01:11:48,800 >> OKAY. 1904 01:11:48,800 --> 01:11:50,880 IF THERE ARE NO FURTHER 1905 01:11:50,880 --> 01:11:55,680 QUESTIONS, WE CAN MOVE ON TO OUR 1906 01:11:55,680 --> 01:11:57,480 NEXT PROPOSED INITIATIVE, WHICH 1907 01:11:57,480 --> 01:11:59,240 IS ENTITLED PARTNERSHIPS FOR THE 1908 01:11:59,240 --> 01:12:01,960 DEVELOPMENT OF NOVEL 1909 01:12:01,960 --> 01:12:03,920 THERAPEUTICS TO COMBAT 1910 01:12:03,920 --> 01:12:05,800 ANTIBIOTIC RESISTANT BACTERIA 1911 01:12:05,800 --> 01:12:08,600 AND FUNNING I. 1912 01:12:08,600 --> 01:12:10,160 ZUOYU XU WILL GIVE THIS 1913 01:12:10,160 --> 01:12:10,720 PRESENTATION. 1914 01:12:10,720 --> 01:12:11,480 ARE YOU THERE? 1915 01:12:11,480 --> 01:12:14,560 >> I AM HERE, THANK YOU EMILY. 1916 01:12:14,560 --> 01:12:19,120 >> YEAH, GOOD AFTERNOON, 1917 01:12:19,120 --> 01:12:19,400 EVERYONE. 1918 01:12:19,400 --> 01:12:21,360 I'M ZUOYO, XU IS PRONOUNCED 1919 01:12:21,360 --> 01:12:26,440 ASHOE, AND PROGRAM OFFICER FOR 1920 01:12:26,440 --> 01:12:30,160 THERAPEUTIC TO COMBAT AND WITH 1921 01:12:30,160 --> 01:12:31,200 THE BACTERIAL DMID AND IT'S MY 1922 01:12:31,200 --> 01:12:32,960 PLEASURE TO PRESENT TO YOU 1923 01:12:32,960 --> 01:12:36,120 PARTNERSHIPS FOR THE DEVELOPMENT 1924 01:12:36,120 --> 01:12:39,400 OF NOVEL THERAPEUTICS TO COMBAT 1925 01:12:39,400 --> 01:12:40,320 ANTIBIOTIC RESISTANT BACTERIA 1926 01:12:40,320 --> 01:12:47,200 AND THE THE FUNGI. 1927 01:12:47,200 --> 01:12:50,440 OKAY, I SEE THAT. 1928 01:12:50,440 --> 01:12:53,920 THE OBJECTIVE FOR THIS CONCEPT 1929 01:12:53,920 --> 01:12:55,560 IS TO SUPPORT PRECLINICAL 1930 01:12:55,560 --> 01:13:00,720 DEVELOPMENT OF A NEW CLASSES OF 1931 01:13:00,720 --> 01:13:01,200 ANTIBIOTICS. 1932 01:13:01,200 --> 01:13:05,640 AND NONTRADITIONAL ANTIMICROBIAL 1933 01:13:05,640 --> 01:13:13,640 THERAPEUTICS ACTING AGAINST 1934 01:13:13,640 --> 01:13:15,360 MULTIDRUG-RESISTANT 1935 01:13:15,360 --> 01:13:17,880 ACINETOBACTERIAER, PSEUDOMONAS, 1936 01:13:17,880 --> 01:13:19,880 ENTERO BACTERIA CAEE AND CANDIDA 1937 01:13:19,880 --> 01:13:24,880 AURIS AND THIS IS A NEW PROPOSAL 1938 01:13:24,880 --> 01:13:30,200 AND WE PARTNERSHIP WITH R01 AND 1939 01:13:30,200 --> 01:13:32,080 ANTICIPATE 6-8 AND THE FIRST 1940 01:13:32,080 --> 01:13:37,480 YEAR TOTAL COST FOR AWARD 1941 01:13:37,480 --> 01:13:42,520 INITIATIVE IS $4 MILLION. 1942 01:13:42,520 --> 01:13:47,280 >> THE BACKGROUND, AS WE KNOW 1943 01:13:47,280 --> 01:13:48,200 ANTIBI BOTTIC 1944 01:13:48,200 --> 01:13:48,680 RESISTANCE--ANTIBIOTIC 1945 01:13:48,680 --> 01:13:50,520 RESISTANCE IS A TOP THREAT TO 1946 01:13:50,520 --> 01:13:53,680 PUBLIC HEALTH NEEDS AND IT IS 1947 01:13:53,680 --> 01:13:58,240 PRIORITY OF THE GLOBAL ACROSS 1948 01:13:58,240 --> 01:13:58,720 THE GLOBE. 1949 01:13:58,720 --> 01:14:01,360 THERE ARE NATIONAL AND 1950 01:14:01,360 --> 01:14:06,240 INTERNATIONAL EFFORTS TO ADVANCE 1951 01:14:06,240 --> 01:14:08,120 EABT BIOTICS RESISTANCE, THE W. 1952 01:14:08,120 --> 01:14:10,480 H. O. COVERED THE PRIORITY 1953 01:14:10,480 --> 01:14:20,080 THERAPEUTICS LIST FOR R&D--AS 1954 01:14:20,080 --> 01:14:20,320 CRITICAL. 1955 01:14:20,320 --> 01:14:22,360 BUT WHY THE VECTOR FOR MONEY, 1956 01:14:22,360 --> 01:14:29,560 SECOND IS A SUED MOANIS 1957 01:14:29,560 --> 01:14:32,400 ALLOGENOSA, AND THE ENTHUSIASMER 1958 01:14:32,400 --> 01:14:36,960 O BACTERIAIARIAL SEA. 1959 01:14:36,960 --> 01:14:41,840 AND THEN THE [INDISCERNIBLE] 1960 01:14:41,840 --> 01:14:44,200 MANY ABOUT THE FUNGAL INFECTIONS 1961 01:14:44,200 --> 01:14:46,760 HERE, THAT IS IN THE NEW YORK 1962 01:14:46,760 --> 01:14:49,760 TIMES SHOW THAT FOR THE 1963 01:14:49,760 --> 01:14:52,880 INFECTIONS BY THE CANDIDA AURIS 1964 01:14:52,880 --> 01:14:57,440 AND THE CDC LISTED THESE AS 1965 01:14:57,440 --> 01:15:02,320 URENTLY NEEDS TO FIND 1966 01:15:02,320 --> 01:15:04,000 ANTIBIOTICS. 1967 01:15:04,000 --> 01:15:05,280 THE U.S. GOVERNMENT LAUNCHED AS 1968 01:15:05,280 --> 01:15:12,040 A NATIONAL ACTION PLAN FOR 1969 01:15:12,040 --> 01:15:13,240 COMBATING ANTIBIOTIC RESISTANT 1970 01:15:13,240 --> 01:15:14,840 PROGRAM IN 2014 CALLING FOR A 1971 01:15:14,840 --> 01:15:17,040 FEDERAL RESPONSE TO ADDRESS THE 1972 01:15:17,040 --> 01:15:19,800 GROWING THREATS OF ANTIBIOTIC 1973 01:15:19,800 --> 01:15:20,080 RESISTANCE. 1974 01:15:20,080 --> 01:15:28,720 THIS PLAN HAS BEEN RENEWED FOR 1975 01:15:28,720 --> 01:15:29,760 2020 TO 2025. 1976 01:15:29,760 --> 01:15:33,080 AND RECENTLY UPDATED THE NIAR 1977 01:15:33,080 --> 01:15:35,600 RESEARCH FRAMEWORK THE INSTITUTE 1978 01:15:35,600 --> 01:15:39,280 DESCRIBED A STREAMLINED RATE OF 1979 01:15:39,280 --> 01:15:40,760 INNOVATIVE STRATEGIC APPROACH TO 1980 01:15:40,760 --> 01:15:44,480 UPON A. E. R. RESEARCH THAT 1981 01:15:44,480 --> 01:15:45,880 INCLUDES REINVIGORATING GRAM 1982 01:15:45,880 --> 01:15:47,600 NEGATIVE DRUG DISCOVERY, 1983 01:15:47,600 --> 01:15:52,480 HARNESSING THE IMMUNE SYSTEM AND 1984 01:15:52,480 --> 01:15:54,640 DEVELOPING NONTRADITIONAL 1985 01:15:54,640 --> 01:16:01,280 PROLAPSE TO TREAT INFECTIOUS 1986 01:16:01,280 --> 01:16:01,880 DISEASE. 1987 01:16:01,880 --> 01:16:05,880 IN 2019 A. R. THREATS REPORT, 1988 01:16:05,880 --> 01:16:11,000 THE CDC ESTIMATED THAT AT THE 1989 01:16:11,000 --> 01:16:14,200 LEAST, 2.8 MILLION PEOPLE 1990 01:16:14,200 --> 01:16:17,720 DEVELOP AN ANTIBIOTIC RESISTANCE 1991 01:16:17,720 --> 01:16:22,320 TO INFECTIONS AND MORE THAN 1992 01:16:22,320 --> 01:16:24,000 35,000 PEOPLE DIE AS A RESULT OF 1993 01:16:24,000 --> 01:16:25,200 THIS IN THE STATES. 1994 01:16:25,200 --> 01:16:27,440 TO MAKE A NATIONAL CAUSE TO 1995 01:16:27,440 --> 01:16:28,480 ACHIEVE THE RESISTANCE, 1996 01:16:28,480 --> 01:16:34,160 INFECTIONS CAN BE MORE THAN 4.6 1997 01:16:34,160 --> 01:16:34,960 BILLION DOLLARS ANNUALLY. 1998 01:16:34,960 --> 01:16:36,960 SO THIS CONCEPT WILL FOCUS ON 1999 01:16:36,960 --> 01:16:44,520 WHAT I JUST MENTIONED THE TOP 4 2000 01:16:44,520 --> 01:16:44,800 PATHOGENS. 2001 01:16:44,800 --> 01:16:50,800 THAT'S PRIORITY AND CRITICAL AND 2002 01:16:50,800 --> 01:17:13,160 URGENT. 2003 01:17:13,160 --> 01:17:16,200 SHOWED HERE, GLOBE ALTHOUGH 2004 01:17:16,200 --> 01:17:18,080 [INDISCERNIBLE] FOR THE 2005 01:17:18,080 --> 01:17:18,560 [INDISCERNIBLE]. 2006 01:17:18,560 --> 01:17:22,240 TWELVE NEW ANTIBIOTICS HAVE BEEN 2007 01:17:22,240 --> 01:17:23,440 APPROVED SINCE 2014, MOST OF THE 2008 01:17:23,440 --> 01:17:26,200 DRUGS ARE NEW MEMBERS OF 2009 01:17:26,200 --> 01:17:30,840 EXISTING CLASSES OF ANTIBIOTICS. 2010 01:17:30,840 --> 01:17:35,640 REGARDING CANDIDA AURIS IS IN 2011 01:17:35,640 --> 01:17:35,920 DEVELOPMENT. 2012 01:17:35,920 --> 01:17:39,120 DESPITE EXTENSIVE EFFORT TO 2013 01:17:39,120 --> 01:17:42,440 STIMULATE THE [INDISCERNIBLE] IT 2014 01:17:42,440 --> 01:17:46,400 STILL REMAINS SEEN AND 2015 01:17:46,400 --> 01:17:46,760 [INDISCERNIBLE]. 2016 01:17:46,760 --> 01:17:50,840 ESPECIALLY AS THE GRAM NEGATIVE 2017 01:17:50,840 --> 01:17:51,280 PATHOGENS. 2018 01:17:51,280 --> 01:17:54,240 SO WAIT TO EVEN NEW CLASSES OF 2019 01:17:54,240 --> 01:17:59,080 ANTIBIOTICS AS WELL AS 2020 01:17:59,080 --> 01:18:01,680 NONTRADITIONAL ANTIMICROBIAL 2021 01:18:01,680 --> 01:18:05,240 THERAPEUTICS TO COMBAT 2022 01:18:05,240 --> 01:18:05,680 ANTIBIOTIC RESISTANCE. 2023 01:18:05,680 --> 01:18:10,240 SCOPE OF THIS SUPPORT? 2024 01:18:10,240 --> 01:18:12,720 AS ALREADY DISCUSSED, THE 2025 01:18:12,720 --> 01:18:13,760 CONCEPT SUPPORTS PRECLINICAL 2026 01:18:13,760 --> 01:18:18,240 DEVELOPMENT OF A NEW CLASSES OF 2027 01:18:18,240 --> 01:18:21,280 ANTIBIOTICS IN THE 2028 01:18:21,280 --> 01:18:22,440 NONTRADITIONAL ANTIMICROBIAL 2029 01:18:22,440 --> 01:18:26,800 THERAPEUTICS THAT ACT AGAINST 2030 01:18:26,800 --> 01:18:28,400 MULTIDRUG RESISTANCE PSEUDOMOAN 2031 01:18:28,400 --> 01:18:33,360 ISOTOPE AND ENTERO BACTERIA ACA 2032 01:18:33,360 --> 01:18:34,520 OR CANDIDA AURIS. 2033 01:18:34,520 --> 01:18:36,200 OF THE [INDISCERNIBLE] STATE, A 2034 01:18:36,200 --> 01:18:40,640 FEW KEY WORDS HERE. 2035 01:18:40,640 --> 01:18:44,680 FIRST THE CONCEPT SUPPORTS 2036 01:18:44,680 --> 01:18:45,840 PRECLINICAL DEVELOPMENT, NOT 2037 01:18:45,840 --> 01:18:49,440 EARLY STAGE DISCOVERY OR 2038 01:18:49,440 --> 01:18:52,080 CLINICAL STAGE EVALUATION. 2039 01:18:52,080 --> 01:18:56,120 SECONDLY, IT SUPPORTS NEW 2040 01:18:56,120 --> 01:18:59,080 CLASSES OF ANTIBIOTICS, NOT JUST 2041 01:18:59,080 --> 01:19:01,680 NEW ANTIBIOTICS, AS MENTIONED, 2042 01:19:01,680 --> 01:19:04,200 MOST RECEIPTLY APPROVED 2043 01:19:04,200 --> 01:19:06,960 ANTIBIOTICS, AND THE MOST 2044 01:19:06,960 --> 01:19:08,280 CANDIDA IS IN CLINICAL 2045 01:19:08,280 --> 01:19:11,360 DEVELOPMENT ARE NEW MEMBERS OF 2046 01:19:11,360 --> 01:19:13,640 EXISTING CLASSES. 2047 01:19:13,640 --> 01:19:15,520 THE OVERWHELMING RESISTANCE 2048 01:19:15,520 --> 01:19:25,680 PROBLEMS WILL MAKE THIS NEW 2049 01:19:25,680 --> 01:19:27,840 DRUGS--AND THE EVEN LITTLE OR NO 2050 01:19:27,840 --> 01:19:34,280 SPACE FOR FURTHER MODIFICATIONS 2051 01:19:34,280 --> 01:19:37,560 WHEN NEEDED. 2052 01:19:37,560 --> 01:19:40,840 AND THIRD, NONTRADITIONAL 2053 01:19:40,840 --> 01:19:41,480 MICROBIAL THERAPEUTICS INCLUDE 2054 01:19:41,480 --> 01:19:46,200 BUT ARE NOT LIMITED TO BACTERIAL 2055 01:19:46,200 --> 01:19:47,680 PHAGES THERAPY, APPROACH TO 2056 01:19:47,680 --> 01:19:50,000 [INDISCERNIBLE] THE HOST SYSTEM 2057 01:19:50,000 --> 01:19:53,200 AND THE COUNTERMEASURES TO 2058 01:19:53,200 --> 01:19:58,040 SUPPRESS MILLIONS OF PATHOGENS. 2059 01:19:58,040 --> 01:19:59,160 FINALLY, RESPONSIBLE 2060 01:19:59,160 --> 01:20:01,160 APPLICATIONS MUST TARGET AT 2061 01:20:01,160 --> 01:20:23,560 LEAST 1 OF THE 4 RESISTANT 2062 01:20:23,560 --> 01:20:23,880 PATHOGENS. 2063 01:20:23,880 --> 01:20:28,600 SUPPORTED EFFORTS ARE FORMA 2064 01:20:28,600 --> 01:20:29,720 CODYNAMMICS FORMA COTOXICOLOGYS, 2065 01:20:29,720 --> 01:20:31,440 AND THE STUDIES ADDRESS 2066 01:20:31,440 --> 01:20:34,840 EFFICACY, TOXICITY AND THE 2067 01:20:34,840 --> 01:20:35,120 SAFETY. 2068 01:20:35,120 --> 01:20:39,080 FROM ADDITION TO THAT, GMP 2069 01:20:39,080 --> 01:20:41,160 MANUFACTURE AND IND ENABLING 2070 01:20:41,160 --> 01:20:46,920 ACTIVITIES ARE ALLOWED. 2071 01:20:46,920 --> 01:20:49,800 THE PARTIC PAIGDZ IS STRONGLY 2072 01:20:49,800 --> 01:20:54,760 RECOMMENDED BUT NOT REQUIRED. 2073 01:20:54,760 --> 01:20:57,880 THIS IS BECAUSE OVER DECADES 2074 01:20:57,880 --> 01:21:00,720 ACADEMIC INSTITUTIONS HAVE 2075 01:21:00,720 --> 01:21:04,720 ESTABLISHED THE PLATFORMS AND TD 2076 01:21:04,720 --> 01:21:06,520 FACILITIES AND ACQUIRED NEEDED 2077 01:21:06,520 --> 01:21:09,520 EXPERTISE AND EXPERIENCE IN 2078 01:21:09,520 --> 01:21:12,480 SUPPORT OF NEW ANTIBIOTICS 2079 01:21:12,480 --> 01:21:12,800 DEVELOPMENT. 2080 01:21:12,800 --> 01:21:16,480 THEREFORE, IN THIS CONCEPT, 2081 01:21:16,480 --> 01:21:19,760 WHILE APPRECIATION IN THE ACTUAL 2082 01:21:19,760 --> 01:21:20,880 PARTICIPATION THAT HAS BEEN 2083 01:21:20,880 --> 01:21:22,520 CONTRIBUTING BEAUTY INDUSTRIALLY 2084 01:21:22,520 --> 01:21:26,600 TO THE SUCCESS OF PARTNERSHIP 2085 01:21:26,600 --> 01:21:29,560 PROGRAM, WE DON'T WANT TO 2086 01:21:29,560 --> 01:21:32,160 EXCLUDE THE ACADEMIC IONIZATIONS 2087 01:21:32,160 --> 01:21:46,360 TUITIONS WITH A SIMILAR 2088 01:21:46,360 --> 01:21:46,640 CAPACITY. 2089 01:21:46,640 --> 01:21:51,840 NOW I WOULD LIKE TO DISCUSS WHY 2090 01:21:51,840 --> 01:21:53,920 WE PROPOSE THE PROPOSALS. 2091 01:21:53,920 --> 01:21:56,160 FIRST, THEY PROVIDE A TAYLORED 2092 01:21:56,160 --> 01:21:58,680 EXPERTISE IN A RICH ENVIRONMENT 2093 01:21:58,680 --> 01:22:04,880 FOR PRODUCT DEVELOPMENT OR FOCUS 2094 01:22:04,880 --> 01:22:07,400 THE PROJECTS. 2095 01:22:07,400 --> 01:22:09,080 SECOND, SEEM DRUG DEVELOPMENT 2096 01:22:09,080 --> 01:22:09,800 PROGRAMS USUALLY INVOLVES A 2097 01:22:09,800 --> 01:22:15,000 LARGE NUMBER OF ANIMALS SUCH AS, 2098 01:22:15,000 --> 01:22:17,320 MICE, RATS, RABBITS OR EVEN 2099 01:22:17,320 --> 01:22:19,440 BIGGER ANIMALS AND CONSUME A 2100 01:22:19,440 --> 01:22:22,280 LARGER QUANTITY OF A 2101 01:22:22,280 --> 01:22:27,960 PRODUCT/MATERIALS THAT ARE ALL 2102 01:22:27,960 --> 01:22:28,320 EXPENSIVE. 2103 01:22:28,320 --> 01:22:32,800 R01S CAN PROVIDE A REASONABLE 2104 01:22:32,800 --> 01:22:33,920 BUDGET TO HELP. 2105 01:22:33,920 --> 01:22:36,480 HISTORICALLY WE HAVE RECEIVED A 2106 01:22:36,480 --> 01:22:40,120 ROBUST RESPONSE FROM PIs TO 2107 01:22:40,120 --> 01:22:45,640 PARTNERSHIPS CALLED AND FINALLY, 2108 01:22:45,640 --> 01:22:48,880 THE RETURN ON INVESTMENT IS 2109 01:22:48,880 --> 01:22:49,360 GREAT. 2110 01:22:49,360 --> 01:22:53,080 THE PARTNERSHIPS PROGRAM 2111 01:22:53,080 --> 01:22:54,880 SIMILARLY THERAPEUTICS 2112 01:22:54,880 --> 01:22:56,440 DEVELOPMENT, GRADUATES MAY 2113 01:22:56,440 --> 01:22:59,600 SERVE--ADVANCE TO CLINICAL 2114 01:22:59,600 --> 01:23:04,560 DEVELOPMENT, ALL BE CONSIDERED 2115 01:23:04,560 --> 01:23:13,360 IN OTHER FORMS FORMS--PORTFOLIOS FOR 2116 01:23:13,360 --> 01:23:14,240 FURTHER DEVELOPMENT. 2117 01:23:14,240 --> 01:23:16,160 THANK YOU FOR TAKING THE TIME TO 2118 01:23:16,160 --> 01:23:19,360 REVIEW THIS CONCEPT. 2119 01:23:19,360 --> 01:23:23,520 OVERALL, THE COUNCIL FEEDBACK 2120 01:23:23,520 --> 01:23:24,520 AND VERY POSITIVE. 2121 01:23:24,520 --> 01:23:27,600 COUNCIL FULLY SUPPORTS THE 2122 01:23:27,600 --> 01:23:28,960 PRECLINICAL DEVELOPMENT OF A NEW 2123 01:23:28,960 --> 01:23:31,800 CLASSES OF ANTIBIOTICS AND THE 2124 01:23:31,800 --> 01:23:34,800 NONTRADITIONAL THERAPEUTICS 2125 01:23:34,800 --> 01:23:39,840 BECAUSE THEY ADDRESS UNMET 2126 01:23:39,840 --> 01:23:43,560 PUBLIC HEALTH NEEDS. 2127 01:23:43,560 --> 01:23:44,840 FOR CANDIDA AURIS, IS IN 2128 01:23:44,840 --> 01:23:46,800 DEVELOPMENT BECAUSE WE REALIZE 2129 01:23:46,800 --> 01:23:49,160 THAT THIS EFFORT IS TO ADDRESS 2130 01:23:49,160 --> 01:23:58,120 UNMET NEEDS IN THE TREATMENT OF 2131 01:23:58,120 --> 01:23:59,200 CANDIDA AURIS INFECTIONS. 2132 01:23:59,200 --> 01:24:02,480 COUNCIL ALSO CONSIDERED THAT 2133 01:24:02,480 --> 01:24:03,680 THIS PROPOSED RESEARCH MAY PART 2134 01:24:03,680 --> 01:24:07,160 OF THE NEXT GENERATION SOLUTIONS 2135 01:24:07,160 --> 01:24:07,400 FOR AR. 2136 01:24:07,400 --> 01:24:09,040 COUNCIL SUGGESTS WE PAY 2137 01:24:09,040 --> 01:24:11,880 ATTENTION TO ANIMAL MODELS, 2138 01:24:11,880 --> 01:24:14,960 DEVELOPED AND LEAD OPTIMIZATION 2139 01:24:14,960 --> 01:24:19,160 HAD WHEN APPLICATION COME IN, 2140 01:24:19,160 --> 01:24:29,920 SINCE THIS ARE IMPORTANT AND 2141 01:24:29,920 --> 01:24:30,280 USEFUL. 2142 01:24:30,280 --> 01:24:36,840 AS WE JUST DISCUSSED THIS 2143 01:24:36,840 --> 01:24:39,080 CONCEPT TO SUPPORT DEVELOPMENT 2144 01:24:39,080 --> 01:24:41,880 OF NEW CLASSES OF ANTIBIOTICS 2145 01:24:41,880 --> 01:24:43,640 AND NONTRADITIONAL THERAPEUTICS 2146 01:24:43,640 --> 01:24:49,400 THAT IS TARGETING MULTIDRUG 2147 01:24:49,400 --> 01:24:52,880 RESISTANCE PATHOGENS AND THE NEW 2148 01:24:52,880 --> 01:24:58,960 CONCEPT, WE WILL USE RO1 2149 01:24:58,960 --> 01:25:00,520 MECHANISM, 6-SIT CITATIONS WILL 2150 01:25:00,520 --> 01:25:01,360 BE AWARDED. 2151 01:25:01,360 --> 01:25:01,720 THANK YOU. 2152 01:25:01,720 --> 01:25:11,480 I'M HAPPY TO TAKE YOUR 2153 01:25:11,480 --> 01:25:12,440 QUESTIONS. 2154 01:25:12,440 --> 01:25:15,080 >> THANK YOU ZUOYO, DO YOU HAVE 2155 01:25:15,080 --> 01:25:17,080 ANY QUESTIONS OR ADDITIONAL 2156 01:25:17,080 --> 01:25:19,280 FEEDBACK FROM COUNCIL MEMBERS. 2157 01:25:19,280 --> 01:25:21,240 I'M NOT SEEING ANY RAISED HANDS 2158 01:25:21,240 --> 01:25:30,320 ON MY SCROOM GALLERY. 2159 01:25:30,320 --> 01:25:31,040 OKAY. 2160 01:25:31,040 --> 01:25:31,240 OKAY. 2161 01:25:31,240 --> 01:25:31,520 THANK YOU. 2162 01:25:31,520 --> 01:25:32,280 >> THANK YOU. 2163 01:25:32,280 --> 01:25:34,280 SO WE WILL KEEP MOVING FORWARD 2164 01:25:34,280 --> 01:25:35,840 ON OUR AGENDA. 2165 01:25:35,840 --> 01:25:38,320 THE NEXT AND LAST PRESENTATION 2166 01:25:38,320 --> 01:25:40,520 IS DEVELOPMENT AND OPTIMIZATION 2167 01:25:40,520 --> 01:25:41,480 OF NEXT-GENERATION IMMUNE O 2168 01:25:41,480 --> 01:25:43,360 LOGIC ASSAYS TO SUPPORT 2169 01:25:43,360 --> 01:25:47,160 INFLUNNENSA CLINICAL STUDIES AND 2170 01:25:47,160 --> 01:25:48,560 TRIALS. 2171 01:25:48,560 --> 01:25:52,360 AND DR. CHELSEA LANE FROM THE 2172 01:25:52,360 --> 01:25:53,520 RESPIRATORY DISEASE BRANCH WILL 2173 01:25:53,520 --> 01:25:54,120 PRESENT THIS. 2174 01:25:54,120 --> 01:25:54,440 >> GREAT. 2175 01:25:54,440 --> 01:25:55,800 THANK YOU SO MUCH EMIMPEDIMENTSY 2176 01:25:55,800 --> 01:25:56,880 FOR THE INTRODUCTION AND THANKS 2177 01:25:56,880 --> 01:26:00,480 FOR THE OPPORTUNITY TO PRESENT 2178 01:26:00,480 --> 01:26:01,000 THIS CONCEPT TODAY. 2179 01:26:01,000 --> 01:26:03,240 SO MY NAME IS CHELSEA LANE, I'M 2180 01:26:03,240 --> 01:26:05,520 A PROGRAM OFFICER WITHIN THE 2181 01:26:05,520 --> 01:26:06,640 RESPIRATORY DISEASES BRANCH AND 2182 01:26:06,640 --> 01:26:09,360 I'LL BE PRESENTING THIS CONCEPT 2183 01:26:09,360 --> 01:26:11,040 FOR FY23 ENTITLED DEVELOPMENT 2184 01:26:11,040 --> 01:26:14,200 AND OPTIMIZATION OF NEXT 2185 01:26:14,200 --> 01:26:15,560 GENERATION IMMUNEOLOGICAL ASSAYS 2186 01:26:15,560 --> 01:26:16,560 TO SUPPORT INFLUENZA CLINICAL 2187 01:26:16,560 --> 01:26:17,320 STUDIES AND TRIALS. 2188 01:26:17,320 --> 01:26:19,480 SO THE OBJECTIVE OF 2189 01:26:19,480 --> 01:26:21,640 THIS INITIATIVE IS SUPPORT 2190 01:26:21,640 --> 01:26:22,520 COLLABORATIVEY MULTIDISCIPLINARY 2191 01:26:22,520 --> 01:26:24,440 RESEARCH TO DEVELOP AND 2192 01:26:24,440 --> 01:26:25,680 OPTIMIZE, NEXT GENERATION 2193 01:26:25,680 --> 01:26:28,360 IMMUNEOLOGICAL ASSAYS THAT ARE 2194 01:26:28,360 --> 01:26:29,040 READILY UTILIZED AND CLINICAL 2195 01:26:29,040 --> 01:26:31,040 STUDIES AND TRIALS BY THE END OF 2196 01:26:31,040 --> 01:26:32,280 THE 5 YEAR PROJECT PERIOD. 2197 01:26:32,280 --> 01:26:35,640 SO THIS WILL BE A NEW INITIATIVE 2198 01:26:35,640 --> 01:26:40,520 AND WOULD UTILIZE THE PHASED 2199 01:26:40,520 --> 01:26:41,880 UH2-/UH3 COOPERATIVE MECHANISM 2200 01:26:41,880 --> 01:26:43,480 WHICH WILL WILL DESCRIBE IN A 2201 01:26:43,480 --> 01:26:44,800 SUBSEQUENT SLIDE. 2202 01:26:44,800 --> 01:26:45,960 WE ANTICIPATE AWARDING 3-5 2203 01:26:45,960 --> 01:26:47,280 APPLICATIONS AND THE PHOTTAL 2204 01:26:47,280 --> 01:26:49,160 COST FOR THIS INITIATIVE WOULD 2205 01:26:49,160 --> 01:26:51,560 BE AROUND 5 MILLION IN TOTAL 2206 01:26:51,560 --> 01:26:53,600 COST FOR YEAR 1. 2207 01:26:53,600 --> 01:26:55,880 SO IN 2018, NIAID PUBLISHED THE 2208 01:26:55,880 --> 01:26:57,440 STRATEGIC PLAN TEEJIC PLAN FOR 2209 01:26:57,440 --> 01:26:58,680 ADDRESSING RESEARCH AREAS TO 2210 01:26:58,680 --> 01:27:01,480 CREATING SAFE AND EFFECTIVE 2211 01:27:01,480 --> 01:27:02,440 INFLUENZA VACCINES AND A 2212 01:27:02,440 --> 01:27:04,200 SCHEMATIC OF THIS PLAN IS 2213 01:27:04,200 --> 01:27:06,400 ILLUSTRATED HERE AND FOCUSES ON 2214 01:27:06,400 --> 01:27:08,640 3 KEY AREAS ARE INFLUENZA 2215 01:27:08,640 --> 01:27:10,160 RESEARCH, RESEARCH AREA 1 THAT 2216 01:27:10,160 --> 01:27:10,880 INVOLVES IMPROVING THE 2217 01:27:10,880 --> 01:27:12,080 UNDERSTANDING OF THE 2218 01:27:12,080 --> 01:27:15,760 TRANSMISSION, NATURAL HISTORY, 2219 01:27:15,760 --> 01:27:17,600 AND PATHOGENESIS OF INFLUENZA 2220 01:27:17,600 --> 01:27:17,880 INFECTION. 2221 01:27:17,880 --> 01:27:20,600 RESEARCH AREA 2, WHICH INVOLVES 2222 01:27:20,600 --> 01:27:22,120 THE PRECISE CHARACTERIZATION OF 2223 01:27:22,120 --> 01:27:23,000 PROW PROTECTIVE INFLUENZ 2224 01:27:23,000 --> 01:27:25,200 IMMUNITY OCCURS AND HOW TO 2225 01:27:25,200 --> 01:27:26,320 TAYLOR VACCINATION RESPONSES TO 2226 01:27:26,320 --> 01:27:29,000 ACHIEVE IT AND RESEARCH AREA 3 2227 01:27:29,000 --> 01:27:30,840 WHICH AIMS AT SUPPORTING THE 2228 01:27:30,840 --> 01:27:33,520 RATIONAL DESIGN OF UNIVERSAL 2229 01:27:33,520 --> 01:27:34,880 INFLUENZA VACCINES INCLUDING 2230 01:27:34,880 --> 01:27:36,200 DESIGNING IMMUNE O GENS ANDAD 2231 01:27:36,200 --> 01:27:38,960 JUSTICE ACCESS VENTS TO BOOST 2232 01:27:38,960 --> 01:27:40,200 IMMUNITY AND EXTEND THE 2233 01:27:40,200 --> 01:27:41,400 PREPARATION, THE PLAN INCLUDES 2234 01:27:41,400 --> 01:27:43,440 COST CUTTING RESEARCH AREAS AS 2235 01:27:43,440 --> 01:27:45,320 IS DESIGNATED HERE WITHIN THE 2236 01:27:45,320 --> 01:27:49,280 RED ARROWS, SO WITHIN OBJECTIVE 2237 01:27:49,280 --> 01:27:50,440 2.4 RESEARCH AREA 2 IT 2238 01:27:50,440 --> 01:27:51,800 SPECIFICALLY CALLS OUT A NEED 2239 01:27:51,800 --> 01:27:54,720 FOR DEVELOPMENT OF NEW ASSAYS 2240 01:27:54,720 --> 01:27:57,240 AND REAGENTINGS, PARTICULARLY AS 2241 01:27:57,240 --> 01:27:58,240 NEW VACCINE PLATFORMS AND 2242 01:27:58,240 --> 01:28:01,600 ANDROGEN ROUGH ATOMGENIC TARGETS 2243 01:28:01,600 --> 01:28:02,160 EVOLVE. 2244 01:28:02,160 --> 01:28:12,360 SO ON MARCH 31st, 2019 THE 2245 01:28:12,360 --> 01:28:20,000 NIAID HOSTED I MEETING ENTITLED 2246 01:28:20,000 --> 01:28:21,160 IMUGEYOLOGICAL ASSAYS CORRELATES 2247 01:28:21,160 --> 01:28:23,400 OF PROTECTION FOR NEXT 2248 01:28:23,400 --> 01:28:24,760 GENERATION INFLUENZA ACSEENS AND 2249 01:28:24,760 --> 01:28:26,640 THESE WILL BE NEEDED TO PROTECT 2250 01:28:26,640 --> 01:28:30,880 THE EFFICACY OF NEXT GENERATION 2251 01:28:30,880 --> 01:28:35,240 INFLUENZA VACCINES INCLUDING 2252 01:28:35,240 --> 01:28:38,640 BROADLY USED INFLUENZA VACCINES 2253 01:28:38,640 --> 01:28:39,440 AND VACCINE CANTIDATES. 2254 01:28:39,440 --> 01:28:41,320 SO ALL OF THE RESEARCH BEING 2255 01:28:41,320 --> 01:28:44,200 DONE UNDER OUR NETWORK, DEPICTED 2256 01:28:44,200 --> 01:28:46,080 HERE TO THE LEFT HAS LED TO AN 2257 01:28:46,080 --> 01:28:47,960 EXPANDED NUMBER OF COHORTS OF 2258 01:28:47,960 --> 01:28:49,920 DIFFERENT AGED AND AT-RISK 2259 01:28:49,920 --> 01:28:51,600 POPULATIONS AS WELL AS AN 2260 01:28:51,600 --> 01:28:52,520 EXPANDED NUMBER OF CLINICAL 2261 01:28:52,520 --> 01:28:56,040 TRIALS WITH DIFFERENT TYPES OF 2262 01:28:56,040 --> 01:28:57,720 VACCINE CANDIDATES. 2263 01:28:57,720 --> 01:28:58,520 HENCE THE EXPANDED 2264 01:28:58,520 --> 01:29:00,280 INFRASTRUCTURE HAS LED TO A NEED 2265 01:29:00,280 --> 01:29:02,480 FOR NOVEL HIGH THROUGH PUT 2266 01:29:02,480 --> 01:29:03,560 ASSAYS TO DETERMINE CORRELATES 2267 01:29:03,560 --> 01:29:07,480 OF PROTECTION RATHER THAN THE 2268 01:29:07,480 --> 01:29:08,760 CLASSICAL INHIBITION, AND 2269 01:29:08,760 --> 01:29:09,560 MICRONEUTRALLIZATION ASSAYS. 2270 01:29:09,560 --> 01:29:11,640 AS WELL AS APPROVED SAMPLING 2271 01:29:11,640 --> 01:29:15,640 TECHNIQUES FOR EXAMPLE, MUCOSAL 2272 01:29:15,640 --> 01:29:18,520 SAMPLING, FOR MUCOSAL ASSAYS ARE 2273 01:29:18,520 --> 01:29:19,720 NONINVASIVE, TECHNIQUES OR 2274 01:29:19,720 --> 01:29:21,160 ASSAYS THAT UTILIZE SMALLER 2275 01:29:21,160 --> 01:29:26,440 VOLUMES FOR EXAMPLE, FOR 2276 01:29:26,440 --> 01:29:28,320 PEDIATRIC POPULATIONS. 2277 01:29:28,320 --> 01:29:29,640 SO CURRENTLY INVESTIGATOR 2278 01:29:29,640 --> 01:29:30,920 INITIATED RESEARCH ON 2279 01:29:30,920 --> 01:29:32,320 IMMUNEOLOGICAL ASSAY DEVELOPMENT 2280 01:29:32,320 --> 01:29:34,320 IS LIMITED AND RELATED ASSAY 2281 01:29:34,320 --> 01:29:35,960 DEVELOPMENT ACTIVITIES UNDER 2282 01:29:35,960 --> 01:29:36,880 BROADER PROGRAMS ARE IN GENERAL 2283 01:29:36,880 --> 01:29:39,560 SPECIFIC TO THE NEEDS OF THAT 2284 01:29:39,560 --> 01:29:39,840 PROGRAM. 2285 01:29:39,840 --> 01:29:42,680 SO THE GOAL OF THIS INITIATIVE 2286 01:29:42,680 --> 01:29:44,080 WILL BE TO COMPLEMENT EXISTING 2287 01:29:44,080 --> 01:29:44,680 PROGRAMS BY PULLING OUTSIDE 2288 01:29:44,680 --> 01:29:46,080 INVESTIGATOR WHO IS ARE 2289 01:29:46,080 --> 01:29:49,200 DEVELOPING NOVEL ASSAYS TO 2290 01:29:49,200 --> 01:29:50,920 EXPAND OR NIAID CLINICAL 2291 01:29:50,920 --> 01:29:57,080 PROGRAMS ASSAY DEVELOPMENT 2292 01:29:57,080 --> 01:29:57,840 CAPABILITIES. 2293 01:29:57,840 --> 01:30:00,000 SO THE SCOPE OF THIS INITIATIVE 2294 01:30:00,000 --> 01:30:01,680 IS DEVELOPING ASSAYS FOR MUCOSAL 2295 01:30:01,680 --> 01:30:03,720 IMMUNE RESPONSES OR PLATFORM 2296 01:30:03,720 --> 01:30:05,360 TECHNOLOGIES THAT ARE MORE HIGH 2297 01:30:05,360 --> 01:30:05,680 THROUGH PUT. 2298 01:30:05,680 --> 01:30:07,320 ONE EXAMPLE OF THE LATTER COULD 2299 01:30:07,320 --> 01:30:09,880 INCLUDE A MORE HIGH THROUGH PUT 2300 01:30:09,880 --> 01:30:11,200 CRYOEM TECHNOLOGY THAT CAN 2301 01:30:11,200 --> 01:30:13,800 CHARACTERIZE A LARGER NUMBER OF 2302 01:30:13,800 --> 01:30:16,680 CLINICAL SAMPLES FOR ANTIBODY 2303 01:30:16,680 --> 01:30:17,440 RESPONSES ILLICITTED BY 2304 01:30:17,440 --> 01:30:18,640 VACCINATION OR INFECTION, OTHER 2305 01:30:18,640 --> 01:30:20,120 ACTIVITIES THAT WILL BE 2306 01:30:20,120 --> 01:30:22,680 CONSIDERED IN SCOPE IMPROVE 2307 01:30:22,680 --> 01:30:24,080 SAMPLING TECHNOLOGIES IT TO 2308 01:30:24,080 --> 01:30:25,280 SAMPLE MUCOSAL IMMUNE RESPONSES 2309 01:30:25,280 --> 01:30:27,680 FOR TEAKNIQUES THAT ARE 2310 01:30:27,680 --> 01:30:31,440 NONINVASIVE OR UTILIZE SMALLER 2311 01:30:31,440 --> 01:30:32,680 VOLUMES. 2312 01:30:32,680 --> 01:30:33,240 APPLICANTS, APPLICATIONS 2313 01:30:33,240 --> 01:30:34,440 THAT--APPLICANTS WOULD BE 2314 01:30:34,440 --> 01:30:35,880 REQUIRED TO DOCUMENT ACCESS TO 2315 01:30:35,880 --> 01:30:37,760 CLINICAL STUDY OR TRIAL SAMPLES 2316 01:30:37,760 --> 01:30:40,000 AND APPLICATIONS THAT WOULD BE 2317 01:30:40,000 --> 01:30:40,840 CONSIDERED NONRESPONSIVE INCLUDE 2318 01:30:40,840 --> 01:30:43,040 BASIC RESEARCH FOCUSED ON 2319 01:30:43,040 --> 01:30:46,800 BIOMARKER DISCOVERY, RESEARCH 2320 01:30:46,800 --> 01:30:53,000 FOCUSED ON CLASSICAL 2321 01:30:53,000 --> 01:30:54,960 HEMOGLIEWTDINNATION, MICROOR 2322 01:30:54,960 --> 01:30:55,800 [INDISCERNIBLE] APPLICATION 2323 01:30:55,800 --> 01:30:58,400 ASSAYS AND APPLICATIONS THAT 2324 01:30:58,400 --> 01:31:00,480 PROPOSE A CLINICAL TRIAL. 2325 01:31:00,480 --> 01:31:04,160 SO THIS WOULD UTILIZE THE UH2/3 2326 01:31:04,160 --> 01:31:07,320 PROGRAM FOR NIAID STAFF WHO HAVE 2327 01:31:07,320 --> 01:31:09,720 SUBJECT MATTER EXPERTISE IN 2328 01:31:09,720 --> 01:31:10,320 DEVELOPMENT AND OPTIMIZATION. 2329 01:31:10,320 --> 01:31:11,520 THE RESEARCH STRATEGY MUST 2330 01:31:11,520 --> 01:31:12,840 INCLUDE MILESTONES TO BE 2331 01:31:12,840 --> 01:31:14,680 ASSESSED AT THE END OF THE UH2 2332 01:31:14,680 --> 01:31:18,880 PHASE AND PRIOR TO THE END OF 2333 01:31:18,880 --> 01:31:20,440 THE UH2 PHASE, PRIOR TO THE END 2334 01:31:20,440 --> 01:31:21,560 OF THE TRANSMISSION PACKAGE 2335 01:31:21,560 --> 01:31:23,520 WHICH INUDPGA KLF-TWOS THE 2336 01:31:23,520 --> 01:31:25,000 PROGRESS REPORT DETAILING THE 2337 01:31:25,000 --> 01:31:26,680 PROGRESS TOWARD THE MILESTONES 2338 01:31:26,680 --> 01:31:28,440 AS WELL AS DESCRIPTION OF HOW 2339 01:31:28,440 --> 01:31:30,080 THEY PROPOSED FOR THE UH 3 PHASE 2340 01:31:30,080 --> 01:31:32,960 IS SUPPORTED BY THE COMPLETION 2341 01:31:32,960 --> 01:31:34,280 OF THE UH 2 PHASE MILESTONES. 2342 01:31:34,280 --> 01:31:36,800 SO EXAMPLES OF PHASE 1 2343 01:31:36,800 --> 01:31:38,200 ACTIVITIES MAY INCLUDE 2344 01:31:38,200 --> 01:31:39,640 OPTIMIZATION OF SAMPLE 2345 01:31:39,640 --> 01:31:44,120 COLLECTION PROCEDURES AND 2346 01:31:44,120 --> 01:31:46,040 IDENTIFYING ASSAY AND PLATFORM 2347 01:31:46,040 --> 01:31:54,080 SAMPLES AND ACTIVITIES COULD 2348 01:31:54,080 --> 01:31:55,000 INCLUDE ASSAY DEVELOPMENT AND 2349 01:31:55,000 --> 01:31:56,920 THE FACE 1 OR 2 ACTIVITIES THAT 2350 01:31:56,920 --> 01:31:59,000 ARE PROPOSED AND APPLICATIONS 2351 01:31:59,000 --> 01:32:00,000 CAN TAIL LORA RODRIGUEZ 1 AND 2 2352 01:32:00,000 --> 01:32:01,400 ACTIVITIES TO FIT THE CURRENT 2353 01:32:01,400 --> 01:32:11,360 STAGE OF TWEPMENT FOR THEIR 2354 01:32:11,360 --> 01:32:11,720 SPECIFIC ASSAY. 2355 01:32:11,720 --> 01:32:18,720 I WANT TO TAKE A MINUTE TO THANK 2356 01:32:18,720 --> 01:32:21,680 DR. FERNANDEZ-SESMA AND 2357 01:32:21,680 --> 01:32:23,040 DR. GREENBERG, FOR THEIR SUPPORT 2358 01:32:23,040 --> 01:32:23,680 OF THE INITIATIVE. 2359 01:32:23,680 --> 01:32:25,840 THEY ALSO RECOGNIZE THE NEED FOR 2360 01:32:25,840 --> 01:32:28,480 NOVEL HIGH-LIEU PUT ASSAYS AND 2361 01:32:28,480 --> 01:32:30,200 EMPHASIZE THE IMPORTANCE OF 2362 01:32:30,200 --> 01:32:31,240 SAMPLING TECHNOLOGIES, SPECIALLY 2363 01:32:31,240 --> 01:32:34,720 THOSE THAT ARE NONINVASIVE AND 2364 01:32:34,720 --> 01:32:41,040 SAMPLING OBVIOUSLY FOR PEDIATRIC 2365 01:32:41,040 --> 01:32:41,320 POPULATION. 2366 01:32:41,320 --> 01:32:44,720 SO THIS IS THE RECAP SLIDE FOR 2367 01:32:44,720 --> 01:32:46,080 THE INITIATIVE CONCEPT AND I AM 2368 01:32:46,080 --> 01:32:47,200 HAPPY TO ADDRESS ANY QUESTIONS 2369 01:32:47,200 --> 01:32:50,880 ANYONE MAY HAVE AT THIS TIME. 2370 01:32:50,880 --> 01:32:56,200 >> THERE ARE ANY QUESTIONS OR 2371 01:32:56,200 --> 01:32:59,280 COMMENTS FROM ANY SUBCOUNCIL 2372 01:32:59,280 --> 01:32:59,520 MEMBERS? 2373 01:32:59,520 --> 01:33:00,080 ANNA? 2374 01:33:00,080 --> 01:33:01,680 >> I JUST WANT TO SAY THIS HAS 2375 01:33:01,680 --> 01:33:07,800 BEEN A LONG ONGOING QUESTION OR 2376 01:33:07,800 --> 01:33:10,720 PROBLEM OR LACK OF A BIG NEED IN 2377 01:33:10,720 --> 01:33:13,040 THE INFLUENZA FIELD BECAUSE WE 2378 01:33:13,040 --> 01:33:23,080 RELY HEAVILY ON VERY KIND OF OLD 2379 01:33:23,080 --> 01:33:24,040 FASHIONED TYPE OF--I THINK ALSO 2380 01:33:24,040 --> 01:33:27,120 IT WAS IN THE DISCUSSION FOR 2381 01:33:27,120 --> 01:33:33,120 OTHER, MAYBE OTHER TARGETS FOR 2382 01:33:33,120 --> 01:33:34,560 THE ASSAYS OR PARTICULAR HOW 2383 01:33:34,560 --> 01:33:37,280 MANY WERE VERY ENCOURAGING AND I 2384 01:33:37,280 --> 01:33:39,840 THINK IT'S IMPORTANT WE DON'T 2385 01:33:39,840 --> 01:33:42,280 JUST FOCUS MOSTLY ON THE HA BUT 2386 01:33:42,280 --> 01:33:43,520 IT'S AN ONGOING PROBLEM THAT HAS 2387 01:33:43,520 --> 01:33:45,080 TO BE ADDRESSED AND WE ARE 2388 01:33:45,080 --> 01:33:48,400 REALLY SUPPORTIVE, WE WERE VERY 2389 01:33:48,400 --> 01:33:49,880 SUPPORTIVE OF THESE HOPEFULLY 2390 01:33:49,880 --> 01:33:50,960 VERY IMPORTANT THING WILL COME 2391 01:33:50,960 --> 01:33:52,160 OUT OF THIS INITIATIVE BECAUSE 2392 01:33:52,160 --> 01:33:54,280 THERE IS A BIG NEED FOR THAT. 2393 01:33:54,280 --> 01:33:57,840 IT'S AMAZING WE HAVE SO MUCH 2394 01:33:57,840 --> 01:33:59,120 RESEARCH AND INFLUENZA, WE STILL 2395 01:33:59,120 --> 01:34:01,120 DON'T HAVE VERY HIGH THROUGH PUT 2396 01:34:01,120 --> 01:34:09,120 ASSAYS THAT ARE USED WIDELY ALL 2397 01:34:09,120 --> 01:34:10,480 OVERALL STRATEGY THE WORLD. 2398 01:34:10,480 --> 01:34:13,560 >> HARRY DO HAVE YOU YOUR HAND 2399 01:34:13,560 --> 01:34:14,800 UP? 2400 01:34:14,800 --> 01:34:16,880 >> YEAH, I ENDORSE WHAT ANA SAID 2401 01:34:16,880 --> 01:34:20,840 AND I WOULD SIMPLY SAY THAT WITH 2402 01:34:20,840 --> 01:34:24,200 THE ADVENT OF RNA BASED 2403 01:34:24,200 --> 01:34:27,160 VACCINES, THERE REALLY IS GOING 2404 01:34:27,160 --> 01:34:30,080 TO BE MORE VACCINATION WHERE 2405 01:34:30,080 --> 01:34:32,080 NEUROMITT DACE IS A LEGITIMATE 2406 01:34:32,080 --> 01:34:34,080 TARGET THAT CAN BE STANDARDIZED 2407 01:34:34,080 --> 01:34:39,040 AND THE ASSAYS ARE PRETTY OLD 2408 01:34:39,040 --> 01:34:40,080 FASHIONED FOR NEUROMENA DICE AND 2409 01:34:40,080 --> 01:34:43,880 IT'S IMPORTANT TO GET THOSE IN 2410 01:34:43,880 --> 01:34:45,280 PLACE BECAUSE PRETTY SOON YOU 2411 01:34:45,280 --> 01:34:48,080 WILL HAVE ALL SORTS OF RNA 2412 01:34:48,080 --> 01:34:49,000 VACCINATION EFFORTS WITH FLU AND 2413 01:34:49,000 --> 01:34:55,240 IF WE'RE STILL DOING NEUROMENA 2414 01:34:55,240 --> 01:34:56,840 DAZE, TELL BE INSANE. 2415 01:34:56,840 --> 01:35:01,800 >> I AGREE COMPLETELY. 2416 01:35:01,800 --> 01:35:05,880 >> I DON'T SEE ANY OTHER HANDS 2417 01:35:05,880 --> 01:35:06,160 RAISED. 2418 01:35:06,160 --> 01:35:07,240 ANY OTHER FINAL COMMENTS OR 2419 01:35:07,240 --> 01:35:11,040 FEEDBACK FROM THE GROUP? 2420 01:35:11,040 --> 01:35:14,120 WELL, WE GET TO FINISH EARLY 2421 01:35:14,120 --> 01:35:14,920 THEN. 2422 01:35:14,920 --> 01:35:15,920 SO THANK YOU. 2423 01:35:15,920 --> 01:35:18,520 THANKS TO THE SUBCOUNCIL MEMBERS 2424 01:35:18,520 --> 01:35:19,840 FOR PARTICIPATING AND FOR DOING 2425 01:35:19,840 --> 01:35:21,840 YOUR HOME WORK AND COMING 2426 01:35:21,840 --> 01:35:22,120 PREPARED. 2427 01:35:22,120 --> 01:35:24,200 THANKS TO ALL THE PRESENTERS 2428 01:35:24,200 --> 01:35:25,000 TODAY. 2429 01:35:25,000 --> 01:35:27,320 I THINK OUR NEXT COUNCIL MEETING 2430 01:35:27,320 --> 01:35:29,000 WILL BE--WELL IT WILL BE MAY 2431 01:35:29,000 --> 01:35:30,720 COUNCIL, I DON'T EXACTLY KNOW 2432 01:35:30,720 --> 01:35:32,160 THE DATE BUT WE WILL SEE YOU 2433 01:35:32,160 --> 01:35:33,840 THEN IF NOT SOONER. 2434 01:35:33,840 --> 01:37:10,200 SO THANK AND YOU FAREWELL.